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ABSTRACT 
 
 
 The greatest threat for an influenza pandemic at this time is posed by the highly 
pathogenic H5N1 avian influenza virus. To date, 63% of the 436 known human cases of 
H5N1 infection have proven fatal. Animals infected by H5N1 viruses have demonstrated 
acute neurological signs ranging from mild encephalitis to motor disturbances and coma. 
However, no studies have examined the longer-term neurologic consequences of H5N1 
infection. We show that this virus travels from the peripheral nervous system into the 
central nervous system (CNS) to higher levels of the neuroaxis, using C57BL/6J mice 
that are infected by the A/VN/1203/04 H5N1 virus (without adaptation). In regions 
infected by H5N1 virus, we observe activation of microglia and alpha-synuclein 
phosphorylation and aggregation that persists long after resolution of the infection.  
 
 To determine if the pathology worsened with age, we examined: 1) substantia 
nigra pars compacta (SNpc) tyrosine hydroxylase positive dopaminergic neuron number 
and striatal dopamine and its metabolites contents through 90 days post infection (dpi), 2) 
examined the inflammatory effect of infection by quantitatively measuring the total 
number of resting and activated microglia in the SNpc and then examined the production 
of cytokines in regions of the brain infected by H5N1. We found that infection with 
H5N1 induces a reversible reduction of both the number of dopaminergic neurons in the 
SNpc and the amount of dopamine and its metabolites in the striatum. Examination of 
other indolamines demonstrated a significant and sustained reduction of serotonin in 
regions of the brain infected with H5N1. We also observed that areas of the brain infected 
with H5N1 expressed altered levels of pro-inflammatory cytokines, chemokines and 
growth factors. 
 
 We examined if H5N1 priming potentiates paraquat (PQ) induced neurotoxicity in 
the basal ganglia. We found that H5N1 priming did not increase the sensitivity of 
C57BL/6J mice to intraperitoneal (ip) administration of paraquat. Rather, H5N1 priming 
protects the dopaminergic neurons from PQ-induced neurodegeneration and diminishes 
immune response produced by PQ in the CNS. 
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CHAPTER 1. INTRODUCTION* 
 
 
1.1 Parkinson’s Disease (PD) 
 
 Parkinson’s disease (PD) was first described in 1817 by Dr. James Parkinson in a 
paper entitled “An Essay on the Shaking Palsy” (1). PD is a progressive neurodegenerat-
ive disorder that is characterized by both motor and autonomic symptoms. The most 
common motor symptoms include bradykinesia, hypokinesia/akinesia, rigidity, tremor 
and postural imbalance. The incidence of PD is approximately 1-2% of the adult 
population older than 50 years of age. Current estimates from the Parkinson's Disease 
Foundation put the number of people suffering from this disease at 4.1 million 
worldwide. It is predicted to rise to 8.7 million based on a projected increase in lifespan. 
In fact, there are more individuals diagnosed with PD than with multiple sclerosis, 
muscular dystrophy and amyotrophic lateral sclerosis (Lou Gehrig’s Disease) combined 
(2). 
 
 
1.2 Functional Neuroanatomy Underlying PD 
 
 
1.2.1 Basal ganglia 
 
 The basal ganglion is made up of a group of nuclei located at the base of the 
forebrain and midbrain that sends projections to motor cortex, thalamus and 
mesencephalic structures. In humans, the basal ganglia is comprised of the striatum, the 
pallidum that includes the internal and external segment of globus pallidus, the substantia 
nigra, and the subthalamic nucleus (3). 
 
 
1.2.2 The circuitry of basal ganglia 
 
 The basal ganglia receive external information from most of the cerebral cortex, 
thalamic nuclei, and limbic structures. The striatum, which is made of two distinct parts, 
the caudate and the putamen, is the main input structure of the basal ganglia. It sends its 
output signal to other nuclei of the basal ganglia, including the pallidum and the 
substantia nigra pars reticulata. Within the striatum, the majority of synapses occur on 
GABA(γ-aminobutyric acid)ergic, medium spiny neurons (MSN), that make up about 
95~97% of the total population of striatal neurons (4). The internal segment of the globus 
pallidus (GPi) and the substantia nigra pars reticulata (SNpr) provide the main output 
from the basal ganglia. 
 
* Sections 1.4 and 1.8 of this chapter adapted with permission. Jang H, Boltz DA, 
Webster RG, Smeyne RJ. Viral parkinsonism. Biochim Biophys Acta 1792(7), 714-721, 
(2009) (5). 
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 The GPi receives input signals from the striatum directly or indirectly via the 
subthalamic nucleus (STN) followed by the external segment of the globus pallidus 
(GPe).The GPi sends projections to the thalamic nuclei that innervate the motor-related 
areas of the cortex. The pallidal neurons are tonically active in the absence of an input 
signal and stop firing when they receive inhibitory input from the striatum. The pallidal 
neurons are inhibitory GABAergic neurons, as a result, the input from the striatum 
removes the tonic inhibition from the target of the pallidal neurons (4). The input and the 
output components form two closed circuits that begin and end at the cerebral cortex (Fig 
1.1A). In the direct pathway, signal is relayed the following order, cerebral cortex → 
striatum (inhibitory) → GPi (inhibitory) → thalamus → cerebral cortex, so that the net 
effect on the cortex is excitatory. In the direct pathway, dopaminergic neurons of the SN 
synapse on D1 receptors in the striatum, providing a dopaminergic stimulatory response 
to the striatal projecting neurons. In the indirect pathway, the components communicate 
in the following order, cerebral cortex→ striatum (inhibitory) → GPe (inhibitory) → 
STN (excitatory) → GPi (inhibitory) → thalamus → cerebral cortex, so that the net effect 
on the cortex is inhibitory. In contrast to the direct pathway, dopamine acts on the striatal 
projection neurons through the dopamine D2 receptor which is inhibitory in response to 
dopamine stimulation (4). 
 
 
1.2.3 Basal ganglia and PD 
 
 The major motor symptoms of PD appear when approximately 60% of the 
dopaminergic neurons have degenerated. The subsequent reduction in striatal dopamine 
affects the two pathways differentially. Low DA input to the stimulatory D1 receptors 
results in less firing of inhibitory striatal neurons in the direct pathway. As a result, 
neurons in GPi become more active and inhibit the thalamic neurons. The reduction of 
dopamine in the indirect pathway provides less activation of D2 receptors and 
consequently, less inhibition of the striatal neurons. Consequently, inhibitory striatal 
neurons become more active and increase the inhibition of neurons in the GPe. 
Sequentially, excitatory STN neurons increase the excitatory input to the neurons in the 
GPi, enhancing the firing of GPi, and further suppressing the activity of thalamic 
neurons. Overall, low DA input gives rise to a stronger inhibitory tone of basal ganglia 
output to their targets through both the direct and indirect pathways. This is the cause of 
the bradykinesia and the hypokinesia symptoms observed in PD (Fig 1.1B) (3). 
 
 
1.3 Epidemiology of PD  
  
 The estimated prevalence of PD in industrialized countries is 0.3% of the total 
population and 1% in people over 60 years of age. Regionally, North America, South 
America, and Europe record the highest prevalence of PD, while Asia and Africa record 
the lowest prevalence. Because the prevalence rates are affected by the difference in the 
survival of the patients, the incidence rates are a more reliable indicator of PD risk. 
Recently reported annual incidence rates, having been adjusted for age and/or gender, are 
13.4 per 100,000 people per year in industrialized countries (2). 
 2
 
 
Figure 1.1 The Functional Neuroanatomy of the Basal Ganglia  
 
These diagrams demonstrate the circuitry of the basal ganglia in normal (A) and PD brain 
(B). The output of the basal ganglia is regulated by the fine balance between the direct 
and indirect pathways that both promote and suppress body movements, respectively. In 
the normal state, the afferent dopaminergic signal from the substantia nigra pars 
compacta (SNpc) enhances the direct pathway and suppresses the indirect pathway, 
producing a positive net effect on the stimulation of cortical motor areas. In PD, the 
depletion of dopamine in the striatum gives rise to an imbalance and suppression of the 
thalamocortical activity. Blue lines represent the excitatory pathways and red lines 
display the inhibitory pathway. GP, globus pallidus; GPe, external segment of GP; GPi, 
internal segment of GP; STN, subthalamus nucleus; D1, D1 dopamine receptors; D2, D2 
dopamine receptors. 
 
Source: Modified with permission from Elsevier. Albin RL, Young AB, and Penney, JB. 
The functional anatomy of basal ganglia disorders. Trends Neuroscience 12, 366-375 
(1989) (6). 
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 Age is the most potent risk factor that contributes to the incidence of developing 
Parkinson’s disease. The incidence rates increase rapidly over 60 years of age, with only 
4% of PD patients developing the disease when they are under the age of 50 years (2). 
Gender is also a factor that contributes to PD incidence rates. For men, the incidence rate 
is 19 per 100,000, which are 91% higher than that of women, whose incidence is 9.9 per 
100,000. Based on race/ethnicity, the highest incidence rates are recorded for Hispanic 
populations (16.6), followed by non-Hispanic white (13.6), Asian (11.3), and Black (10.2 
per 100,000) populations, suggesting that race/ethnicity also affects the incidence of 
PD(2). 
 
 
1.4 Etiology of PD  
 
 The underlying cause(s) for the vast majority of PD cases are unknown. 
Controversy still exists as to how much of the disease results from strict genetic 
causation, a purely environmental factor, or the combination of the two risk factors (7, 8).  
Empirical evidence suggests that less than 10% of all diagnosed parkinsonism has a strict 
familial etiology. At this time, there have been 13 identified parkinsonian loci, although 
mutations in just five of these genes, alpha-synuclein (PARK 1), parkin (PARK2), 
PINK1 (PARK6), DJ-1 (PARK7), and LRRK2 (PARK8) make up the bulk of these cases 
(9). In addition to genetic mutations leading to the onset of Parkinson’s disease, there are 
also clear environmental factors that lead to parkinsonism. These cases of parkinsonism 
are often referred to as secondary parkinsonism and can result from a myriad of causes 
including infectious agents (10), drugs (11), toxins (12), vascular insults (13), trauma 
(14), and although rare, other pathological problems such as tumors (15, 16). 
 
 
1.4.1 Genetic factors 
  
 At this time, there have been 13 identified parkinsonian loci, although there are 
mutations in just eight of these genes, alpha-synuclein (PARK 1), parkin (PARK2), 
UCH-L1 (PARK5), PINK1 (PARK6), DJ-1 (PARK7), LRRK2 (PARK8), ATP13A2 
(PARK9), and Omi/HtrA2 (PARK13) (Table 1.1). However, these cases of familial PD 
account for less than 10% of the total number of PD cases (9). 
 
 
1.4.2 Environmental toxin factors 
 
 The role of environmental toxins has been a focus of PD research in recent years 
in response to the “Case of the Frozen Addicts”. People attempting to synthesize a 
designer narcotic drug accidentally produced 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) that when injected, inflicted the user with a syndrome almost 
identical to idiopathic PD. Later, MPTP  was shown to be a neurotoxin which selectively 
kills dopaminergic cells in the SNpc in both humans and non-human primates (17). Once 
administered, MPTP crosses the blood-brain barrier and is converted to its toxic form,
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Table 1.1 Locations and Types of Mutations of the Familial PD-Related Genes 
 
Locus Gene Chromosomal location Type of mutation Inheritance
PARK1 SNCA 4q PM, Dupl, Tripl AD 
PARK2 Parkin 6q PM, Dupl, Tripl, Ins, Del AR 
PARK5 UCH-L1 4p PM AD 
PARK6 PINK1 1p PM, Ins, Del AR 
PARK7 DJ-1 1p PM, Del AR 
PARK8 LRRK2 12p-q PM, Del AD 
PARK9 ATP13A2 1p PM, Del AR 
PARK13 Omi/HtrA2 2p PM AD 
 
SNCA, alpha-synuclein; UCH-L1, Ubiquitin carboxyl-terminal hydrolase L1; PINK-1, 
PTEN induced putative kinase 1; LRRK2, leucine-rich repeat kinase 2; PM, point 
mutation; Ins, insertion; Del, deletion; Dupl, duplication; Tripl, triplication; AR, 
autosomal recessive; AD, autosomal dominant. 
 
Source: Modified with permission from Blackwell Publishing. Carola Schiesling, Nicole 
Kieper, Kay Seidel and Rejko Krüger. Review: Familial Parkinson's disease – genetics, 
clinical phenotype and neuropathology in relation to the common sporadic form of the 
disease. Neuropathology and Applied Neurobiology 34, 255–271(2008)(18). 
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1-methyl-4-phenyl-pyridinium (MPP+) by monoamine oxidase B(MAO-B) in glial cells 
(19). MPP+ is taken up by dopaminergic neurons through the dopamine transporter 
(DAT). In neurons, MPP+ inhibits complex I of mitochondria and induces oxidative 
stress (12). 
 
 Paraquat is a widely used herbicide throughout the world. Investigators have 
become interested in paraquat, because in addition to sharing structural similarities to 
MPP+, which is a toxic form of MPTP, it also showed an etiological link to PD in 
epidemiological studies. Paraquat is reduced by several reductases, including 
mitochondrial complex I, to become a PQ monocation free radical (PQ+). Subsequently, 
the PQ free radical is rapidly oxidized by oxygen and produces superoxide radicals and 
reactive oxygen species that can be toxic to the cell (20). 
 
 Rotenone was first isolated from the roots and stems of several plants and has 
been used as a pesticide and fish poison (21, 22). Highly lipophilic, rotenone easily 
penetrates the blood-brain barrier and accumulates in the mitochondria, inhibiting 
complex I of the electron transport chain. 
 
 Epidemiological studies have demonstrated that the residents of rural areas where 
herbicides and pesticides were used extensively, have higher incidences of PD than the 
residents of urban areas (23). However, further research is needed to implicate any 
specific toxin as a cause of sporadic PD. 
 
 
1.4.3 Viral factors 
 
 A number of viruses, including influenza, coxsackie, Japanese encephalitis B, 
western equine encephalitis, herpes, and human immunodeficiency virus (HIV), have 
been associated with both acute and chronic parkinsonism (Table 1.2). 
  
 The hypothesis that viruses or other contaminating agents may be a factor 
initiating primary or secondary parkinsonism often relates to coincidental cases of 
parkinsonism that lie outside of the expected population (5). One of the most famous and 
still controversial examples is the parkinsonism that occurred subsequent to a viral 
encephalopathy that developed following the 1918 influenza pandemic (24). Another 
example that suggests viral agents can act as an initiator of parkinsonism is the 
appearance of parkinsonian clusters. These are groups of individuals who share common 
environments and develop parkinsonism at greater than normal statistical rates without 
the typical risk factors. In fact, the risk of developing Parkinson’s disease is 
approximately 2 times greater for people sharing close quarters, including doctors and 
nurses, teachers, and religion-related jobs. Several of these parkinsonian clusters have 
been described, including those living in Israeli kibbutz’s, a group of college teachers, 
garment workers in a manufacturing factory, a group of actors and producers and 
technical staff working on a television series in Canada (25, 26). 
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Table 1.2 Association of Virus and Parkinsonism  
 
Virus Family Species References 
Herpes simplex virus (27-30) 
Epstein-Barr virus (31) 
Cytomegalovirus (CMV) (28, 30) 
DNA Herpesviridae 
Varicella zoster virus (VZV) (32) 
 
Bornaviridae Borna disease virus (33) 
Orthomyxoviridae Influenza virus Type A (34-43) 
Paramyxoviridae Measles (44, 45) 
Coxsackie virus (46-49) 
Echo virus (50) Picornaviridae 
Polio virus (51) 
Retroviridae Human immunodeficiency virus (HIV) (52-57) 
West Nile virus (58) 
Japanese encephalitis B virus (34, 59-66) 
RNA 
Flaviviridae 
St. Louis virus (67-69) 
 
Source: Modified with permission from Elsevier. Haeman Jang, David A. Boltz, Robert 
G. Webster, Richard Jay Smeyne. Viral parkinsonism. Biochimica et Biophysica Acta 
(BBA) 1792(7), 714-721 (2009)(5). 
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1.4.4 Combination of multiple factors 
 
 It is hypothesized that PD is caused not by a single event but by a combination of 
multiple hit throughout the life of the individual (70-73). If PD results from a 
combination of various insults (including genetic defects, environmental toxin exposure, 
viral infection, natural loss of DA neurons, and/or normal aging), the event that initiates 
disease progression may occur far earlier than the onset of symptoms. Indeed, 
McCormack et al., showed that the exposure to an environmental toxin such as PQ during 
the early postnatal period made the SN more vulnerable to the neurotoxin in adult mice 
(74). In addition, rodents that have been exposed to the bacterial lipopolysaccharide 
(LPS) during prenatal stages show decreased resistance to 6-hydroxydopamine (6-
OHDA) during their adult period (75). These results suggest that these insults in early life 
increase susceptibility to the effects of neurotoxins later in life. 
 
 
1.5 Pathology of PD 
 
 The main neuropathological defect observed in PD is the selective loss of the 
pigmented cells located in the substantia nigra pars compacta (SNpc). Cell loss has also 
been described in the locus coeruleus (76), the dorsal motor nucleus of the vagus nerve 
(77) and throughout the autonomic nervous system (78). The pigmented cells in the SNpc 
are dopamine (DA) producing neurons, and consequently the loss of these cells results in 
a reduction in the number of both afferent fibers and the amount of DA to its main target, 
the striatum (79). When patients lose approximately 70~80% of their striatal DA and 
50~60% of the dopaminergic neurons in the substantia nigra pars compacta (SNpc), the 
typical constellation of parkinsonian symptoms become evident (80). Because the 
progression of cell loss is thought to occur over a protracted period of time in a defined 
spatiotemporal manner, the onset of Parkinson's disease symptoms are often insidious 
(81, 82). 
 
 In addition to neuronal loss, primary PD is also defined by the presence of 
intracytoplasmic aggregates, Lewy bodies (LB) and intraprocess aggregates, Lewy 
neurites (LN). The presence of LB is not limited to the SNpc, but distributed in the 
olfactory bulb, hypothalamus, locus ceruleus, cerebral cortex, vagus nerve, and myenteric 
plexus of the autonomic nervous system (83). LB were first described and linked to PD 
by Frederic Lewy (84) and subsequent studies using electron microscopy revealed that 
these inclusions are made of an unknown filament (85). 
 
 
1.5.1 The role of Lewy bodies (LB) 
 
 It is debated if the abnormal protein aggregation observed in various 
neurodegenerative diseases is protective or deleterious to the cell. The role of LB in PD is 
also unclear. It has been suggested that LB containing-dopaminergic neurons in the SNpc 
are less vulnerable to cell death than LB negative dopaminergic neurons (86). In this 
view, LB can be thought of as resulting from a cellular defensive mechanism like the 
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formation of an aggresome (87). In the cell, the appearance of misfolded or abnormal 
proteins are managed by several cellular protective mechanisms such as the molecular 
chaperones, ubiquitin-proteasome system (UPS) and autophagy lysosome pathway (ALP) 
(87). When the amount of abnormal or aggregated protein exceed the capacity of the UPS 
and/or ALP, cells can sequester them at a single cytoplasmic site near the centriole and 
generate a large inclusion body called an aggresome(88). The aggresome recruits UPS 
components and may facilitate abnormal protein degradation within itself. After 
formation, the aggresome may persist in an insoluble form or be cleared by an unknown 
mechanism (89). 
 
 Like the aggresome, LB contain many components of the UPS including 
ubiquitin-activating enzyme (E1), ubiquitin-conjugating enzyme (E2), ubiquitin-ligase 
(E3), proteasome activator, and heat shock protein(90-92). LB also contain specific 
aggresomal proteins such as γ-tubulin and pericentrin. In a cell culture model, the 
proteolytic stresses driven by proteasome inhibitors or by the over-expression of protein 
induce the formation of aggresome-like inclusions in dopaminergic cells. These 
inclusions have a dense core and peripheral halo, mimicking the shape of LB (93). These 
evidences suggest that LB may be formed by the cellular protective mechanism. 
 
 
1.5.2 The structure and function of α-synuclein 
 
 In 1997, Spillantini et al, were first to describe α-synuclein protein as the main 
component of LB and LN in idiopathic PD (94). At a similar time, a missense mutation in 
the α-synuclein gene was reported in familial PD by another group (95). α-synuclein is a 
member of the synuclein family that includes β-synuclein and γ-synuclein. α-synuclein 
consists of 140-amino acid residues and has three distinct domains. The amino-terminal 
domain (residues 1-70) carries incomplete KTKEGV repeats (96). The hydrophobic 
domain (residues 71-82), also called the non-amyloid component (NAC), appears to be 
accountable for the aggregation of α-synuclein (97). The carboxyl-terminal domain 
(residues 96-140) consists of acidic residues and contains three highly conserved tyrosine 
residues. This region appears to be involved in the solubilization of  high molecular 
weight proteins and may regulate the aggregation of full length α-synuclein (98). Also, 
the deletion of this domain results in the loss of chaperone activity of α-synuclein (99). 
 
 The function of α-synuclein still requires clarification. It is known that α-
synuclein binds to the lipid membrane and selectively inhibits phospholipase D2, which 
may be involved in cytoskeletal regulation and endocytosis. Synphilin-1 is also known to 
bind to α-synuclein where it may act as an adaptor molecule, since it contains ankyrin-
like repeats, a coiled-coil domain and an ATP/GTP binding domain. In vitro, synphilin is 
co-localized with α-synuclein in neurons and facilitates the formation of cytosolic phase-
dense inclusions (100). In vivo, synphilin-1 is detected in the Lewy bodies of idiopathic 
PD (101). These observations suggest that Synphilin-1 may modulate the aggregation of 
α-synuclein and the formation of Lewy bodies. 
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 α-synuclein knock-out mice show morphologically intact brain architecture and 
have no structural deficit in dopaminergic cell bodies, processes and synapses. In 
addition, these mice display normal long term potentiation (LTP) in the hippocampus 
(102) and no deficit in spatial learning (103). However, they show enhanced DA release 
with coupled stimuli by using Ca2+, and decreased striatal DA and DA dependent 
locomotion with amphetamine administration. Based on these observation, Abeliovich et 
al., suggest that α-synuclein may act as an “activity-dependent negative regulator of DA 
neurotransmission” in the presynaptic terminal (102). 
 
 
1.5.3 Association of α-synuclein with the formation of LB in PD 
 
 In mammals, α-synuclein is predominately expressed in the presynaptic nerve 
terminals of the olfactory bulb, amygdala, hippocampus, and cerebral cortex (104). The 
post-translational modifications of α-synuclein are not fully understood. However, in α-
synuclein transfected cells, it is frequently phosphorylated at serine 129 (105). In 
addition, it has been discovered that phosphorylation at serine 129 produces dominant 
pathological changes in familial and idiopathic PD (106). 
 
 The mechanism by which soluble monomeric α-synuclein leaves its assumed 
binding site in presynaptic terminals, combines with other LB components such as 
ubiquitin, and forms insoluble LB and LN (107) is largely unknown. Emerging evidence 
demonstrates that multiple factors may be involved in the aggregation of α-synuclein and 
the formation of LB in PD (108).  
 
 Mutations of the α-synuclein gene, including Ala53Thr, Ala30Pro, and Glu46Lys 
have been identified to be dominantly or recessively inherited in familial PD (95), 
indicating that the mutated α-synuclein gene is directly involved in PD. Furthermore, 
Ala53Thr and Glu46Lys mutated α-synuclein proteins display increased self-assembly 
and fibril formation in vitro (109-111). Environmental toxins, such as rotenone and 
paraquat, are also known to induce a conformational change in α-synuclein and facilitate 
the formation of α-synuclein fibrils in vitro (112). 
 
 A change in cellular protein degradation may also be involved in the α-synuclein 
aggregation and LB formation. It has been demonstrated that α-synuclein is a substrate 
for the UPS (113, 114) whereas the mutated α-synuclein protein inhibits proteasome-
mediated degradation (114). In addition, mutations in the genes encoding two UPS 
enzymes, parkin (a component of a multiprotein E3 ubiquitin ligase complex) and 
ubiqutin C-terminal hydrolase L1 (UCH-L1), are also associated with some cases of 
familial PD (115, 116), supporting the theory that defects in the UPS may result in 
proteinopathies in PD. 
 
 The autophagy lysosome pathway (ALP), a catabolic process in which a cell's 
own components can be degraded by lysosomal machinery, also may have a role in 
synucleinopathies in PD. Cuervo et al., found that the wild type α-synuclein is a substrate 
for lysosomal degradation and is selectively translocated into lysosomes by the 
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chaperone-mediated autophagy pathway (CMA). Interestingly, the A53T and A30P α-
synuclein mutants, showing a high affinity to lysosomal membrane receptors, are targeted 
to lysosomes, but fail to be cleared. Rather, it inhibits the degradation of both mutant α-
synucleins and other CMA substrates (117). Thus, the accumulation of mutant synucleins 
as well as other CMA substrate proteins alters cellular homoeostasis and results in 
neurodegeneration (118). 
 
 
1.5.4 Braak’s pathological observations 
 
 Although the exact role of LB in PD is not yet clear, there is a hypothesis that the 
presence of LB is positively correlated with the progression of PD (119). Braak et al. 
assessed α-synuclein positive LB and LN by a semi quantitative method in 41 cases of 
symptomatic PD, 69 subjects who might have been developing PD, but did not show 
parkinsonian symptoms, and 58 aged matched controls. Interestingly, the distribution of 
LB and LN, ranging from the brainstem to the cerebral cortex, appeared in a hierarchical 
manner that is correlated with PD symptomatic progression. For example, in Braak’s 
stages 1 and 2, both of which are preclinical, the presence of LB and LN is confined to 
the medulla oblongata and olfactory bulb. In this stage, LB and LN initially appear on the 
dorsal IX/X motor nucleus (DMN) then spread into the pontine tegmentum. In Braak 
stages 3 and 4, LB and LN are found in the midbrain, including the SNpc, in addition to 
the areas affected in stage 1 and 2. In stages 5 and 6, in which PD symptoms have 
progressed to their most complete, including dementia, LB and LN are newly detected in 
the neocortex (120, 121). 
 
 These patterns of Braak’s LB and LN progression are somewhat correlated with 
the symptoms that clinicians observe in PD patients. For example, it has been reported 
that autonomic symptoms, including constipation, olfactory dysfunction, and sleep 
disorders may precede motor symptoms by years (122, 123). LB and LN seen in the 
enteric plexuses, dorsal motor nucleus, and olfactory nucleus at Braak’s stage 1 and 2 
may account for the induction of these symptoms. These observations support the 
hypothesis that the formation of LB and LN may be initiated far earlier than when the 
typical motor symptoms appear, as in sporadic PD. 
 
 The question arises, what might trigger such LB pathology in the DMN, a nucleus 
that integrates fibers that innervate visceral organs, including the lung, heart, 
gastrointestinal tract as well as olfactory nucleus in the early phase of PD? Some viruses 
including influenza and Herpes simplex have been proposed to attack the enteric nervous 
system (ENS) and to be transmitted into the DMN by retrograde transport (124). 
Interestingly, influenza virus seems to be associated with LB formation. Interferon 
induced protein MxA, which plays a role in defense against influenza virus, was found in 
LB and swollen processes in sporadic PD (43). However, no direct evidence that 
influenza virus induces the formation of LB in idiopathic PD has been presented. 
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1.5.5 Neuroinflammation 
 
 More evidence suggests that neuroinflammation may play an important role in PD 
progression. Two classes of glial cells, astrocytes, and microglia, are thought to play 
different roles in the survival of neurons. Astrocytes, the most numerous cell type in the 
CNS, have a role in maintaining brain homeostasis and the blood brain barrier, 
responding to brain damage, and producing neurotrophic factors. Microglia, the resident 
mononuclear phagocytic cells in the CNS, are present in a resting state but become 
activated following trauma or metabolic insult. They play a key role as the initial line of 
defense in the CNS, producing proinflammatory cytokines such as tumor necrosis factor 
alpha (TNF-α), interleukin beta (IL-1β), and interferon gamma (IFN-γ) (125).  
 
 The increased number of activated microglia and enhanced levels of pro-
inflammatory mediators such as IL-1β, IL-6, TNF-α, inducible nitric oxide synthase 
(iNOS), and cyclooxygenase-2 (COX-2) have been detected in the cerebrospinal fluid 
(CSF) and the brain parenchyma of idiopathic PD patients (126-130). In addition, the 
postmortem study of MPTP-intoxicated PD patients reveal that gliosis and clustering of 
microglial cells existed decades after the initial intoxication (131). Epidemiological 
studies also support this notion, demonstrating that chronic non-steroid-anti-
inflammation-drug (NSAID) users have lower PD incidence than non regular users (132-
134). However, when and how neuroinflammation occurs in PD is still largely unknown. 
 
 
1.6 Treatment of PD 
 
 
1.6.1 Pharmacological treatments 
  
 Levodopa, a precursor molecule in DA synthesis, was first introduced for human 
use in the late 1960’s (135) and has been the main treatment for PD for more than 40 
years (136). Unlike dopamine, L-dopa can cross the blood brain barrier freely, be 
transported into the dopaminergic neuron through amino acid transporter systems, and be 
converted to dopamine by dopa-decarboxylase (137). A peripheral dopa decarboxylase 
inhibitor (DDC) and catechol-O-methyltransferase (COMT) are often co-administered to 
prolong the peripheral half life of levodopa, and increase it’s availability in the CNS 
(138). So far, L-dopa, used in conjunction with a peripheral dopa decarboxylase inhibitor, 
has been shown to be the most effective way to relieve symptoms in the early and mid-
stages of PD (139). 
 
 About 40-75% of patients who have had 4-6 years of levodopa therapy develop 
side effects, such as motor fluctuations and dyskinesias (140, 141). Fluctuations in motor 
performance are thought to be outcomes of the rise and fall of L-dopa levels in plasma 
following each daily dose (142). The progressive loss of dopaminergic neurons results in 
a reduction in the storage capacity of dopamine terminals. Consequently, dopamine levels 
in the synapse readily reflect the levodopa levels in plasma and motor fluctuations 
become worse (143). Dyskinesias, and choreic or dystonic involuntary movements are 
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also correlated with prolonged L-dopa treatment. The exact mechanism underlying 
dyskinesias is not fully understood. However, it is generally accepted that the pulsatile 
stimulation caused by fluctuating and discontinuing levels of L-dopa in the brain may 
affect the output of the basal ganglia and induce dyskinesias (144) 
 
 The dopamine agonists, including bromocriptine, pergolide, pramipexole, 
ropinirole, lisuride, and cabergoline have been used singly or in combination with L-
dopa. In contrast to L-dopa, dopamine agonists alone less provoke the motor side effects 
in de novo patients. However, it can cause non-motor side effects such as gastrointestinal 
disorders, sleep attack, and impulsive control disorder (145). 
 
 Selegiline and rasagiline, potent type B monoamine oxidase (MAO-B) inhibitors, 
have been used to treat PD since the 1970s (146). Although they are less effective than 
either L-dopa or dopamine agonists, they are well tolerated and are able to delay or 
reduce dopaminergic treatment by increasing the cerebral level of dopamine (147). 
 
 
1.6.2 Surgical treatments and deep brain stimulation 
 
 Pallidotomy and thalamotomy were performed before L-dopa was developed as a 
drug therapy. In these procedures, small lesions are made in the globus pallidus or the 
ventrolateral thalamus to relieve PD related tremors or rigidity, respectively. Although 
such surgical procedures provided substantial improvements in PD symptoms, they often 
resulted in cognitive impairment and other side effects (148). 
 
 Deep brain stimulation (DBS) was introduced as a substitute to thalamic lesioning 
by Benabid et al. in 1987. An electrode, connected to a programmable pulse generator, is 
placed in, and permanently stimulates the target areas, either Gpi or STN. DBS is very 
effective in reducing motor fluctuation and dyskinesias in advanced PD, although it has 
some potential to provoke neuropsychological dysfunction (149).  
 
 
1.6.3 Human mesencephalic tissue transplantation 
 
 The first clinical trial of transplantation of human fetal ventral mesencephalic 
(VM) tissue into PD patients was performed in the 1980s. VM tissues were derived from 
6 -9 week old human embryos and placed on either one or both sides of the striatum (150, 
151). Patients who had VM tissue implanted showed substantial improvement in the 
Unified Parkinson's Disease Rating Scale (UPDRS) and the activities of daily life (ADL) 
scale, represented by increased fluorodopa uptake on PET scan, as well as normal DA 
release (152). Furthermore, postmortem pathology studies at 18 months after 
transplantation revealed that the grafted DA neurons survived well and reinnervated the 
host striatum (153). Subsequently, there have been two double blind, placebo controlled 
clinical trials conducted, however, these failed to recapitulate previous results. Compared 
to the sham control groups, the patient receiving transplants showed little or no 
improvement in the UPDRS, despite increased fluorodopa uptake seen in PET scanning. 
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Graft-induced dyskinesias have occurred in approximately 50% of the grafted patients 
within 6-12 months (154). 
 
 Do dopaminergic grafts follow the host PD related pathology? Postmortem 
studies in four patients who died 11-16 years after surgery showed that the grafted 
neurons had α-synuclein positive Lewy bodies and Lewy neurites. However, no Lewy 
bodies and Lewy neurites were found in grafted tissue in the patients who died 4 to 9 
years after surgery. These data suggest that at least a decade is needed to develop LB 
pathology in the grafted tissue (155). 
 
 
1.7 Animal Models for PD  
 
 The key features of PD are progressive neurodegeneration of dopaminergic 
neurons in the SN and motor symptoms such as tremors and bradykinesia. During the last 
few decades, many investigators have aimed to generate animal models that recapitulate 
at least some of the cardinal symptoms of PD. Two approaches, based on either genetic 
manipulation or neurotoxins, are being used to develop a PD model in animals.  
 
 
1.7.1 Genetic model 
 
 1.7.1.1 α-synuclein 
 
 A lot of attention has been focused on the α-synuclein gene, because α-synuclein 
is a major component of LB, and Ala53Thr, Ala30Pro, and Glu46Lys mutations have 
been identified as causative in dominantly or recessively inherited familial PD (95). The 
first transgenic mouse model that over-expressed wild type human α-synuclein showed α-
synuclein positive neuronal inclusions in the SN, neocortex, and hippocampus. Despite 
the degeneration of nerve terminals in the striatum, no obvious loss of DA neurons has 
been found in the SN of these mice (156). 
 
 To determine the effect of α-synuclein defects in dopaminergic neurons, wild 
type, A53T, and A30P α-synuclein mutant mice were used to target α-synuclein 
overexpression or mutation in cells expressing tyrosine hydroxylase (TH). Mice with a 
single gene mutation failed to recapitulate DA cell loss and did not display synuclein 
pathology. Mice with double mutations (A30P/A53T) in the human form of α-synuclein 
exhibited a progressive loss of dopaminergic neurons in the SN with decreased motor 
activity. However, the pathological relevance is controversial since the double mutation 
of α-synuclein protein has not been found in human familial PD (157). 
 
 The first conditional transgenic mouse in which the expression of α-synuclein was 
regulated by the tetracycline system, has been established by Nuber et al. These mice 
showed a modest loss of dopaminergic neurons in the SN without any synuclein-positive 
inclusions. In addition, they showed reduced neurogenesis and neurodegeneration in the 
hippocampus without fibrillary inclusions. When α-synuclein gene expression is turned 
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off, the progression of PD-like phenotypes is alleviated, but not reversed, indicating that 
continuous expression of the α-synuclein gene is necessary for disease progression (158). 
 
 Unlike the mouse model, α-synuclein overexpression in Drosophila showed a 
stronger PD-like phenotype. Over-expression of mutant (A53T and A30P) or wild type α-
synuclein in flies resulted in a progressive loss of dopaminergic neurons in the 
dorsomedial clusters and correlated with a loss of climbing ability. In addition, α-
synuclein positive inclusions were observed in dopaminergic neurons (159). 
 
 1.7.1.2 Leucine-rich repeat kinase (LRRK) 2 
 
 The leucine-rich repeat kinase (LRRK) 2 gene contains 51 exons and encodes a 
large protein composed of 2527 amino acids. RNA expression occurs predominantly in 
the basal ganglia and the hippocampus. The protein encoded by the LRRK2 gene 
includes several independent domains including a leucine-rich repeat (LRR) domain, a 
kinase domain, a Roc GTPase domain and a C-terminal WD40 domain (160).  
  
 Mutations in LRRK2 have been recognized in approximately 7% of familial PD 
cases as well as 1-3% of idiopathic PD cases. So far, at least 20 polymorphic loci in the 
LRRK2 gene have been identified and linked to familial PD. Among them, the G2019S 
missense mutation is the most common, accounting for up to 6% of familial cases in 
Europe (161). Unlike other PD-associated genes, the LRRK2 G2019 mutation gives rise 
to late-onset PD which has a clinically similar phenotype to idiopathic PD. However, the 
exact mechanism by which the LRRK2 mutation induces the disease is unknown (162). 
 
 In Drosophila models, over expression of either wild type or G2019S mutated 
LRRK2 causes adult-onset dopaminergic neuron degeneration, accompanied by 
decreased motor activity that is alleviated by L-DOPA treatment. In contrast to this, 
transgenic flies that overexpress R144C mutated LRRK showed no difference in the 
number of DA neurons. Y1699C or I2020T mutant flies, however, display a significant 
loss of DA neurons in the dorsomedial protocerebral posterior lateral (PPL1) cluster and 
the dorsolateral protocerebral posterior medial (PPM1/2) clusters at the age of 60 days, 
but not at 10 days old, suggesting that the neurotoxicity of the LRRK2 mutant requires a 
certain amount of time to be manifested (163) 
 
 1.7.1.3 Parkin  
 
 Mutations in parkin, a component of E3 ubiquitin ligase encoded by the PARK2 
gene, is identified as the cause of autosomal recessive juvenile parkinsonism (ARJP) in 
humans (164). It is assumed that the loss of parkin function may impair the ubiquitin-
proteasome system and subsequently cause the neurotoxic accumulation of its substrates. 
Indeed, many substrates of parkin such as CDCrel (septin 5), Cyclin E, and far upstream 
element-binding protein-1 (FBP-1) were found accumulated in the brain of parkin 
associated PD patients, even though the DA neuron specific substrates have not been 
reported (162). 
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 Parkin null mutant mice have been generated by several independent groups. 
However, none of these transgenic mice exhibited typical PD pathologies. In addition, the 
accumulation of Parkin substrates was not detected in the brain (162). In the fly model, 
the parkin null mutation results in a significant and progressive loss of DA neurons in the 
protocerebral posterior lateral-1 (PPL-1) cluster. Moreover, the neurodegenerative 
phenotype of parkin mutants is more severe when combined with loss-of-function 
mutations of glutathione S-transferase S1 (GstS1), an important detoxification enzyme 
that reduces oxidative stress. A subsequent study also revealed that overexpression of 
GstS1 suppresses DA neurodegeneration in the parkin mutant flies, suggesting that 
overexpression of GstS1 has potential therapeutic value in the treatment of PD (165). 
 
 
1.7.2 Neurotoxin models 
 
 Before the advent of genetic models, the majority of experimental PD studies 
relied on toxin based models. Toxin-based models recapitulate nigrostriatal 
neurodegeneration, however the degeneration process is often acute compared to 
idiopathic PD, which requires decades to develop in humans (12). 
 
 1.7.2.1 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 
 
 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) as a agent that could 
induce parkinsonism was discovered by investigation of  the “Frozen Addict” cases in 
1982. A home drug developer accidentally prepared MPTP as a byproduct during the 
process of making a heroin derivative, MPPP (1-methyl-4-phenyl-4-
propionoxypiperidine), and a group of drug addicts who self-administered MPTP 
developed severe acute parkinsonism (17). Further studies discovered that MPTP 
selectively induces nonreversible dopaminergic neuron death in the SN and depletion of 
DA in the striatum in those patients. MPTP, a lipophilic compound, can readily cross the 
blood-brain barrier. Once inside the brain, MPTP is converted into the toxic metabolite, 
MPP+ (1-methyl-4-phenylpyridinium) by monoamine oxidase B in glial cells. MPP+ is 
taken up by the dopamine transporter and accumulates in dopaminergic neurons in the 
SN. Once in the neuron, MPP+ inhibits complex I of electron transport chain in 
mitochondria and consequently produces oxidative damage, leading to cell death (12). 
 
 In primates, MPTP causes irreversible and severe parkinsonian symptoms which 
are not distinguishable from those of idiopathic PD. These include the degeneration of 
dopaminergic neurons in the substantia nigra, LB pathology, and motor symptoms which 
can be ameliorated with L-dopa or dopamine agonist (17). The main drawback of the 
primate MPTP model is that the disease progression is more rapid than that of idiopathic 
PD, which develops over a few decades (166).  
 
 Rodents show variable amounts of susceptibility to MPTP toxicity, which is 
dependent upon the species and strain of the animal. Rats are resistant and some strains of 
mice are susceptible to MPTP toxicity. The C57BL/6J strain is well known as the most 
sensitive strain to MPTP and largely used as a MPTP induced PD model (167). However, 
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little or no motor symptoms or LB pathology is observed after MPTP treatment in this 
strain (168). 
 
 1.7.2.2 6-Hydroxydopamine (OHDA) 
 
 6-Hydroxydopamine (OHDA) is the first chemical known to have neurotoxic 
effects on the catecholaminergic pathway. 6-OHDA can be directly injected either into 
the SN or striatum. Injection into the SN causes rapid DA cell death, while the striatal 
injection of 6-OHDA induces a slow retrograde degeneration of neurons in the SN. Once 
it is delivered, 6-OHDA is selectively accumulated in the SN neurons and presumably 
kills neurons by inducing free radical damage. Numerous species are sensitive to 6-
OHDA, including mice, cats, dogs, monkeys and rats, and a quantifiable motor deficit is 
present without LB pathology (166) 
 
 1.7.2.3 Rotenone 
 
 Rotenone was isolated from the roots and stems of several plants and has been 
used as a pesticide and fish poison. Highly lipophilic, rotenone easily penetrates the 
blood-brain barrier, accumulates in the mitochondria, and inhibits complex-I of the 
electron transport chain. Although complex-I in the mitochondria is evenly distributed 
throughout cells in the brain, only the dopamine neurons in the SN selectively degenerate 
with exposure to rotenone. This suggests that the dopamine neurons in the SN are 
particularly sensitive to rotenone (169). 
 
 In the rat, in addition to inducing the loss of SN DA neurons, rotenone induces 
formation of LB, which have not been noted in either the 6-OHDA or MPTP models. 
Chronic, intravenous administration of rotenone produces PD-like motor symptoms, such 
as bradykinesia, postural instability, and tremors. These symptoms improve with 
administration of L-dopa or dopamine agonist treatments (169). 
 
 However, the rotenone model does pose several disadvantages. First, PD-like 
pathology induced by rotenone is variable, depending on the protocol of administration of 
rotenone. Second, the association between PD-like motor symptoms and the loss of 
dopaminergic neurons has not been fully confirmed in the rotenone model. These motor 
changes may also be caused by the abnormalities arising in the cardiac system, stomach, 
and liver that are seen in the rotenone model (170).  
 
 1.7.2.4 Paraquat and maneb 
 
 Paraquat is a herbicide widely used throughout the world. Investigators are 
interested in paraquat, because not only does it share structural similarities with MPP+, 
the toxic form of MPTP, but also provides an etiological link to PD in epidemiological 
studies (20). Paraquat is reduced by several reductases, including mitochondrial complex 
I, and becomes a PQ monovalent cation (PQ+). Subsequently, PQ free radicals are 
rapidly oxidized by oxygen and produce superoxide radicals and reactive oxygen species 
that are toxic to the cell (20). Paraquat produces a dose dependent loss of dopaminergic 
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neurons in the SN and a decrease in tyrosine hydroxylase immunoreactivity in the 
striatum (171). The up-regulation and aggregation of α- synuclein is also observed in the 
rodent PQ model (171). 
 
 Maneb is an agricultural fungicide. The mechanism of maneb toxicity is not clear, 
however, it is hypothesized that maneb crosses the blood brain barrier and inhibits 
mitochondrial complex III (172). There is a report that chronic exposure to maneb causes 
PD-like symptoms in humans (173). In a mouse model, maneb showed a synergistic 
effect on nigrostriatal degeneration when it was co-administered with paraquat. The loss 
of DA fibers and the turnover rate of DA and DOPAC were greater with exposure to both 
toxins than to either toxin administered alone (174, 175). This study lends support to the 
theory that a combination of environmental toxins may have synergistic effects on the 
development of PD (170) 
 
 
1.8 Viral-Induced Parkinsonism 
 
 
1.8.1 Influenza virus  
 
 Neurological symptoms associated with influenza have been reported as far back 
as 1385 and intermittent outbreaks with similar symptoms have occurred at other times 
during influenza outbreaks (176, 177). The Influenza virus has also been implicated as 
both a direct and an indirect cause of Parkinson’s disease, based on clinical descriptions 
and epidemiological studies (42, 178-182). 
 
 Influenza viruses are negative sense, single-strand RNA viruses. Influenza viruses 
belong to the family of Orthomyxoviridae which comprises influenza A, B, C, Isavirus 
and Thogotovirus, based on differences in their nucleoprotein (NP) and matrix protein 
(M) (183). Influenza A and B viruses are highly contagious pathogens that cause mild to 
severe infections in humans. Two glycoproteins, the haemagglutinin (H or HA) and 
neuraminidase (N or NA), determine the antigenicity of influenza A and B. Further, 
Influenza A virus is clustered into sixteen H (H1-H16) and nine N(N1-N9) subtypes, 
based on antigenic analysis of the HA and NA genes (184). 
 
 Most influenza viruses attack the mucosa of the respiratory tract and are 
transmitted into the respiratory epithelial cells, as well as other types of cells. Replication 
is very fast and can occur within 6 hours after infection. Clinical symptoms include acute 
onset of fever, myalgias, and respiratory symptoms (185, 186). However, in severe cases, 
influenza infection may result in primary viral pneumonia, secondary bacterial 
pneumonia, or complications involving the central nervous system (182, 187-189). 
 
 1.8.1.1 Viral structure  
 
 Influenza viruses have pleomorphic shapes with an average diameter of 120nm. 
Eight RNA gene segments of influenza A encode three polymerase complexes 
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(Polymerase B1, B2 and A protein), two surface glycoproteins (HA, NA), and other 
associated proteins including nucleoprotein (NP), matrix proteins (M1, M2), and non-
structural protein (NS). These gene segments are encapsulated by nucleoprotein (NP) 
(Fig 1.2) (184). 
 
 Haemagglutinin, a 76 kDa glycoprotein, is composed of homotrimers. Each 
subunit spans and protrudes from the envelope membrane and is presented on the outer 
surface, serving as the major surface antigen of influenza virus recognized by 
neutralizing antibodies (190). The precursor polypeptide HA0 is synthesized and cleaved 
by host originated trypsin-like protease into two subunits, HA1 and HA2 (191). The head 
of HA1 contains the receptor binding site and binds to either alpha 2-3 or 2-6 linked sialic 
acid on the host cell surface, depending on the amino acid sequence in the binding 
pocket. The amino terminus of HA2 is very important for viral-cell membrane fusion. 
The cleavage of HA0 is a prerequisite for virus infectivity and is dependent upon the 
presence of host-originated protease. Therefore, the distribution of proteases in the tissue 
and the ability to cleave viral HA by the proteases are the main determinants of 
pathogenicity of influenza virus (191, 192).  
 
 Neuraminidase is a homotetramer and each monomer contains an enzymatically 
active globular head domain and a membrane linked stalk domain. NA cleaves the 
linkage between a terminal sialic acid and a D-galactose or D-galactosamine residue and 
has an essential role in releasing progeny viral particles from the infected cells (193, 
194).  
 
 Matrix proteins, M1 and M2 are encoded by the M gene. M1 protein interacts 
with the cytosolic domain of HA, NA, and M2 protein and forms a layer to separate the 
ribonucleoprotein (RNP) complexes from the viral membrane, providing rigidity to the 
membrane (195). The M1 protein is also reported to regulate viral RNP nuclear transport 
(196). M2, a splice variant of M mRNA, is an integral membrane protein and displays ion 
channel activity for the regulation of pH. This function of the M2 protein acidifies the 
interior of the viral particle and induces dislocation of RNP from M1 proteins and ejects 
RNP into the cytoplasm (196). 
 
 Basic polymerase 2 (PB2), basic polymerase 1 (PB1), and acidic polymerase 
protein (PA) are encoded by segments 1, 2, and 3, respectively. These polymerase 
proteins interact with nucleoprotein (NP) and form a polymerase complex for viral 
transcription and replication (184). PB2 is targeted to the nucleus of the infecting cell by 
its nuclear localization signal. PB2 binds the 5’ cap structure of viral mRNA and 
generates cap primers to initiate viral mRNA synthesis. PB1 also contains nuclear 
localization signals and is transported into the host nucleus. PB1 plays an important role 
in the assembly of the polymerase complex and the polymerization of RNA (197). Like 
PB1 and PB2, PA provides a nuclear localization signal and is packed into the nucleus of 
the infected cell. PA is thought to be involved in viral transcription and replication, but 
the exact function of PA is not fully understood (184). 
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Figure 1.2 Structure of Influenza Virus 
 
HA: Haemagglutinin, NA: Neuraminidase, M1: Matrix proteins 1, M2: Matrix proteins 2, 
PB1: Basic polymerase 1, PB2: Basic polymerase 2, PA: Acidic polymerase protein, NP: 
nucleoprotein, NS: Non structural protein. 
 
Source: Reprinted with permission from Elsevier. Robert G. Webster. The importance of 
animal influenza for human disease. Vaccine 20, S16–S2012, (2002) (198). 
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 Nucleoprotein (NP), a phosphorylated basic protein, contains an RNA-binding 
domain in the amino terminus and binds to the backbone of the viral RNA. It has been 
suggested that NP switches viral RNA polymerase from transcription to replication based 
on the observation that a temperature sensitive mutant of NP synthesizes only mRNA, but 
not complementary RNA (cRNA), at the nonpermissive temperature. NP is also thought 
to be involved in nuclear transportation of viral RNA at an early phase of viral infection 
(184, 199). 
 
 Non-structural protein (NS) 1 is derived from segment 8 of the influenza A virus, 
while NS2 is encoded by the spliced mRNA of segment 8. NS1 is the only known 
nonstructural protein at this time. It functions to inhibit splicing and nuclear export of 
cellular mRNA, and to enhance viral protein expression by binding to cellular RNA and 
viral RNA (184). Recently it has been reported that NS1 protein of A/HK/483/97(H5N1) 
makes the virus less susceptible to the antiviral proteins, interferon, and tumor necrosis 
factor alpha (200). NS2 is incorporated in viral particles. NS2 carries nuclear export 
signals and has an essential role when the progeny viral RNPs are exported from the 
nucleus to the cytoplasm of the infected cell (201). 
 
 1.8.1.2 Life cycle of the influenza A virus 
 
 The life cycle of the influenza A virus is initiated by the binding of HA to the 
sialic acid receptor on the host cell surface. The sialic acid linkage to galactose by α2-3 or 
α2-6 is the main factor that determines host specificity (202). The virus enters the host 
cell by clathrin-coated receptor mediated endocytosis and the vesicle harboring the whole 
virus then fuses with endosomes. The acidic environment of the endosome triggers a 
conformational change of HA, allowing the fusion of HA with the vesicular membrane. 
The proton influx mediated by the M2 ion channel induces dissociation of the M1 from 
the vRNP, resulting in uncoating of the virus. The viral RNPs are translocated to the host 
cell nucleus where transcription and replication occur (202). 
 
 vRNAs serve as templates for both cRNA and mRNA. PB2 polymerase 
recognizes and binds to the 5’end of host mRNA and cleaves it 10-15 nucleotides away 
from the cap structure. The viral polymerase complex uses the cleaved cap structure as 
primers for viral mRNA transcription (203). Viral mRNA that is capped and 
polyadenylated is then exported to the cytoplasm. The mRNAs encoding viral membrane 
proteins such as HA, NA, and M2 are translated by ribosomes in the rough endoplasmic 
reticulum. Subsequently, these proteins pass to the secretory pathway at the trans-Golgi 
for glycosylation, then move to the host cell surface and are incorporated into the host 
cell membrane (202). The mRNAs encoding the other proteins, PB2, PB1, PA, NP, NS1, 
and NS2 are translated by free ribosomes in the cytosol. PB2, PB1, PA, and NP are then 
transported back into the nucleus and initiate complementary RNA (cRNA) transcription 
using vRNAs as templates. As a full length copy of the vRNA, cRNA serves as a 
template for the synthesis of progeny virus genomes and newly synthesized progeny 
vRNA forms vRNP binding proteins. M1 proteins, which contain nuclear localization 
domains, then bind to vRNP and promote the nuclear export of vRNPs. NS2 protein is 
thought to be involved in enhancing the function of M1 protein. 
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 vRNPs are transported into the cell membrane where the envelope proteins are 
located and are composed of viral particles. When newly assembled virus particles bud 
off from the host cell membrane, NA cleaves the sialic acid receptors on the host cell and 
allows virus particles to leave the host cell (202) (Fig 1.3). 
 
 
1.8.2 Previous human influenza pandemics 
 
 Influenza A viruses were the etiological agents of a number of pandemics in the 
last century including the 1918 H1N1 pandemic, the 1957 H2N2 pandemic, and the 1968 
H3N2 pandemic. The 1918 flu pandemic, the most catastrophic pandemic, infected 500 
million people, which was about 20-40% of the total world population at that time. 
Twenty to forty million people died with acute influenza symptoms in that single year 
(204). The impact was so profound that it reduced the average life expectancy in the USA 
by over 10 years, and of the reduction of the population was also thought to affect the end 
of the First World War (204).  
 
 
1.8.3 Von Economo’s disease and postencephalic parkinsonism 
 
 There is a large body of evidence that influenza can directly lead to encephalitis 
(178, 182, 188, 205-212). However, the link with Parkinson’s disease is somewhat 
controversial. Much of the linkage of parkinsonism with influenza and many other 
viruses stems from an outbreak of encephalitis lethargica (EL), also known as von 
Economo’s disease, and the postencephalic parkinsonism that occurred subsequent to the 
1918 pandemic influenza outbreak caused by type A H1N1 influenza virus (213). It is 
thought that at least 500,000 cases of EL occurred from 1917 until 1940 (39).  
 
 Von Economo discussed the etiology of what he observed and ruled out external 
sources such as bad sausages (wurstvergiftung) and due to the timing around WWI, 
poison gas (gasvergiftung). He also ruled out meningitis and polio due to the fact that the 
patients he saw had no contact with each other, each of these diseases were independent, 
and no evidence of epidemics occurred as was usually seen with these two diseases.  He 
did discuss the possibility of this being related to “grippe” which was another name for 
influenza. Because his cases, as well as a few others (Cruchet described a similar 
outbreak of “sleeping sickness” in a number of French soldiers) (214), occurred prior to 
the major outbreak of pandemic influenza, von Economo ultimately concluded that what 
he saw was a separate disorder from direct influenza infection. However, he was not able 
to rule out influenza as a prodromal disease. Further studies of this disease have 
described 28 specific subtypes of von Economo’s encephalitis. Of these subtypes, only 
three will be relevant should another influenza pandemic occur.  These three subtypes are 
the somnolent-opthalmoplegic type, the parkinsonian type, and the juvenile 
pseudopsychopathia type (215). The second type is most related to PD. The features of 
postencephalic parkinsonism (PEP) have both shared and distinct symptomatology to 
idiopathic Parkinson’s disease. Similarities include many of the classic motor symptoms 
including bradykinesia, tremors, and some parkinsonian “mask-like” features such as  
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 M1, Matrix protein 1  M2, Matrix protein 2 
 HA, Hemagglutinin  vRNP, Viral ribonucleoprotein 
 NA, Neuraminidase  NP, Nucleoprotein 
 
 
Figure 1.3 Life cycle of influenza virus  
 
Source: Reprinted with permission from Bao Y., P. Bolotov, D. Dernovoy, B. Kiryutin, 
L. Zaslavsky, T. Tatusova, J. Ostell, and D. Lipman. The Influenza Virus Resource at the 
National Center for Biotechnology Information. J. Virol 82(2), 596-601 (2008)(216). 
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ptosis, while differences can include facial twitching, myoclonus, catatonia, mutism, the 
lack of Lewy bodies, and the presence of neurofibrillary tangles that are common to 
Alzheimer’s disease (215). 
 
 Most PEP cases occurred within 6 months to 1 year following an episode of acute 
EL while others developed parkinsonian symptoms after the passage of decades (217). At 
least 50% of PEP patients had a clinical history of acute EL (218). Epidemiological 
studies of PEP patients showed that PEP had a single etiology related to viral infections 
around the 1920s. In addition, individuals who were born between 1892 and 1929, a 
period of Spanish flu pandemic, had a higher incidence of PD later in life (219, 220). 
These pieces of evidence suggest a possible link between PEP and the 1918 flu 
pandemic. 
 
 A causal link between PEP and the 1918 flu pandemic, however, has never been 
fully demonstrated and remains controversial. It has also been shown that several type A 
influenza viruses, travel into the nervous system following systemic infection 
(neurotropism) (180, 221, 222).  Related to the finding of H1N1 neurovirulence, 
immunofluorescent staining against antigens from two type A influenza strains have been 
found in the brain of a number of EL patients, suggesting that at some time, a 
neurovirulent form of influenza was present in the brain (36). However, influenza RNA 
fragments were not found in the archival brain autopsy samples of EL and PEP patients, 
suggesting that 1918 influenza virus was either not neurotropic or the direct cause of EL 
(223). In addition, the levels of anti-influenza A antibody in the serum or CSF of PD 
patients was not significantly different from that of age matched controls (224). 
 
 As suggested by Vilensky’s writings in a report for the Sophie Cameron Trust 
(207), proving a negative in this case is difficult. The lack of recovery of viral RNA from 
EL or PEP patients is not surprising. First, and especially in the case of PEP patients, the 
time from infection to symptoms was many years and the viral infection would have been 
transient.  In addition, it has been shown in many cases of encephalitis as well as toxin 
induced parkinsonism that the offending agent may cause a long lasting immune response 
in the brain that persists many years after the insult has resolved, leading to a “hit and 
run” mechanism where the original insult is no longer present, but the secondary sequelae 
persists (225). 
 
 
1.8.4 Other viruses 
 
 1.8.4.1 Coxsackie virus 
 
 The Coxsackie virus was first isolated from human feces in the town of 
Coxsackie, New York, in 1948 by G. Dalldorf (226, 227). The Coxsackie virus is a 
member of the Picornaviridae family of viruses in the genus termed Enterovirus. 
According to the Center for Disease Prevention and Control, there are 66 serotypes of 
enterovirus and these include 3 polioviruses. Coxsackie viruses are RNA viruses that 
primarily affect children and young adults (228). Infection with Coxsakie virus can easily 
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be passed from person to person and been associated with a number of diseases, 
including meningitis (229), myocarditis (230), and pericarditis (231). 
 
 Acute parkinsonism has been noted after infection with Coxsackie virus (48, 49), 
although an association with traditional adult-onset idiopathic Parkinson’s disease has 
never been established.  As with the influenza virus, it is possible that early infection with 
the Coxsackie virus can induce a long lived activation of glial cells that would predispose 
the subject to succumb to oxidative insult much later in life (230). 
 
 1.8.4.2 Japanese encephalitis B, St. Louis and West Nile viruses 
 
 Japanese encephalitis B (JEBV), St. Louis, and West Nile virus are single strand 
DNA viruses that are transmitted by the bite of culicine mosquitoes (232-234). Although 
infection with these three viruses are often resolved prior to any CNS involvement, on 
rare occasion, these viruses can lead to encephalitis (235). In fact, JEBV is the most 
common cause of encephalitis in Asia (236). If infection does involve the CNS, the 
regions of the brain noted to become involved include the thalamus, basal ganglia, brain 
stem, cerebellum, hippocampus, and cerebral cortex (237-239). Ogata et al 
experimentally infected Fisher rats with JEBV and noted a marked gliosis in the SNpc, in 
a pattern typical of the lesions seen in Parkinson’s disease (64). Behaviorally the rats 
exhibited bradykinesia that was reversed with administration of L-DOPA and a MAO 
inhibitor, suggesting that the virus had the ability to directly induce one of the cardinal 
symptoms of Parkinson’s disease. 
 
 Parkinsonism secondary to St. Louis encephalitis has also been described. Like 
JEBV, this virus primarily affects children and the aged, although numerous cases of 
infection and secondary parkinsonism have been reported in all age groups. Pranzatelli et 
al reported a number of cases of secondary parkinsonism in children, one of which 
appeared to be the result of active St. Louis encephalopathy (68). In this case, the patient 
had features of moderate parkinsonism (The Unified Parkinson's Disease Rating Scale 
score of 92 and The Modified Hoen and Yahr staging of 5) with predominant symptoms 
of dysphasia and dystonic posture. The parkinsonism symptoms did not progress and 
resolved after a few months. During the clinical course of the parkinsonism, an MRI 
revealed a slight enhancement of the basal ganglion. In the adult cases, each patient 
presented with involvement of the substantia nigra as determined by an MRI (67). The 
first patient was a 21-year-old male who presented with a 1-week history of fever and 
headache. Neurologic examination was normal, and an admitting diagnosis of aseptic 
meningitis was made. The symptoms progressed with new symptoms of fever, ataxia, 
nystagmus, and tremulousness. MRI imaging revealed a T2-weighted bilateral hyper 
intensity in the substantia nigra without enhancement. In a second case, a 37-year-old 
male with a history of paranoid schizophrenia and seizures presented with fever and 
confusion and was generally unresponsive to commands. Other symptoms included 
diffuse nuchal rigidity, generalized hypertonicity, and abnormal postures including flexed 
upper extremities, a bilateral Babinski response, and an absent gag reflex. Like the 
previous patient, MRI imaging showed an asymmetric T2-weighted non-enhanced hyper-
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intensity in the substantia nigra. Similar lesions have been reported in other cases of St. 
Louis encephalopathies. 
 
 1.8.4.3 Human immunodeficiency virus (HIV) 
 
 Human immunodeficiency virus (HIV, originally called HTLV) is a retrovirus 
that has been shown to be the cause of acquired immunodeficiency syndrome (AIDS) 
(240). Infection with HIV results in a failure of the immune system, leading to life-
threatening opportunistic infections. The underlying cellular lesion in HIV is a 
progressive loss of CD4+ T cells whose levels inversely correlated with the viral load. In 
addition to the loss of the peripheral immune system, one of the most commonly 
associated pathologies from HIV infection involves motor disturbances (241, 242).  The 
involvement of the CNS can occur quickly since HIV has been detected in the brain 
within two weeks of the initial infection (243). Once in the brain, HIV can infect the three 
major cell types: neurons, astrocytes, and microglia (244-246). Depending on the size of 
the study cohorts, it has been estimated that from 5-50% of all AIDS patients suffer from 
some sort of motor dysregulation including those seen in Parkinson’s disease such as 
bradykinesia, cogwheel rigidity, and tremors (242). These movement disorders result 
from both primary HIV infection and secondary opportunistic infections.  Primary HIV-
associated parkinsonism often appears within several months of the diagnosis of HIV 
infection (241) and its appearance portends a poor prognosis. Cerebral imaging (CT and 
MRI) of HIV-induced parkinsonism has shown lesions at various levels of the basal 
ganglia including calcifications throughout the basal ganglia, hypodense lesions of the 
striatum (247), putamen hypertrophy (248, 249) as well as intensifying lesions of the 
basal ganglia (250, 251) and midbrain (252). Functional imaging using [18F] 
fluorodeoxyglucose PET have shown that early CNS changes in AIDS involve thalamic 
and basal ganglia hyper metabolism while cortical and subcortical gray matter hypo 
metabolism was more characteristic of later CNS changes (253). 
 
 
1.9 Current H5N1 Influenza Panzootic 
 
 Currently, the highly pathogenic type A influenza virus (H5N1) is thought to be a 
pandemic threat. Although transmission from bird to human is rare, the outbreak of 
H5N1 virus in Hong Kong in 1997 demonstrated that direct transmission from bird to 
human without genetic reassortment was possible (254). So far, over 436 human cases 
with a fatality rate of approximately 50% have been reported (255). Because the H5N1 
influenza virus has never been associated with influenza outbreak in humans and there is 
no acquired immunity, and the chance of this becoming pandemic is great if the virus 
acquire the ability to transmit from human to human. The World Health Organization 
(WHO) warned that should H5N1 become pandemic in humans (255) there will likely be 
2 to 7.4 million deaths globally with 134–233 million outpatient visits and 1.5–5.2 
million hospital admissions. 
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1.9.1 Evidence of neurotropism 
 
 The highly pathogenic H5N1 influenza virus, which currently has pandemic 
potential, has been shown to be neurotropic (181, 221, 256)). Animal populations 
infected with H5N1 demonstrate clear motor effects that include abnormal postures, 
difficulty in maintaining an upright posture, and inability to initiate movement(181, 221, 
256). The onset of post-influenza encephalopathies are not limited to animals as there is 
one case report of human exposure to H5N1, a 4 year old boy and his 9 year old sister, 
both of whom presented with rapid encephalopathy followed by coma and death (207); 
its rapid course and lack of resources did not allow MRI studies to be performed. In 
addition to this one published case report, there are other reports of post-H5N1 influenza 
infection encephalitis, including a 67-year-old woman from Indonesia's West Java 
province who, in addition to her severe respiratory symptoms, developed encephalitis 
(257). 
 
 In a study examining neurovirulence in mice, Lipatov et al (181) examined 5 
influenza viruses isolated in Hong Kong in 2001, of which 4 were neurotropic 
(Ck/HK/YU822.2/01, Ph/HK/FY155/01, Ck/HK/FY150/01, Ck/HK/NT873.3/01) and 1 
was not (Ck/HK/YU562/01). This group did extensive sequence analysis of the viruses 
and found that there was not a common set of mutations that induced neurotropism, 
suggesting that there were different ways for these influenza viruses to become 
neurotropic. They found that multiple basic cleavage sites in the surface hemagglutinin 
proteins were necessary, but not sufficient, to make these viruses neurovirulent.  In 
addition, they also suggested that specific changes in polymerase proteins PB2 and PA, 
which are important in transcription and replication of viral RNAs (258), are also 
implicated in this process. Also, several studies have found that mutations in the Mx 
gene, which regulates GTPase activity (259, 260) and acts as an important downstream 
effector of interferon (261), also regulates Type A influenza neurotropism.  It is not 
known if there are any genetic differences that may confer resistance to the neurotropic 
behavior of H5N1 in mice (i.e. the animals can be systemically affected by virus, but be 
protected from nervous system involvement). 
 
 
1.9.2 The possible routes of entry into the central nervous system (CNS) 
 
 It has been demonstrated that the A/WSN/33 strain of influenza virus enters the 
CNS via the olfactory epithelium and nerve (CN 1) (262). It has also been hypothesized 
that it can enter the CNS through other cranial nerves, including the vagus and trigeminal 
nerves (263-266). These three nerves have processes that innervate visceral organs and 
tissues that would be the first contacted by an intranasal viral infection such as the 
olfactory epithelium (olfactory nerve, CN I), orofacial mucosa (trigeminal nerve, CN V) 
and digestive system (Vagus nerve, CN X). The basis of this hypothesis, which does not 
have any direct proof such as isolation of the virus from axons of these nerves, is two-
fold.  First, examination of the CNS following infection via intranasal routes shows that 
the virus is first seen in the regions innervated by these nerves.  Second, the virus can be 
detected (indirectly by the presence of immunohistochemical detection of viral nuclear 
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protein, anti NP) in the visceral ganglia (256, 266). One argument against this route of 
entry into the CNS is that the A/WSN/33 strain of influenza has an affinity for the 
substantia nigra, a neuronal population without any direct anatomical connection to the 
cranial nerve system (267). This suggests that the influenza virus may also enter into the 
CNS via different mechanisms of axonal transport such as through the ependymal cells 
lining of the ventricles and shedding into the CSF. Here, it can freely transmit through the 
whole neuraxis, through the blood and extravasation from penetrating capillaries in the 
brain or invasion into the CNS through attenuation of the blood-brain-barrier around the 
circumventricular organs. 
 
 
1.9.3 Scope and objective of dissertation 
 
 Preliminary data from our laboratory revealed that the H5N1 virus is neurotropic 
and infects multiple brain nuclei, including the substantia nigra pars compacta (SNpc). 
With the following specific aims, we determine if H5N1 viral infection can either directly 
or indirectly induce a parkinsonian pathology. 
 
 1.9.3.1 Specific aim 1 
 
 Determine the temporal and spatial localization of H5N1 influenza virus infection 
in the CNS after intranasal inoculation. The highly pathogenic H5N1 virus 
(A/VN/1203/04) will be administered intranasally to seven week old female C57BL/6J 
mice at doses of 102 EID50. Brains and spinal cords will be harvested at 1, 3, 7, 10, 21, 60 
and 90 days post-infection, frozen and serially sectioned. Immunostaining will be utilized 
to assess the time course of infection, map the temporal and spatial localization of the 
influenza virus, and to determine the route of viral infection into the CNS. 
 
 1.9.3.2 Specific aim 2 
 
 Determine if the highly pathogenic H5N1 influenza virus infection in the CNS 
results in pathological changes that lead to neurodegeneration and parkinsonian 
pathology. Seven week old female C57BL/6J mice will be exposed to the H5N1 virus 
(A/VN/1203/04) as described above. Brains and spinal cords will be harvested at 1, 3, 7, 
10, 21, 60 and 90 days post-infection. Samples will be processed for immunohisto-
chemistry. Immunostaining and western blot analysis will be performed to assess the 
extent of neurodegeneration and parkinsonian pathology.  
 
 1.9.3.3 Specific aim 3 
 
 Determine if the highly pathogenic H5N1 influenza virus infection affects the 
anatomy and pharmacology of the basal ganglia and other systems, known to be affected 
in Parkinson’s disease. Seven week old female C57BL/6J mice will be exposed to H5N1 
virus (A/VN/1203/04) as described above. The SNpc and striatum will be collected from 
at least 4 animals at the time points 1, 10, 21, 60 and 90 days post-infection. Using 
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stereology, the SNpc will be assessed to determine the number of tyrosine hydroxylase 
(TH) positive dopaminergic neurons. The striatal dopamine (DA), 3, 4-dihydroxyphen- 
ylacetic acid (DOPAC) and homovanillic acid (HVA) will be measured by high 
performance liquid chromatography (HPLC). 
 
 1.9.3.4 Specific aim 4 
 
 Determine if prior viral infection with H5N1 increases CNS vulnerability to the 
known parkinsonian toxin paraquat. Seven week old female C57BL/6J mice will be 
exposed to H5N1 virus (A/VN/1203/04) as described above. Mice surviving the viral 
challenge and age matched non-infected controls will be injected with paraquat (PQ) 
using low (5mg/kg) concentrations of paraquat hydrochloride, every 3rd day for 21 days, 
starting on day 60 after inoculation. Saline will be administered for control groups. The 
number of TH-positive dopaminergic neurons will be assessed by stereological methods. 
The amount of striatal DA, DOPAC, and HVA will be measured by HPLC. 
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CHAPTER 2. HIGHLY PATHOGENIC H5N1 INFLUENZA VIRUS CAN  
ENTER THE CENTRAL NERVOUS SYSTEM AND INDUCE 
NEUROINFLAMMATION AND NEURODEGENERATION* 
 
 
2.1 Introduction  
 
 At the time of initiation of this project, the greatest influenza pandemic threat was 
posed by the highly pathogenic H5N1 avian influenza virus. To date, 63% of the 436 
known human cases of H5N1 infection have proved fatal (255). Animals infected by 
H5N1 viruses have demonstrated acute neurological signs ranging from mild encephalitis 
to motor disturbances to coma (180, 268-270). However, no studies have examined the 
longer-term neurologic consequences of H5N1 infection. Using the C57BL/6J mouse, a 
strain that can be infected by the A/VN/1203/04 H5N1 virus without adaptation, we show 
that this virus travels from the peripheral nervous system into the CNS to higher levels of 
the neuroaxis. In regions infected by H5N1 virus, we observe activation of microglia and 
alpha-synuclein phosphorylation and aggregation that persists long after resolution of the 
infection. We also observe a significant, but temporal reduction of tyrosine hydroxylase 
positive dopaminergic neurons in the substantia nigra pars compacta, at 60 days post-
infection. Our results suggest that a pandemic H5N1 pathogen, or other neurotropic 
influenza virus, could initiate CNS disorders of protein aggregation including Parkinson’s 
diseases. 
 
 
2.2 Materials and Methods 
 
 All experimental infection of animals and handling of live H5N1 viruses were 
performed in a Biosafety level 3+ laboratory approved for use by the U.S. Department of 
Agriculture and exclusively utilized by the Division of Virology and other approved 
scientists at St. Jude Children’s Research Hospital for highly pathogenic avian influenza 
work. 
 
 
2.2.1 Virus stock preparation and inoculation of mice with H5N1 
 
 Stock viruses were prepared by propagating neurotropic A/VN/1203/04 (H5N1) 
influenza virus for one passage in the allantoic cavity of 10-days-old embryonated 
chicken eggs for 40 to 48 hours at 37˚C. Viral infectious titers were determined using the 
method of Reed and Muench (271), and expressed in log10 of the 50% egg infectious 
dose per 1.0 ml of fluid (EID50/mL). 
 
* Chapter 2 adapted with permission. Jang H, Boltz D, Sturm-Ramirez K, Shepherd KR, 
Jiao Y, Webster R, Smeyne RJ. Highly pathogenic H5N1 influenza virus can enter the 
central nervous system and induce neuroinflammation and neurodegeneration. Proc 
Natl Acad Sci 106 (33), 14063-8 (2009) (270). 
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6-8 week old C57BL/6J mice (Jackson Labs, Bar Harbor, ME) were anesthetized by 
isofluorane inhalation and infected intranasally with 30 µL of allantoic fluid diluted in 
PBS to the target virus infectious titer (102 EID50).  
 
 
2.2.2 Immunocytochemistry 
 
 1, 2, 3, 7, 10, 21, 60 and 90 days following intranasal inoculation of H5N1, mice 
were deeply anesthetized with Avertin and transcardially perfused with 0.9% saline 
followed by 10% neutral buffered formalin. Brains and visceral organs were removed and 
postfixed for 3 weeks in 10% neutral buffered formalin to ensure that virus particles 
present in the tissue have been killed. The tissue was subsequently cryoprotected in 30% 
sucrose/phosphate buffered saline (PBS), serially-sectioned at 20μm, and mounted onto 
polyionic slides (12-550, Superfrost-plus, Fisher, Pittsburgh, PA). H5N1 influenza virus 
was detected with a pool of four monoclonal antibodies raised against the nuclear protein 
(NP) of influenza virus A/WSN/33 (H1N1) (272). The monoclonal antibodies target four 
different antigenic epitopes of the NP protein and detect all known subtypes of influenza 
A viruses. Three different animals were used to determine the pattern of H5N1 influenza 
virus expression at each time point. H5N1 influenza virus location was mapped using 
images generated from an electronic atlas (273) and a CNS nucleus template (274). The 
volume of virus was scored in a semi-quantitative manner that has been detailed (274). 
 
 Antibodies directed against glial fibrillary acidic protein (GFAP) (rabbit, G4546, 
Sigma, St. Louis, MO, 1:500) were used to detect astrocytosis and antibodies directed 
against ionized calcium binding adaptor molecule -1 (Iba-1) (rabbit, 019-19741, Wako 
Chemicals, Richmond, VA, 1:500) was used to detect microgliosis (12). Activated 
caspase-3 (rabbit, 559565, BD Biosciences, San Jose, CA) and Fluoro Jade B (AG310, 
Chemicon, Temecula, CA) staining to mark apoptotic and necrotic cells, respectively, 
were examined as previously described (275). Antibodies directed against tyrosine 
hydroxylase (TH) (rabbit, P40101-0, PelFreeze, Rogers, AK, 1:500) were used to detect 
dopaminergic neurons. Alpha synuclein (mouse, 610786, BD Biosciences, San Jose, CA, 
1:1000) and pSer129 SYN (mouse, 014-20281 WAKO, Richmond, VA, 1:1000) 
immunocytochemistry were performed on frozen sections using standard protocols (12). 
Transmission electron microscopy was performed as previously described (276) 
 
 
2.2.3 Dorsal root ganglia (DRG) neuron culture and microfluidic chamber studies 
 
 Dissociated dorsal root ganglia (DRG) neurons were prepared as previously 
described (277). Briefly, DRG neurons were dissected from 6 to 8 weeks old female 
C57BL/6J mice and incubated in 60 units of papain (3126, Worthington, Freehold, NJ) 
/Hank’s balanced salt solution (HBSS) (14170, GIBCO, Carlsbad, CA) for 10min at 37˚C. 
Subsequently, 12mg of collagenase (4176, Worthington, Freehold, NJ) and 100μL of 
dispase (10269638001, Roche Diagnostics, Indianapolis, IN) were added and reacted 
with dissociated DRG neurons for 10min at 37˚C. The pellet was washed twice with 
F12/10% FBS medium (11765 GIBCO, Carlsbad, CA) to remove enzymes and given 
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0.5ml fresh medium. The ganglia were triturated 10 times using a fire-polished Pasteur 
pipette. 60,000 dissociated cells within 20 μL were plated into the somal compartment of 
microfluidic chambers (SND150, Xona Microfluidics LLC, Aliso Viejo, CA) (278) 
which is placed on a cover glass previously coated with laminin (L2020, Sigma, St. Louis, 
MO) and poly-D-Lysine (BD354210, BD Biosciences, San Jose, CA). After 30 minutes 
to allow cell attachment, cultures were rinsed and 150 microliters of fresh culture 
medium containing 10 ng/ml nerve growth factor (NGF 2.5s, N6009, Sigma, St. Louis, 
MO) was added to the process compartment of the microfluidic chamber. Cultures were 
maintained in a humidified 37˚C chamber with 5% CO2 for 12 days and the culture 
medium was changed every three days. 
 
 2 x 106 plaque-forming unit (PFU) of H5N1 (VN/1203/04) virus in 20 microliters 
serum free medium was loaded in the axonal side of the compartment. After one hour, the 
microfluidic axonal chamber was washed 2 times by adding 130 μL of serum free media 
to the top reservoir and collecting the flow through in the bottom reservoir. 130 μL of 
medium with serum was then added to the top and bottom reservoirs on the axonal side to 
maintain the hydrostatic balance. At the 1h, 24h, 48hr and 72hr after infection, cells were 
rinsed with 1X PBS twice and fixed by 4% paraformaldehyde for 10min followed by post 
fixation for 2 weeks to kill residual virus or viral particles. Virus was detected by 
immunohistochemical methods as described above. Antibodies directed against neuron-
specific β-III tubulin (rabbit, ab18207, Abcam, Cambridge, MA, 1:500) were used to 
label cell bodies and processes of DRG neurons. Images were captured by using a Leica 
SP1 upright laser scanning confocal microscope. 
 
 
2.2.4 Quantification of phosphorylated α-synuclein expression 
 
 To ensure consistency in this analysis, all sections were processed on the same 
day using the same solutions and antibody preparations, including lot numbers. 16μm 
coronal frozen sections were washed with 0.1M PBS. One set of sections were incubated 
with 10μg/mL proteinase K (25530, Invitrogen, Carlsbad, CA)/0.1M PBS solution for 
10min at room temperature, and another set of adjacent sections were washed with 0.1M 
PBS without proteinase K. These different methods specifically allow identification of 
insoluble versus soluble pSer129SYN, respectively (56). All sections were blocked with 
the Mouse-on-Mouse (M.O.M) blocking solution (PK-2200,Vector Laboratories, 
Burlingame, CA) for 1h and incubated overnight at 4˚C with anti-mouse phospho Ser129 
antibody (mouse, 014-20281,WAKO, Richmond, VA, 1:1000) diluted in M.O.M diluent 
solution. Sections were incubated with a biotinylated secondary antibody for 30min and 
then incubated with avidin-biotin complex (PK-6102,Vector Laboratories, Burlingame, 
CA) for 15min and washed 5 times with 0.1M PBST for 5min each and developed with 
3-3’ diaminobenzine (DAB) (D-5905, Sigma, St. Louis, MO) as the chromogen. Sections 
were rinsed with tap water and dehydrated, cleared and mounted with Permount (SP15-
500, Sigma, St. Louis, MO). Images were captured at 10x using the virtual slice program 
in the Microbrightfield system (Microbrightfield, Williston, VT) attached to an Olympus 
BX60 microscope. All images for analysis were taken at the same light intensity at one 
sitting to control for variations in bulb intensity and camera chip differences. All images 
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were saved as a .tif file and optical densities of the rostral hippocampus, olfactory bulb, 
locus coeruleus, solitary nucleus and cerebellum were obtained on raw images using the 
NIH image program (ImageJ, version 1.43, National Institute of Health, Bethesda, MD). 
The density of the background from each section was also obtained and subtracted from 
the region density to give a final number. Statistical analysis was performed using 
GraphPad statistical software (Prism, version 4.03, GraphPad Software, La Jolla, CA). 
 
 
2.2.5 Stereological assessment of SNpc dopaminergic neuron number 
  
 The total number of tyrosine hydroxylase positive neurons in both hemispheres of 
SNpc was estimated using the optical fractionator method (279) from Stereo Investigator 
(version 7.0, MicroBrightField, Colchester, VT). The broad outlines of the SNpc in both 
hemispheres were delineated at low power (4× magnification). An unbiased counting 
frames (60 × 60μm) placed at the intersections of a grid (frame size 200 × 200μm) were 
randomly superimposed on a video image of the contoured sections. Sections were 
examined under high power (100× magnification) objective lens on a BX51 microscope 
(Olympus, Center Valley, PA) with a MAC5000 motorized XYZ axis computer-
controlled stage and a CX9000 CCD video camera (MicroBrightField, Colchester, VT). 
TH-positive neurons were counted at the depth that their nucleus is focused, in each 
counting area. The reliability of the estimates were measured by calculation of the 
coefficient of error (279). Gundersen coefficients of error for m=1 were all less than or 
equal to 0.10. Statistical significance was calculated using a one-way ANOVA followed 
by Student-Newman-Keuls post hoc test (280).  
 
 
2.3 Results 
 
 
2.3.1 Body weight loss in H5N1 virus infected mice  
 
 We intranasally inoculated the highly pathogenic and neurotropic A/VN/1203/04 
(H5N1) virus to 163 6 to 8 week old C57BL/6J mice (Jackson Laboratories, Bar Harbor, 
ME) with the 102 egg infection dose (EID50) (281) and monitored the mortality (Fig 2-
1A) and the body weight loss of infected mice (Fig 2-1B). Approximately 60% of mice 
died between 9 and 13 days post infection, recording 60% morality rate which is close to 
that seen in human cases (Fig 2-1A). Six days post-infection (dpi), 88% of the mice 
demonstrated weight loss; by day 9 dpi, weight loss was greater than 10% of initial body 
weight. All of the infected animals that showed weight loss showed neurological signs 
including ataxia, tremor and hind leg paralysis. Approximately half of these animal’s 
symptoms became so severe that they had to be euthanized. The remainder showed 
milder neurological signs and recovered by day 21 post inoculation (Fig. 2-1B). 
 
 
 
B 
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Figure 2.1 Percent Survival and Body Weight Change in the Infected Animals 
 
About half of H5N1 infected C57BL/6J mice died between 9-12 days post infection, representing 60% of mortality rates (A). Among 
these populations, 14% of mice didn’t show any signs of infection with absence of body weight loss (Blue colored). 40% of mice 
showed around 10-20% of weight loss with or without neurological symptoms including hind leg paralysis, tremor, and lethargy 
around 10 days post infection and then gradually gained weights and recovered (Green colored). 48% of mice showed more than 20% 
body weight loss from the initial body weight, presenting neurological symptoms, including hind leg paralysis, tremor, and lethargy, 
and died around days 10-15 days post infection (B). Error bars represent the standard error of mean (s.e.m). 
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2.3.2 Spatial and temporal distribution of H5N1 virus 
 
 The neurological signs observed in the infected mice suggested involvement of 
several levels of the neuraxis. We mapped the progression of the H5N1 virus through the 
nervous system by using immunohistochemical detection of the H5N1 nucleoprotein 
(NP) (Table 2.1). H5N1 virus was first detected on day 2-3 dpi in the myenteric 
(Auerbach’s) plexi of the enteric nervous system (Fig. 2.2A) and in neurons within the 
dorsal root ganglia (Fig. 2.2B) of the peripheral nervous system. H5N1 virus was first 
observed in the CNS on day 3 dpi in the brainstem solitary nucleus (Fig. 2.2C), which 
receives primary afferent signals from various visceral regions and organs, including lung 
and gut (282). On day 7 dpi, virus was found in the vagal and hypoglossal brainstem 
nuclei and in the midbrain locus coeruleus and SNpc (Fig, 2.2D). Outside of the 
brainstem and midbrain, H5N1 virus was detected in the periglomerular and mitral (Fig. 
2.2E) cells of the olfactory bulb and in neurons within the spinal cord (principally in the 
thoracic region) (Fig. 2.2F). On day 10 dpi, H5N1 infection had spread to all levels of the 
central neuraxis but did not involve all structures (Fig 2.3) (Fig 2.4). By day 21, the 
surviving animals displayed no visible neurological signs and H5N1 virus was not 
detected in the CNS. The pattern of infection in lung and brain suggested that active 
infection lasted approximately 10 days, as described in humans (207). 
 
 
2.3.3 Cell type specific H5N1 virus infection   
 
 In the CNS, the virus was detected in neurons (Fig. 2.2G) and microglia (Fig. 
2.2H) but was not seen in astrocytes (Fig. 2.2I). The presence of virus in brainstem 
neurons was supported by transmission electron microscopy, which revealed structures of 
the shape and size characteristic of H5N1 influenza virus (283) in the cytoplasm (Fig. 
2.2J) and nucleus. 
 
 
2.3.4 Retrograde transport of H5N1 virus in vitro 
 
 Our observation of H5N1 virus first in the enteric and peripheral nervous systems 
and then slightly later in the CNS, first in the solitary brainstem nucleus and subsequently 
in other brainstem nuclei (Table 1, Fig 2.1-4), suggests that the A/VN/1203/04 virus may 
enter the CNS via cranial nerves, a mechanism used by other strains of H5N1 (17, 18). 
This hypothesis was tested by using Microfluidic chambers that allow neuronal cell 
bodies and their processes to be grown in one compartment while their processes extend 
through 150-μm wide microgrooves into a separate process compartment (278). We 
added H5N1 virus to the process compartment for 1 hour and detected virus in the cell 
bodies (Fig. 2.5A) and their processes (Fig. 2.5B) within the following 24 hours. Because 
hydrostatic pressure differences between chambers would have confined extracellular 
virus to the process compartment, this finding showed that the virus detected in neuronal 
soma had been transported intracellularly. Direct exposure of cell bodies to H5N1 
influenza also resulted in infection (Fig. 2.5C). These results demonstrate that H5N1  
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Table 2.1 Semi-Quantitative Analysis of H5N1 Expression in the CNS and Lung 
 
Dpi Lung Ctx OB DRG of thoracic level Thal SNpc LC RN Vest n Pons Solitary n VII X XII 
1 + - - ND - - - - - - - - - - 
3 ++ - - + - - - - - - + - - - 
7 ++ - + ND - + + - + - ++ - ++ ++ 
10 + ++ ++ ++ ++ ++ ++ + ++ ++ +++ ++ ++ +++ 
21 - - - ND - - - - - - - - - - 
60 - - - ND - - - - - - - - - - 
90 - - - ND - - - - - - - - - - 
 
Semiquantitative immunohistochemical measurement of the percentage of anti-NP-positive cells at the indicated days post infection 
with H5N1 virus, +, 0%–33%; ++, 34%–67%; +++, 67–100%; -, none, ND, not determined; Ctx, cerebral cortex; OB, olfactory bulb; 
DRG, dorsal root ganglia; Thal, thalamus; SNpc, substantia nigra pars compacta; LC, locus coeruleus; RN, red nucleus; Vest n, 
vestibular nucleus; Solitary n, solitary nucleus; VII, facial nucleus; X, vagal nucleus; XII, hypoglossal nucleus. 
 
 
 
 
 
 
 
 
Figure 2.2 Localization of H5N1 Influenza Virus in the Nervous System 
 
(A), 3 days post-inoculation (dpi) with H5N1, the virus is detected in Auerbach’s plexus 
of the enteric nervous system (arrow) by using an antibody to the viral nucleoprotein 
(NP). (B), In the thoracic dorsal root ganglia, viral NP is first detected on day 3 dpi; by 
day 10 dpi, virtually all large and medium-sized neurons (arrows), but few small neurons, 
are NP-positive. (C), At day 3 dpi, NP protein (red) is first detected in the neurons (white 
arrows) of the brainstem solitary nucleus. Blue stain is DAPI. (D), At day 7 dpi, NP 
protein (green; arrows) is detected in dopaminergic neurons in the SNpc (red, anti-TH). 
(E), At day 7 dpi, NP protein (brown) is found in the periglomerular cells (arrows) and 
mitral cells (arrowheads) of the olfactory bulb. (F), At day 10 dpi, NP protein is found in 
the spinal cord, primarily at the thoracic level. High levels of NP are seen around 
Clarke’s column (arrow) and the intermediolateral cell column (arrowhead). (G), NP 
protein (red) is found in the nuclei of neurons in the brainstem (blue, DAPI; green, anti-
beta3-tubulin). (H), NP protein (red) is found in the nuclei and cytoplasm of microglia 
(blue, DAPI; green, anti-Iba-1; areas of colocalization are yellow). (I), NP protein (red; 
arrows) is not observed in astrocytes (green, anti-GFAP). (J), Transmission electron 
micrograph of a neuron in the brainstem shows a virus particle of the shape and size 
characteristic of H5N1 in the cytoplasm (arrow). The mitochondrion (arrowhead) shows 
relative size. (K), Transmission electron micrograph of an axon traversing the brainstem 
shows virus particles of the characteristic shape and size of H5N1 in the axoplasm 
(arrow). Arrowheads indicate the myelin sheath surrounding the axon. Scale bars 
(microns): A) 20, B) 50, C) 25, D) 45, E) 50, F) 200, G) 10, H) 6, I) 12, J) 0.200, K) 
0.120. 
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Figure 2.3 Localization of H5N1 Influenza Virus in Lung, Enteric Nervous System, 
Olfactory Bulb, and Brainstem 
 
H5N1 virus is detected in lung starting at 3 days post infection (dpi). (A), At day 7 dpi, 
the virus is detected in bronchi (black arrows) as well as around the alveolar sacs (red 
arrows). An enlargement of the box marked in (A) is seen in (B). (C), Virus is not 
detected in bronchi or alveoli of age matched control mice. (D), An, enlargement of box 
in (C). (E), At day 3 dpi, H5N1 virus is detected in the neuronal ganglia of the enteric 
nervous system (arrow). (F), An enlargement of the box in (E). (G), Virus is not detected 
in enteric ganglia of control mice. (H), An enlargement of box in (G). (I), At day 7 dpi, 
foci of H5N1 virus are detected in all layers of the olfactory bulb. (J), An enlargement of 
box in (I). (I), H5N1 virus is detected in foci spanning the granule cell layer (gcl) and 
mitral cell layer (mcl). (K), Virus is not detected in the olfactory bulb of control mice. 
(L), An enlargement of box in (K). H5N1 virus is detected in the nucleus of the solitary 
tract starting at day 3 dpi (M), At day 7 dpi, the virus is detected in this nucleus as well as 
its adjacent dorsal motor nucleus of the vagus nerve. An enlargement of the box marked 
in (M) is seen in (N). (O), Virus is not detected in nucleus of the solitary tract or dorsal 
motor nucleus of the vagus nerve of control mice. (P), An enlargement of box in (O). (Q), 
At day 7 dpi, H5N1 virus is detected throughout many brainstem nuclei. (R), An 
enlargement of box in (Q). (S), Virus is not detected brainstem of control mice. (T), An 
enlargement of box in (S). Scale bars: A and C, 100 μm; B, D, E, G, J, L, N and P, 25μm; 
F and H, 10μm; M, O, R and T, 50μm.  
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Figure 2.4 Localization of H5N1 Influenza Virus in Brainstem, Diencephalon, and Cortex  
 
(A), At day 10 dpi, H5N1 is detected in locus coeruleus. (B), An enlargement of the box 
marked in (A). (C), H5N1 virus is not detected locus coeruleus of control animals. (D), 
Enlargement of box in (C). (E), At day 10 dpi, H5N1 is detected in the substantia nigra 
pars compacta (arrow). (F), An enlargement of the box in (E). (G), Virus is not detected 
in substantia nigra of control animals. (H), An enlargement of box in (G). (I) At day 10 
dpi, H5N1 is seen in focal regions of the diencephalon. This foci is observed in the 
ventrolateral thalamic nuclei. (J) An enlargement of box in I. (K) Virus is not detected in 
the thalamus of control animals. (L) An enlargement of box in K. (M) At day 10 dpi, 
H5N1 is detected in the foci of the cerebral cortex. One foci in the primary motor cortex 
is shown. An enlargement of the box marked in (M) is seen in (N). (O) Virus is not 
detected in cerebral cortex in control mice. (P) An enlargement of box in (O). Scale bars: 
A, C, E, G, I, K, M and O, 250 μm; B, D, F, H, J, L, N and P, 50μm.
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Figure 2.5 Transport of H5N1 Virus through Axons in Microfluidic Chambers 
 
(A), A/Vietnam/1203/04 (H5N1) influenza virus (2 x 106 PFU suspended in 20 μL of 
serum-free medium) was added to the process compartments of microfluidic chambers 
containing freshly dissociated dorsal root ganglia (DRG) (55). After 1 hour, the process 
compartment was washed twice by adding 130 μL of serum-free medium to the top 
reservoir and collecting the flow-through in the bottom reservoir. 130 μL of medium 
containing serum was then added to the top and bottom reservoirs of the process 
compartments to maintain hydrostatic balance. Twenty-four hours after addition of H5N1 
virus to the process compartment (bottom), H5N1 NP is detected in neuronal bodies 
within the somal compartment (white arrows). Yellow arrow shows axons (green, beta3-
tubulin) traversing the series of 150-μm–wide grooves between the compartments. (B), 
High power photomicrograph of DRG axons (green, beta3-tubulin) growing though the 
150-μm grooves. Virus particles (arrows) within the axons appear yellow due to 
colocalization with neuronal beta3-tubulin. (C), Neuronal bodies (green) are infected 
after direct exposure to H5N1 virus (red, viral NP protein; arrows). Yellow indicates 
colocalization of proteins. Scale bars: A, 160 μm; B, 6 μm; C, 60 μm. 
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virus can infect neurons following peripheral infection as well as by hematogenous 
spread directly infecting cells as would occur following its release from dying cells. 
 
 
2.3.5 Increased phosphorylation of alpha-synuclein protein in infected region 
 
 One of the hallmarks of neurodegenerative disorders including Parkinson’s and 
Alzheimer’s disease is the aggregation of alpha-synuclein (107). This aggregation has 
been shown to be dependent on the phosphorylation of a number of serine residues in the 
synuclein protein (SYN), of which serine 129 appears to be most important (106). In 2-3 
month old uninfected C57BL/6J mice, we observed pSer129SYN in few, if any, neurons  
at any level of the central neuraxis, including the dopaminergic neurons of the substantia 
nigra pars compacta (Fig. 2.6A). However, in H5N1 virus infected mice, we observed 
pSer129SYN-positive neurons at various levels of the neuroaxis including the brainstem 
and midbrain (Fig. 2.6B), hippocampus and cortex. The phosphorylation on Serine 129 
residue appears to be directly related to H5N1 infection, as uninfected structures within 
the CNS did not show pSer129SYN upregulation. Using NIH Image, we quantified the 
expression of pSer129SYN in olfactory bulb, hippocampus, locus coeruleus, brainstem 
and cerebellum. Animals infected with H5N1 virus infection had significantly increased 
expression of both cellular and secreted pSer129SYN at all levels of the neuraxis 
examined except for cerebellum (Table 2.2). In addition to pSer129SYN expression, we 
also noted aggregated alpha-synuclein in hippocampus (Fig. 2.6C), cortex and brainstem, 
as seen in human proteinopathies such as Parkinson’s and Alzheimer’s diseases (107). 
 
 
2.3.6 Apoptosis and long-term activation of microglia  
 
 To determine whether H5N1 virus infection of the CNS resulted in cell death, we 
examined markers of apoptotic and necrotic cell death (activated caspase 3 (275) and 
FluoroJade B staining (284), respectively). We also assessed dopaminergic neuron 
number in the substantia nigra pars compacta (SNpc). In regions of the brain where 
A/VN/1203/04 virus had been detected, we found apoptotic (Fig. 2.6D) but not necrotic 
cells. We also noted activated microglia (Fig. 2.6E), which indicate an inflammatory 
process (285), in these regions. Microgliosis persisted in the CNS after the acute infection 
resolved and was observed during the entire 90-day study period (Fig. 2.6F). This 
prolonged inflammatory response is similar to that described in humans with idiopathic 
Parkinson’s disease (286) and with parkinsonism induced by the neurotoxin MPTP (131).  
 
 
2.3.7 A reduction in the number of tyrosine hydroxylase (TH) positive dopaminergic 
neuron in the SNpc  
 
 Cell counts of TH-positive dopaminergic neurons in the SNpc 60 days following 
H5N1 virus infection demonstrated a 17% reduction of TH-positive dopaminergic 
neurons (8963 ± 384 in control and 7481 ± 453 in H5N1 virus infected mice, n=4, p≤ 
016).
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Figure 2.6 H5N1 Influenza Virus Induces a Parkinsonian Phenotype 
 
(A), In uninfected C57BL/6J mice, no pSer129SYN is seen in dopaminergic neurons of 
the SNpc (green). (B), At day 60 dpi, pSer129SYN (white arrows) is seen in the nuclei of 
dopaminergic neurons (green) in the SNpc. (blue, DAPI nuclear stain.) (C), At day 90 
dpi, aggregated alpha synuclein (arrows) is seen in the hippocampus. (D), At day 10 dpi, 
activated caspase-3 (arrows) is seen in brainstem regions that contain NP protein (red). 
The cells expressing activated caspase-3 do not appear to be NP-positive. (E), At day 10 
dpi, activated microglia marked by anti-Iba-1 (green; yellow arrow) surround infected 
cells (red; white arrow). (F), At day 60 dpi, activated microglia (arrows) persist in 
midbrain regions and all other regions previously infected by H5N1. Findings were 
similar at day 90 dpi Scale bars: A and B, 30 μm; C, 25 μm; D, 40 μm; E, 35 μm; F, 50 
μm. 
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Table 2.2 Relative Density Measurements of pSer129SYN Expression in Brain  
 
 
The brain areas were stained with anti-pSer129SYN antibody by immunohistochemistry. Both soluble pSer129SYN (Proteinase-K, 
non treated) and insoluble (Proteinase-K, treated) forms of this phosphoprotein were determined. Statistical analysis was performed 
using GraphPad software (error bars, s.e.m.). 
Proteinase-K, non treated  Proteinase-K, treated 
Structure 
Control H5N1 Statistics  Control H5N1 Statistics 
Olfactory bulb 100 ± 19 178 ± 27 p ≤ 0.05  100 ± 19 189 ± 23 p ≤ 0.01 
Hippocampus 100 ± 21 277 ± 21 p ≤ 0.001  100 ± 21 244 ± 25 p ≤ 0.001 
Locus coeruleus 100 ± 20 120 ± 12 n.s.  100 ± 7 168 ± 10 p ≤ 0.001 
Solitary nucleus 100 ± 18 190 ± 13 p ≤ 0.001  100 ± 7 163 ± 8 p ≤ 0.001 
Lower brainstem 100 ± 17 274 ± 37 p ≤ 0.001  100 ± 21 135 ± 14 n.s. 
Cerebellum 100 ± 8 100 ± 3 n.s.  100 ± 16 108 ± 12 n.s. 
 
 
 
 
 
 
 
 
 
 
 
 
2.4 Discussion 
 
 Reports of influenza-associated neurological syndromes are found as far back as 
1385 and have continued through more recent influenza outbreaks (5). There is a 
substantial amount of evidence that influenza can directly lead to encephalitis (5, 28-33), 
although the link with development of neurodegenerative diseases including Parkinson’s 
disease are controversial. Much of the linkage of parkinsonism with influenza are based 
on the postencephalic parkinsonism that followed an outbreak of von Economo’s 
encephalopathy (EL) subsequent to the 1918 pandemic influenza outbreak (213). This 
includes epidemiological data (2, 3) and physical findings of type A influenza antigens in 
EL patients (36). Evidence against the role of influenza as a parkinsonian agent include 
the lack of viral RNA recovered from brains of postencephalic parkinsonian patients 
(223), the absence of any known mutations that would make the 1918 species of H1N1 
virus neurotropic (213), and questions regarding the timeline of pandemic flu and EL 
(42). Recently, Kobasa et al administered the 1918 H1N1 influenza virus that was 
generated by plasmid-based reverse genetics and found no evidence of direct 
neurotropism (38). However, this engineered virus did induce a robust induction of 
cytokines including monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory 
protein-1β (MIP-1β), monocyte chemotactic protein-2 (MIP-2), macrophage 
inflammatory protein-3α (MIP-3α), IL-1β, IL-6, IL-12 (p40), IL-18 and granulocyte-
colony stimulating factor (G-CSF) (39), which can be secondarily activated in the brain 
without direct infection (40). Several of these cytokines have been implicated in the 
pathophysiology of Parkinson’s disease (41). 
 
 In many cases of encephalitis, as well as toxin-induced parkinsonism, the 
offending agent may cause a long lasting immune response in the brain that persists many 
years after the insult has resolved (131), leading to a “hit and run” mechanism where the 
original insult is no longer present but the secondary sequelae persists (287). This would 
fit our observations that H5N1 virus is not detectable in the brain after 21dpi, but there is 
a long-lasting activation of microglia and a significant decrease through 60 days of TH-
positive dopaminergic neurons in SNpc. Thus, if one accepts that influenza can activate 
the innate CNS immune system (43, 44) and may induce a loss of neurons, there would 
be the necessity of a second hit that would lead to development of additional neuronal 
loss passing the threshold necessary for induction of parkinsonian symptoms (288) that 
would not have occurred without the priming that occurs via the influenza infection (46). 
 
 In conclusion, we find that the highly infectious, neurotropic A/VN/1203/04 
(H5N1) virus progresses from the peripheral nervous system into the CNS, where it 
activates the innate immune response in the brain. We have also shown for the first time 
that H5N1 influenza infection of the CNS can induce not only parkinsonian symptoms 
but also a significant increase in phosphorylation and aggregation of alpha synuclein, 
which likely results in the observed SNpc dopaminergic neuron degeneration (47). Thus, 
we suggest that any pandemic influenza that activates the immune system in brain could 
contribute to CNS disorders of protein aggregation (20, 48) and viruses may be an 
important etiological agent in the developmental sequelae of neurodegenerative diseases 
including Parkinson’s disease.
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CHAPTER 3. INFLAMMATORY EFFECTS OF HIGHLY PATHOGENIC H5N1 
INFLUENZA VIRAL INFECTION IN THE CENTRAL NERVOUS SYSTEM 
 
 
3.1 Introduction 
 
 Viral infection is one mechanism that has been implicated in initiation and 
progression of parkinsonism. The etiology of Parkinson’s disease is multivariate, ranging 
from identified genetic mutations to strict environmental causation (289). There is a 
significant literature that documents parkinsonism following exposure to viruses (5), 
including the influenza virus (42). While most influenza infections in humans result in 
upper respiratory tract infections, occasionally the brain is also be affected. In fact, 
involvement of the CNS during influenza infections can be fatal, particularly in young 
patients (290). 
 
 Experimental evidence has shown that type A influenza viruses are neurotropic, 
i.e. they can travel into the nervous system following systemic infection (180, 221, 222), 
a finding confirmed with the H5N1 influenza virus (256, 270). Once in the CNS, H5N1 
(A/VN/1203/04) infection can initiate a parkinsonian pathology that includes 
bradykinesia, a decreased in the number TH-positive dopaminergic neurons in SNpc, 
increased levels of alpha-synuclein phosphorylation and aggregation, and activation of 
microglia; each of which persisted at least 60 days after resolution of the infection (270). 
To determine if the pathology worsened with age, we examined: 1) SNpc tyrosine 
hydroxylase-positive dopaminergic neuron number and striatal dopamine and its 
metabolites contents through 90 days post infection, 2) the inflammatory effect of 
infection by quantitatively measuring the total number of resting and activated microglia 
in the SNpc, and 3) the production of cytokines in regions of the brain infected by H5N1 
influenza virus. We found that infection with H5N1 influenza virus induces a significant, 
but transient reduction of both TH-positive dopaminergic neurons in the SNpc and 
dopamine (and its metabolites) in the striatum. Examination of other indolamines 
demonstrated a significant and sustained reduction of serotonin in regions of the brain 
infected with H5N1 influenza virus. We also observed that areas of the brain infected 
with H5N1 influenza virus expressed increased levels of proinflammatory cytokines, 
chemokines, and growth factors. 
 
 
3.2 Materials and Methods 
 
 All experiment using the highly pathogenic H5N1 influenza virus 
(A/VN/1203/04) were conducted in a biosafety level 3+ laboratory approved for use by 
the U.S. Department of Agriculture and the Centers for Disease Control. This facility is 
authorized for the exclusive use of the Division of Virology and other approved scientists 
at St Jude Children’s Research Hospital. 
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3.2.1 Virus stock preparation and inoculation of mice with H5N1 
 
 Stock viruses were prepared by propagating neurotropic A/VN/1203/04 (H5N1) 
allantoic cavity of 10-days-old embryonated chicken eggs for 40 to 48 hours at 37˚C. 
Virus stock was aliquoted then stored at -70˚C until use. Viral infectious titers were 
determined using the method of Reed and Muench (271), and expressed in log10 of the 
50% egg infectious dose per 1.0 ml of fluid (EID50/mL). 6-8 week old C57BL/6J female 
mice (Jackson Labs, Bar Harbor, ME) were anesthetized by isofluorane inhalation and 
infected intranasally with 30 µL of allantoic fluid diluted in PBS to the target virus 
infectious titer (102 EID50). One group of animal received 0.9% saline was used as age-
matched control. 
 
 
3.2.2 Immunocytochemistry 
 
 Mice were deeply anesthetized with Avertin and transcardially perfused with 
0.9% saline followed by 10% neutral buffered formalin at 10, 21, 60 and 90 days post 
infection. Brains were removed and postfixed for 3 weeks in 10% neutral buffered 
formalin to ensure that the virus particles present in the tissue have been killed. Brains 
were cryoprotected with 30% sucrose in PBS, serially sectioned in the coronal plane at 40 
micrometers and placed in PBS filled 24 well plates. Free floating sections were 
immunolabeled with antibodies directed against tyrosine hydroxylase (TH) (rabbit, 
P40101-0, PelFreeze, Rogers, AK, 1:500) (to identify dopaminergic neurons) and ionized 
calcium binding adapter protein-1 (Iba-1) (rabbit, 019-19741, Wako Chemicals, 
Richmond, VA, 1:500) (to identify microglia) overnight. Primary antibodies were 
visualized using the ABC method (PK-6102,Vector Laboratories, Burlingame, CA) with 
chromogens, 3,3-diaminobenzidine (SK-4100 Vector Laboratories, Burlingame, CA) (for 
DA neurons) and the Vector VIP substrate (SK-4600 Vector Laboratories, Burlingame, 
CA) (for microglia) respectively. Sections were mounted on Superfrost-Plus (12-550, 
Fisher, Pittsburgh, PA) slide and counter stained with neutral red to visualize Nissl 
substance, and then dehydrated, cleared and mounted with Permount (SP15-500, Sigma, 
St. Louis, MO). 
 
 
3.2.3 Stereological cell count using the optical fractionator methods 
 
 The total number of TH-positive neurons in both hemispheres of SNpc was 
estimated using the optical fractionator method (279) from StereoInvestigator (version 
7.0; MicroBrightField, Colchester, VT). The outline of the SNpc in both hemispheres was 
delineated at low power (4× magnification). An unbiased counting frame (60 × 60μm) 
was placed at the intersections of a grid (frame size 200 × 200μm) randomly 
superimposed on a video image of the contoured sections. Sections were examined under 
a high power (100× objective lens, numerical aperture (NA)= 1.3) on a BX51 microscope 
(Olympus, Center Valley, PA) with a MAC5000 motorized XYZ axis computer-
controlled stage and a CX9000 CCD video camera (MicroBrightField, Colchester, VT). 
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 TH-positive DA neurons were counted at the depth at which their nucleus was 
focused in each counting area. The reliability of the estimates was measured by 
calculation of coefficient of error (279). Gundersen coefficients of error for m=1 was all 
less than or equal to 0.10. Statistical significance was calculated using a one-way 
ANOVA followed by Student-Newman-Keuls post hoc test (280). The longest length of 
neuronal cell body was measured using the Neurolucida program (version 7.0, 
MicroBrightField, Colchester, VT). Raw data was converted to percent of control. 
 
 Based on the shape and morphology (291), the number of the activated and the 
resting microglia in both hemispheres of the SNpc were estimated using the same 
methods described above. 
 
 
3.2.4 Biochemical measurement of monoamine neurotransmitters 
 
 At 10, 21, 60 and 90 days post infection, C57BL/6J mice were deeply 
anesthetized with Avertin and transcardially perfused with 0.9% saline to remove the 
majority of the blood from the brain vasculature. Brains were rapidly removed and placed 
in a brain matrix (BS-AL-5000C, Braintree Scientific, Braintree, MA) and sliced into 1 
mm thick sections and placed on an ice-cooled plate. Tissues were dissected from the SN 
(Bregma: -2.70 to -3.70), striatum (Bregma: +0.14 to +1.26mm), brainstem (Bregma: -
5.40 to -6.70mm), cortex (Bregma: -1.70 to -2.70mm), and hippocampus (Bregma: -1.70 
to -2.70mm) (273). Tissues were homogenized in a chilled 0.3M perchloric acid and 
centrifuged for 15 minutes at 10,000g at 4˚C. The supernatants were saved and stored at -
70˚C until used. A variety of monoamine transmitters; dopamine (DA), and its 
metabolites 3,4-dihydroxyphenylacetic acid (DOPAC), and homovanillic acid (HVA); 
norepinephrine (NE); 5-hydroxytryptamine (5-HT) and its metabolites 5-
hydroxyindoleacetic acid (5-HIAA) were analyzed using reverse-phase ion pairing HPLC, 
combined with electrochemical detection (EC) detection under isocratic elution 
conditions. The amount of monoamine neurotransmitters in the tissues were determined 
by injecting known concentration of monoamine neurotransmitters and extrapolating 
from a standard curve. Statistical difference was determined using a one-way ANOVA 
followed by Student-Newman-Keuls post hoc test (292). 
 
 
3.2.5 Quantification of cytokines, chemokines and growth factors 
 
 The concentration of interleukin (IL)-1α, IL-1β, IL-2, IL-6, IL-9, IL-10, IL-
12(p70), IL-13, tumor necrosis factor alpha (TNF-α), interferon gamma (IFN-γ), 
granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte colony-
stimulating factor (G-CSF), macrophage colony-stimulating factor (M-CSF), eotaxin, 
interferon-inducible protein 10 (IP-10), cytokine-induced neutrophil chemoattractant 
(KC), monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory proteins 
(MIP)-1α, MIP-1β and vascular endothelial growth factor (VEGF) proteins was 
simultaneously analyzed from dissected brain regions and lung, using the Luminex 200 
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system (Luminex Corp., Austin, TX) and the Milliplex mouse cytokine kit 
(MPXMCYTO-70K-20, Millipore, Billerica, MA). 
  
 At 3, 10, 21, 60 and 90 days post inoculation, dissected tissues were homogenized 
in a buffer containing 50 mM Tris-HCl (pH 7.4), 2.5mM EDTA, 0.1% Triton X-100, 
150mM NaCl with a protease and phosphatase inhibitor cocktail (Complete mini, 
PhosphoStop, Roche, Indianapolis, IN). The tissues lysates were then incubated for 30 
minutes on ice and centrifuged at 12,000g for 15 minutes. Supernatants were aliquoted 
and stored at -70˚C until used. To quantify cytokine levels, the supernatants were 
incubated with the microspheres coated with capture antibodies for each analyte for 2 
hours. After rinsing, biotinylated detection antibodies were added into each well and 
incubated for 1 hour. Streptavidin-phycoerythrin conjugates were added and fluorescence 
intensity was measured by the Luminex 200 reader (Luminex Corp., Austin, TX). 
Concentration of each cytokine was calculated from a 5-parameter logistic curve obtained 
from the known concentration of cytokines, using MILLIPLEX Analyst software 
(Millipore, Billerica, MA, USA). All results were normalized with total protein 
concentration measured from each tissue lysate (pg/25 μg of total protein).  
 
 
3.3 Results 
 
 
3.3.1 Transient loss of TH-positive phenotype in dopaminergic neurons following H5N1 
infection 
 
 To determine if H5N1 infection can directly induce parkinsonism by damaging 
dopaminergic neurons, we stereologically assessed the number of TH-positive 
dopaminergic neurons in the SNpc (Fig 3.1A) and empirically determined the amount of 
total DA, HVA, and DOPAC in the SN, cortex, brainstem, and hippocampus (Fig 3.2A). 
 
 A dramatic decrease in the number of TH-positive neurons in the SNpc was 
observed at the peak of H5N1 infection from 10 to 21 dpi where we measured 
approximately 60% reduction in the number of TH-positive neurons, compared to non-
infected control mice. However, from 21 to 60 dpi, we saw a recovery in neuron number 
which is 20% less than that of control mice. By 90 dpi, we saw no difference in TH-
positive SNpc DA neuron number (Fig 3.1A). At 10 and 60 dpi, TH-positive DA neurons 
appeared shrunken. The longest length of TH-positive neuronal cell bodies was reduced 
by 10 to 20%, however the size of these cells recovered and appeared similar to that seen 
in the non-infected control mice at day 90 dpi (Fig 3.1B). Examination of cells in the 
SNpc showed no evidence of cell division using both morphological and 
immunohistochemical methods. Thus, there is no compelling evidence that DA neurons 
in the SNpc underwent any form of cell division. It is most likely that active H5N1 
infection causes SNpc DA neurons to transiently reduce their metabolic capacity and cell 
size, each leading to a loss of the dopaminergic phenotype in neurons. 
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Figure 3.1 The Size and Number of TH-Positive Dopaminergic Neurons 
 
(A), Following H5N1 infection, the number of TH-positive dopaminergic neurons in the 
SNpc was reduced approximately 60% at 10 dpi and 20% at 60 dpi from the non-infected 
control mice (11170 ± 599 TH-positive DA neurons in control, 4882 ± 429 TH-positive 
DA neurons in H5N1-infected mice at 10 dpi, n=4, P < 0.001; 8195 ± 123 TH-positive 
DA neurons in H5N1-infected mice 60 dpi, n=4, P < 0.01). At 90 dpi, the number of TH-
positive dopaminergic neurons in the SNpc was similar to that of control mice (10090 ± 
259 TH-positive DA neurons in H5N1-infected mice 90 dpi, n=4, n.s.). The atrophic 
shape of TH-positive neurons was frequently detected in the SN of infected mice. (B), 
The longest length of TH-positive neuronal cell bodies was reduced by 10 to 20%, 
however the size of these cells recovered and appeared similar to that seen in the control 
mice at 90 dpi. Statistical significance was determined by one-way ANOVA followed by 
Student-Newman-Keuls test. (*: comparison with control mice; #: comparison with 10 dpi 
mice; @: comparison with 60 dpi mice; *, # and @: p<0.05; **, ## and @@: P<0.001). 
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Figure 3.2 Percent Change in the Amount of DA, DOPAC, and HVA in Brain Following 
H5N1 Infection  
 
(A), At 10 dpi, the amount of striatal DA was significantly decreased, compared to DA 
level of the non-infected control mice. At 90 dpi, DA levels were significantly increased 
from DA levels of 10 dpi mice and recovered to baseline levels. This pattern of a 
transient decrease at 10 dpi followed by recovery at 60 to 90 dpi was also seen in levels 
of HVA and DOPAC in striatum (B-C). In the brainstem, DA, DOPAC, and HVA levels 
were sharply increased at 10 dpi, then returned to their basal levels (G-I). Statistical 
significance was determined by one-way ANOVA followed by Student-Newman-Keuls 
test (*: comparison with control mice; #: comparison with 10 dpi mice; @: comparison 
with 60 dpi mice; *, # and @: p<0.05; **, ## and @@: P<0.001). 
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3.3.2 Transient reduction of dopamine in striatum following H5N1 infection 
 
 We used reverse phase HPLC with electrochemical detection to determine if 
infection with H5N1 affects the level of dopamine and its metabolites in the major target 
of DA neurons in the SNpc, the striatum. At 10 dpi, the amount of striatal DA was 
significantly decreased by approximately 40% from that of non-infected control mice. 
The levels of DA then increased between 60 and 90 dpi at which time it recovered to 
baseline levels (Fig 3.2A). A similar pattern was also seen in the levels of HVA and 
DOPAC (Fig 3.2B-C). We also compared the turnover ratio of DA in the striatum 
((DOPAC + HVA)/DA) to determine if infection with H5N1 altered DA metabolism. 
Despite alterations in levels of DA, its turnover was unchanged. 
 
 
3.3.3 Effect of H5N1 infection on NE and 5-HT levels in the CNS  
 
 Reverse phase HPLC with electrochemical detection was used to determine if 
infection with H5N1 affected levels of NE, 5-HT, and 5-HIAA in the SN, striatum, 
brainstem, cortex, and hippocampus. No significant difference was found in the level of 
NE in the striatum, SN, and brainstem (Fig 3.3A-C). NE level was transiently increased 
approximately 50% in the hippocampus at 60 dpi (Fig 3.3D) and decreased by 70% in the 
cortex at 10 dpi (Fig 3.3E).  
 
 In the striatum and SN, the levels 5-HT were significantly decreased 
approximately 50% from the non-infected control mice at 10 dpi and remained low 
through 90 dpi (Fig 3.4A, C). A similar reduction was seen in 5-HIAA levels (Fig 3.4B, 
D). In cortex, 5-HT was reduced by 85% at 10 dpi and remained reduced through 90 dpi 
(Fig 3.4I). A smaller reduction (70%) was seen in 5-HIAA levels at day 10 dpi (Fig 3.4J) 
that increased slightly to 60% of control levels through 90 dpi. 
 
 
3.3.4 H5N1 infection increases the number of microglia in the SNpc 
 
 Microglia are the resident immune cells of the CNS (293). In surveillance mode, 
they are said to be resting and have a characteristic histological appearance with long 
slender tendrils radiating from a cell body (Fig 3.5A). Once exposed to infection, injury 
or trauma (294) they undergo a transformation in which they retract and thicken their 
processes, assuming a more amoeboid morphology (295) (Fig 3.5B). To determine if 
exposure to H5N1 alters the morphology and number of microglia in the SNpc, we used 
the optical fractionator method to assess resting and activated microglia. Non-infected 
C57BL/6J mice had approximately 7500 total microglia in the SNpc. Approximately 10% 
were structurally classified as activated, while 90% were classified as resting. Sixty days 
after intranasal inoculation with H5N1, we found a 67% increase in total microglia 
number in the SNpc. Examination of microglia subtype revealed a 300% increase in 
activated microglia and a 33% increase in resting microglia. The increase in total 
microglia, as well as percent increase in activated microglia was unchanged from 60 to 
90 dpi (Fig 3.5C), suggesting a long-term -if not permanent- increase in these cells. 
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Figure 3.3 Percent Change in the Amount of NE in Brain Following H5N1 Infection  
 
(A-C), No significant difference was found in the level of NE in the striatum, SN, and 
brainstem. (D), NE level was transiently increased in the hippocampus at 60 dpi, 
compared to the level of control and the 10 dpi mice, and returned to basal levels at 90 
dpi. (E), In cortex, we observed a transient 72% reduction of NE that ebbed at day 10 dpi 
and rebounded to basal levels through 90 dpi. Statistical significance was determined by 
one-way ANOVA followed by Student-Newman-Keuls test (*: comparison with control 
mice; #: comparison with 10 dpi mice; @: comparison with 60 dpi mice; *, # and @: 
p<0.05; **, ## and @@: P<0.001; error bars, s.e.m.). 
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Figure 3.4 Percent Change in the Amount of 5-HT and 5-HIAA in Brain Following 
H5N1 Infection  
 
(A), (C) and (I), The level of 5-HT was significantly reduced in the striatum, SN, and 
cortex at 10 dpi and remained low through 90 dpi. (B), (D) and (J), A similar reduction 
pattern was seen in the level of 5-HIAA. (E-H), Although the mean levels of 5-HT and 5-
HIAA in hippocampus and brainstem trended lower, none of these changes achieved 
statistical significance. Statistical significance was determined by one-way ANOVA 
followed by Student-Newman-Keuls test (*: comparison with control mice; #: comparison 
with 10 dpi mice; @: comparison with 60 dpi mice; *, # and @: p<0.05; **, ## and @@: 
P<0.001).
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Figure 3.5 H5N1 Infection Increased the Number of Activated Microglia 
 
(A) and (B) represents the typical appearance of resting and activated microglia, 
respectively. Both resting and activated microglia were observed in the SN of non-
infected control and H5N1-infected mice. The number of activated microglia was 
increased approximately three fold in the H5N1 infected group, compared to that of 
control (1157 ± 111, in the control group; 3996 ± 283 (60 dpi) and 3863 ± 399 (90 dpi), 
in H5N1-infected mice, n=3 or 4). The total number of microglia was also increased 
about 67% in the H5N1-infected group, compared to that of control (7370 ± 341 in the 
12220 ± 640(dpi 90), n=3 or 4, P < 0.001) (C). 
 Student-
control group; 12140 ± 467 (dpi 60) and 
Statistical significances was determined by one-way ANOVA followed by
Newman-Keuls test (*: p<0.05, **: P<0.001). 
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3.3.5 Effect of H5N1 infection on levels of cytokines, chemokines and growth factors in 
the lung and CNS 
 
 Activated microglia have been shown to produce a variety of cytokines, 
chemokines, and growth factors following infection, as well as after other trauma to 
CNS. The resulting “inflammatory responses” 
the 
to these different insults have been shown 
 be specific to the insult rather than a generalized response to insult (296). Therefore, 
e examined the cytokine, chemokine and growth factor profiles in regions of the CNS 
that were infected by H5N1 both during (day 0-10) and after (days 21-90) the acute 
infectious stage (270). We also measured these proteins in lung, which is the primary site 
of H5N1 influenza infection in mice (270) in humans (297) to determine if alterations 
were specific to the CNS or were in response to, or coincident with, peripheral activation 
of cytokines. 
 
 Some cytokines (IL-1α, IL-1β, IL-2, IL-9, IL-12, IFN-γ and TNF-α) function 
primarily to induce inflammation (pro-inflammatory), while other cytokines (IL-6, IL-10, 
and IL-13) suppress inflammation and are classified as anti-inflammatory (298). 
Chemokines are cytokines that act as chemoattractants and include eotaxin, KC, IP-10, 
MCP-1, MIP-1α, and MIP-1β (299). The cytokines acting as growth and differentiation 
factors that we examined included GM-CSF, M-CSF and VEGF (300). We noted 4 
distinct profiles of induction of these factors: First, we observed that some of these 
proteins transiently increased during the initial phase of infection (through 10 dpi) then 
returned to baseline levels. A second pattern of induction showed a transient decrease in 
expression followed by a return to baseline levels. A third type of cytokine/chemokine 
expression produced a biphasic pattern, with an initial transient increase in expression, 
followed by a return to baseline levels and later, a reinduction at times when the influenza 
virus was no longer detectable by visualization of NP protein. A fourth pattern of 
cytokine/chemokine expression was observed with no changes in cytokine level during 
the active phase of infection, but a later induction of cytokines at dpi 60 (Fig 3.6). 
 
 In the lung, the expression of cytokines, chemokines and growth factors displayed 
3 of the distinct patterns previously described. First, we saw that some of these proteins 
were transiently increased during the initial phase of infection (through day 10 dpi) and 
then returned or decreased to baseline levels. The pro-inflammatory cytokines, 
chemokines and growth factors that displayed this pattern of expression included IL-6, 
IL-12, G-CSF, GM-CSF, IFN-γ, KC, MIP-1α, MIP-1β, and TNF-α. The anti-
inflammatory IL-10 also expressed this profile. The second pattern of expression where 
there is an initial decrease in expression at dpi 10 followed by a return to baseline levels 
(pattern 2) was displayed by the pro-inflammatory cytokine IL-2. The growth factor, 
VEGF displayed a third, biphasic pattern of expression with an initial transient increase, 
followed by a decrease below the baseline level, and another induction at 21, 60 and 90 
dpi after the influenza virus was no longer detectable by immunohistochemical labeling 
of NP protein (pattern 3) (Fig 3.7, Table 3.1). 
 
 
 
to
w
 58
 
 
 
Figure 3.6 Four Distinct Temporal Patterns Seen in Cytokines, Chemokines and Growth
Factors Expression Following H5N1 Infection  
 
Four distinct temporal patterns were observed in the expression of cytokines, chemokine
and growth factors along the time course after H5N1 infection. Pattern 1, a transient 
increase at initial phase of infection (by day 21) followed by retuning to basal level. 
Pattern 2, an initial transient decrease in expression followed by a return to baseline 
levels. Pattern 3, an initial transient increase in expression followed by a return to 
baseline levels and then a reinduction at 60 days after infection. Pattern 4, no changes 
during the active phase of infection, but at a later time there was induction.
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xpression of Cytokines, Chemokines and Growth Factors in the Lung 
ollowing H5N1 Infection  
 The pro-inflammatory cytokines, 
hemokines and growth factors including IL-6, IL-12, G-CSF, GM-CSF, IFN-γ, KC, 
vels (pg/25ug 
of total protein) were presented as mean ± s.e.m (*: comparison with control mice; #: 
comparison with 3 dpi mice; †: comparison with 10 dpi mice; @: comparison with 21 dpi 
mice; ¶: comparison with 60 dpi mice; *, #,†,¶ and @: p<0.05; **, ##, ††,¶¶, and @@: 
P<0.001; error bars, s.e.m.). 
Figure 3.7 E
F
 
Two distinct patterns were observed in the lung.
c
MIP-1α, MIP-1β, and TNF-α, and anti-inflammatory IL-10 were increased during the 
initial phase of infection (through day 10 dpi) and then returned to baseline levels (pattern 
1). The pro-inflammatory cytokine IL-2 showed an initial decrease in expression at 10 
dpi followed by a return to baseline levels (pattern 2). The growth factor, VEGF showed 
an initial transient increase followed by a decrease below the baseline levels and then 
reinduction at 60 days post infection (pattern 3). Statistical significance was determined 
by one-way ANOVA followed by Student-Newman-Keuls test. Cytokine le
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Table 3.1 Level of Cytokines, Chemok
 
Cytokines Control Dpi 3
ines and Growth Factors in the Lung Following H5N1 Infection  
 Dpi 10 Dpi 21 Dpi 60 Dpi 90 
IL-1α 15.27 ± 6.66 37.59 ± 10.83 ± 4.80 B.D.L 47.05 ± 41.94 11.18 ± 5.63  12.72 
IL-1β 58.05 ± 22.46 62.36
IL-2 2.87 ± 1.42 1.88 ±
IL-6 B.D.L 171.8
9 95.23 ± 44.62 32.77
10 B.D.L 2.12 ±
12(p70) B.D.L 0.69 ±
taxin 71.72 ± 6.90 73.37
CSF B.D.L 62.65
-CSF B.D.L 7.58 ±
γ B.D.L 12.69
10 7.95 ± 2.00 1507.
 4.22 ± 0.65 171.7
SF 0.68 ± 0.29 5.23 ±
1 5.99 ± 0.65 
 ± 15.23 ± 2.24 36.04 ± 12.87  36.66 ± 6.50  41.26 ± 6.63 
 B.D.L *,# 2.80 ± 0.50 † 2.32 ± 0.40 † 2.41 ± 0.49 † 
6 1 * 23.60 ± 8.89 # B.D.L # B.D.L # 4.14 ± 3.84 # 
IL-  ± 12 * 41.39 ± 15.36 * B.D.L * 7.19 ± 4.06 * 5.14 ± 2.43 * 
IL-  0.3  7.15 ± 2.28 † B.D.L † 2.14 ± 0.63 † 1.52 ± 0.83 † 
IL-  0.1  B.D.L ## B.D.L ## B.D.L ## B.D.L ## 
Eo  ± 2. 83.68 ± 9.32 43.68 ± 16.33 51.49 ± 5.79 62.56 ± 18.70 
G-  ± 2 87.32 ± 22.77 * 4.96 ± 2.32 38.57 ± 13.92 10.51 ± 3.92 
GM  1.2  B.D.L ## B.D.L ## B.D.L ## B.D.L ## 
IFN-  ± 2. 39.64 ± 17.39 *,# B.D.L † 1.33 ± 0.15 † B.D.L † 
IP- 16 ± .10 602.29 ± 263.09 22.40 ± 9.05 22.98 ± 11.54 9.83 ± 3.31 
KC 0 ± 5 * 20.31 ± 6.87 # 6.59 ± 1.55 # 13.56 ± 3.67 # 17.12 ± 6.75 # 
M-C  1.2 4.48 ± 1.32 1.67 ± 0.56 5.22 ± 0.85 5.90 ± 1.54 * 
MCP- 150.47 ± 52.41 145.67 ± 57.29 B.D.L 4.27 ± 1.41 5.99 ± 2.94 
 3.96 
0.27 
± 59.7
.23 
6 *,#
6 **
93 
4.75 
2 **
50  
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(Lum nex Corp. n, TX). Th escent i anks w acted from oncen h 
cytokine was calculated from
wit rotein co ured f issue lysa μg of total protein). B.D.L represented a value 
below the detectable concentration range of each analyte and was regarded as zero for statistical calculation. St icance 
rmined N  by Stud Keuls ison mice; ith 
3 dpi mice; †: comparison with 10 dpi mice; : comparison with 21 dpi mice; : comparison with 60 dpi mice; *, #,†,  and : p<0.05; 
,¶¶, and 0.001; m e.m.). 
 
 
 
Table 3.1 (continued) 
 
Cytokines Control Dpi 3 pi 10 Dpi 21 Dpi 60 Dpi 90 
MIP-1α ,# †   B.D.L 56.05 ± 18.20 128.62 ± 30.05 **  B.D.L 31.11 ± 13.85 † 25.07 ± 1.09 †
MIP-1
Mean fluorescent intensity of blanks, standards, and samples was measured in duplicate wells, using the Luminex 200 reader 
i , Austi e median fluor
 a 5-parameter 
ntensity of bl
logistic curve obtained from
as subtr
 the known concen
all readings. C
tration of cytokines.
tration of eac
 All results were 
normalized h total p ncentration meas rom each t te (pg/25 
atistical signif
was dete  by one-way A OVA followed
@
ent-Newman-  test (*: compar
¶
 with control #: comparison w
¶ @
**, ##, †† @@: P< ean number ± s.
 
 
 
 
 
 
β  ,# 
α ** ,# 
F  10.59 1. 31.21 † 22.46 #,† † 
B.D.L 44.29 ± 18.00 143.79 ± 34.82 ** B.D.L †† 4.60 ± 0.33 †† B.D.L †† 
TNF- B.D.L 2.35 ± 0.39 1.54 ± 0.26 ** B.D.L ##,†† B.D.L ##,†† B.D.L ##,†† 
VEG 57.45 ± 121.54 ± 10.48 * 72 ± 0.38 *,# 81.71 ± 57.62 ± 86.88 ± 9.35 
 
 In the CNS, we examined the expression of cytokines, chemokines and growth 
factors in 4 separate regions: brainste u , striatum and cortex. In the 
brainstem, t xpression o tokine  growth factors displayed 2 of the 
different pa s desc ed ve y cytokines, chemokines and 
growth t h x s e f 1α, IL-12 (p70), IL-13, eotaxin, G-
CSF, G C  I , S IP-1β, and TNF-α. The anti-
inflam - lso . The level of proinflammatory 
cytokines and growth factors IL-1 splayed pattern 4. They were not 
changed im iately upon tecti creased later when NP protein 
was no long v t in th io ). 
  
 h b g he es, chemokines and growth 
factors d f nd he pro-inflammatory cytokines, 
chemo s  c  th rofile were IL-1β, IL-2, IL-6, G-
CSF, M-CSF, and MCP-1 where t sed at 3 or 10 dpi and then 
returned to baseline levels. 3 tern listed above, with its levels 
increasing prior to day  f we ne and another rise in level at a 
later point af  i tio N levels of the chemokines and 
growth t n IP 4, where expression did not 
change immediately upon detection of the virus, but increased later when NP protein was 
no longer evident in th g  N F-α was detected in the SN 
following exposure to influenza (F
 
 In st e ion ines and growth factors displayed 
profiles 1, 3 e bo tory chemokines and growth 
factors t e  i we . The cytokine that expressed 
profile 3 wa - h h ti- isplayed profile 4. IL-1α, IL-6, 
IL-12 ) 1 -C MIP-1 β, and TNF-α were not 
detected in striatum following exposure to H5N1 influenza (Fig 3.10, Table 3.4). 
 
 In c , e  o  and growth factors displayed 
profiles 1, 2  h am pressed profile 1 were IL-2 
and IL-9. T r  GF ile an anti-inflammatory 
cytokine, IL d a p le 4 0), IL-13, G-CSF, GM-CSF, 
IFN-γ,  M 1 F- rtex following exposure to 
influenza (F .  . 
 
 
3.4 Discussion 
r l m  th ain of the H5N1 influenza virus 
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CP-1, MIP-1α, MIP-1β, and TNF-α and anti-
atory IL-10 were increased during the initial phase of infection (through day 10 
ne levels (pattern 1). The pro-inflammatory 
okines and growth factors including IL-1β, IL-2 and VEGF did not show 
hange
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Figure 3.8 Expression of Cytokines, Chemokines and Growth Factors in the Brainstem 
Following H5N1 Infection  
 
Three distinct patterns were observed in the brainstem. The pro-inflammatory cytokines, 
chemokines and growth factors including IL-1α, IL-12(p70), IL-13, eotaxin, G-CSF, 
M-CSF, IP-10, KC, M-CSF, MG
inflamm
dpi) and then returned or decreased to baseli
ytokines, chemc
c s during the active phase of infection, but at a later time, displayed induction 
(pattern 4). Statistical significance was determined by one-way ANOVA followed by 
Student-Newman-Keuls test and cytokine levels (pg/25ug of total protein) were presented 
as mean ± s.e.m (*: comparison with control mice; #: comparison with 3 dpi mice; †: 
comparison with 10 dpi mice; @: comparison with 21 dpi mice; ¶: comparison with 60 dpi 
ice; *, #,†,¶ and @: p<0.05; **, ##, ††,¶¶, and @@: P<0.001; error bars, s.e.m.). 
Table 3.2 Level of Cytokines, Chemok
tokines Control D
ines and
 3 
 Growth Factors in the Brainstem Following H5N1 Infection  
 
Cy pi Dpi 10 Dpi 21 Dpi 60 Dpi 90 
IL- D 2.01 ± 1.01 *,# B.D.L † B.D.L † B.D.L † 1α B.D.L B. .L 
IL-1 70  6.91 ± 0.84 3.89 ± 1.03 16.29 ± 1.99 *,#,†,@ 11.62 ± 1.35 ¶ 
IL- 08  B.D.L B.D.L 0.23 ± 0.05 *,#,†,@ 0.22 ± 0.06 *,#,†,@
IL- D 35.53 ± 21.63 B.D.L B.D.L B.D.L 
IL-9 .97 .51 B.D.L B.D.L 14.46 ± 5.11 5.82 ± 1.64 
IL- 85 ±  7.44 ± 1.76 *,#, 1.56 ± 0.14 † 3.27 ± 0.81 † 1.49 ± 0.11 † 
IL- 15 ±  * B.D.L # B.D.L # B.D.L # B.D.L # 
IL- 60 ±   4.61 ± 0.99 **,## 0.67 ± 0.44 †† B.D.L †† B.D.L †† 
Eo 26 ±  33.68 ± 6.76 **,## 2.90 ± 0.09 †† 7.56 ± 0.49 †† 6.67 ± 0.67 †† 
G- 39 ±  74.17 ± 29.98 *,# B.D.L †† B.D.L †† B.D.L †† 
GM 82 ±  4.94 ± 1.65 * 1.85 ± 0.54 B.D.L B.D.L 
KC 06 ±  56.88 ± 20.29 *,## 2.00 ± 0.16 † 3.61 ± 0.14 † 2.73 ± 0.30 † 
IFN D.L 54.92 ± 35.98 B.D.L B.D.L B.D.L 
IP-10 57 ±  2661.73 ± 322.66 ** 8.55 ± 2.65 9.64 ± 4.13 B.D.L 
M-CS 6 55 ±  26.94 ± 7.61 **,## 3.13 ± 0.68 † 4.79 ± 0.59 †† 4.42 ± 0.38 †† 
 
β 9.71 ± 2.03 7.
2 B.D.L 0.
6 B.D.L B.
7.23 ± 3.32 23
10 3.68 ± 1.55 1.
12(p70) B.D.L 0.
13 B.D.L 0.
taxin 6.23 ± 1.07 6.
CSF B.D.L 0.
-CSF B.D.L 1.
 2.47 ± 0.44 7.
-γ B.D.L B.
B.D.L 3.
F 4.28 ± 0.7 3.
 ± 1.22
 ± 0.02
.L 
± 12
0.39
0.70
 0.15
 0.06
 0.15
 0.13
 0.87
 2.45
 0.42
 65
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 3  10 21  
Table 3.2 (continued) 
 
Cytokines Control Dpi Dpi Dpi Dpi 60 Dpi 90 
MCP-1  ± 0.63 06.67 *,# † 0.35 †B.D.L 1.48 656.05 ± 3  B.D.L 0.79 ±  B.D.L † 
MIP-1α 20.86 **,##
1β 11 90 ± 17.22 *,## †† 
α .L 9 *,## †† †† †† 
F 5 ± 0.27   ± 0.14 ** * 
B.D.L B.D.L 63.88 ±  B.D.L †† B.D.L †† B.D.L †† 
MIP- B.D.L 5.17 ± 1. 55.  B.D.L B.D.L †† B.D.L †† 
TNF- B.D.L B.D 0.88 ± 0.2  B.D.L  B.D.L  B.D.L 
VEG 1.03 ± 0.23 0.27 ± 0.07 0.6 0.62 4.55 ± 0.79 3.00 ± 0.70 
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Mean fluorescent intensity of blanks, standards, and samples was m ate wells, using the Luminex 200 reader 
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Table 3.3 Level of Cytokines, Chemok
tokines Control Dpi
ines and
 
 Growth Factors in the SN Following H5N1 Infection 
 
Cy  3 Dpi 10 Dpi 21 Dpi 60 Dpi 90 
IL-1 5  47.36 ± 18.78 B.D.L 35.87 ± 15.55 30.99 ± 9.27 α 40.27 ± 21.73 22.0  ± 9.73
IL-1 2 1 * 16.57 ± 6.40 4.61 ± 1.39 # 33.34 ± 5.08 17.27 ± 0.78 
IL-  ± 2  B.D.L # 0.74 ± 0.13 # 2.13 ± 0.14 # 1.28 ± 0.29 # 
IL-6 .L 5.08 ± 0.64 **,## B.D.L †† 0.29 ± 0.11 †† B.D.L †† 
IL- .82 ± .60 23.66 ± 20.63 9.04 ± 2.12 41.86 ± 13.06 16.79 ± 3.71 
IL- 2 ± 0 13.88 ± 5.35 2.41 ± 1.57 3.90 ± 1.37 1.66 ± 0.06 
IL- 3 ±  B.D.L B.D.L 2.56 ± 1.57 B.D.L 
IL-  ± 3  B.D.L # B.D.L # 7.47 ± 2.38 *,@,† B.D.L #,¶ 
Eo 1 ± 8 21.46 ± 5.06 1.91 ± 0.17 6.84 ± 1.43 3.86 ± 0.34 
G- .L 9.58 ± 4.28 *,# B.D.L † B.D.L † B.D.L † 
GM-C .L B.D.L B.D.L 6.15 ± 2.29 **,##,††,@@ B.D.L ¶¶ 
IFN-γ 4 ± 2 5.59 ± 0.17 B.D.L 6.06 ± 3.37 B.D.L 
IP-10  ± 2 2519.40 ± 1700.01 3.06 ± 1.14 12.08 ± 0.68 B.D.L 
KC  ± 1 19.57 ± 9.65 0.83 ± 0.15 3.12 ± 0.69 1.27 ± 0.05 
MCP- .L 97.72 ± 25.34 **,## B.D.L †† B.D.L †† B.D.L †† 
MIP-1 B.D.L .L B.D.L B.D.L 8.96 ± 3.41 **,##,††,@@ B.D.L ¶¶ 
β 9.65 ± 1.90 65.7
2 B.D.L 5.41
 B.D.L B.D
9 16.39 ± 7.15 381
10 16.90 ± 6.08 25.5
12(p70) B.D.L 10.5
13 B.D.L 7.78
taxin 2.69 ± 1.08 18.3
CSF B.D.L B.D
SF B.D.L B.D
 B.D.L 26.5
3.63 ± 1.41 8.70
1.95 ± 0.42 5.55
1 B.D.L B.D
β B.D
 ± 35.2
.31 *
 264
22.4
9.65
.68 *
13.0
21.7
.72 
.34 
 68
69
 0 0 D
Table 3.3 (continued) 
 
Cytokines Control Dpi 3 Dpi 1 Dpi 21 Dpi 6 pi 90 
M-CSF * .46 †  22.90 ± 1.02 7.84 ± 3.70 15.53 ± 5.29 2.16 ± 0 4.40 ± 0.96 † .75 ± 0.23 † 
VEGF 3.59 ± 1.13 2.73 ± 0.84 2.74 ± 0.44 0.86 ± 0.32 5.94 ± 0.88
 
les was m
inex Corp , TX). The  fluorescen ks w ted fro nd concen ach 
cytokine was calculated from ter 
alized wit conc d ue lysat f to D.L represe
below the detectable concentration range of each analyte and was regarded as zero for statistical calculation. Statistical significance 
n-Ke ice; #  
†: c on with 10 omp ith 21 dpi mic p ice; *, #,†,¶ a 0.05; 
, and : P<0.001; m .
 
Mean fluorescent intensity of blanks, standards, and samp easured in duplicate wells, using the Luminex 200 reader 
(Lum ., Austin  median
 a 5-parame
t intensity of blan
logistic curve obtained from
as subtrac
 the known concen
m all readings a
tration of cytokines.
tration of e
 All results were 
norm h total protein entration measure  from each tiss e (pg/25 μg o tal protein). B. nted a value 
was determined by one-way ANOVA followed by Student-Newma uls test (*: comparison with control m : comparison with
3 dpi mice; 
**, ##, ††,¶¶
omparis
@@
dpi mice; @: c
ean number ± s.e.m
arison w
). 
e; ¶: com arison with 60 dpi m nd @: p<
 
 
 
 
 
 @ 4.33 ± 0.78 
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Figure 3.10 Expression of Cytoki
Following H5N1 Infection  
 
In striatum including eotaxin and 
M-CSF were increased on (through day 10 dpi) and then 
returned to baseline lev lammatory cytokine IL-2 was initially 
increased an eturn ter which it reinduced at 60 dpi (pattern 
3). The anti-inflammator anges during the active phase 
of infection, but at a later  4). Statistical significance 
an-Keuls test and 
ki 5u  mean ± s.e.m (*: comparison 
ice; #: comparison with 3 dpi m †: comparison with 10 dpi mice; @: 
parison with 21 dpi m ice; *, #,†,¶ and @: p<0.05; **, 
,¶¶ @@: P<0.001; error bars, s.e.m
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ab 3 th Factors in the Striatum Following H5N1 Infection  
 
Cytok 3 Dpi 10 Dpi 21 Dpi 60 Dpi 90 
le .4 Level of Cytokines, Chemok
ines Control Dpi 
ines and
 
 Grow
IL-1β  ± 8.91 ± 2.03 2.67 ± 0.75 8.58 ± 1.77 7.61 ± 0.97  6.05 ± 1.55 6.94  1.41 
IL-2  ± * B.D.L ## 0.97 ± 0.78 † 0.88 ± 0.07 **,† 0.84 ± 0.25 **,† 
IL-9 9 18.12 ± 5.37 5.94 ± 2.04 21.66 ± 3.18 16.58 ± 5.51 
IL-10  ± B.D.L B.D.L 1.04 ± 0.38 *,†,@ 0.58 ± 0.11 
Eotax  ± 0. 6.38 ± 1.50 *,# 1.57 ± 0.58 † 2.89 ± 0.35 † 2.69 ± 0.52 † 
IP-10 2 ± 5 794.54 ± 734.04 8.03 ± 7.42 12.53 ± 10.74 12.48 ± 6.23 
KC  ± 0. 8.53 ± 5.74 1.02 ± 0.76 0.98 ± 0.39 0.95 ± 0.07 
MCP-1  ± 0. 72.37 ± 59.88 B.D.L  1.24 ± 0.36 B.D.L 
M-CSF  ± 0. 2.88 ± 0.64 *,# 1.19 ± 0.70 † 1.27 ± 0.16 † 1.18 ± 0.27 † 
VEGF  ± 0. 1.34 ± 0.30 1.48 ± 0.63 4.20 ± 0.69 4.29 ± 1.29 
B.D.L 1.14
26.63 ± 8.05 13.9
B.D.L 0.56
in 1.78 ± 0.27 2.46
11.17 ± 8.18 19.0
1.36 ± 0.21 1.98
B.D.L 0.61
0.68 ± 0.14 1.12
3.76 ± 0.72 0.97
 0.25 *
 ± 3.26 
 0.16 
09 
14.6
45 
14 
12 
11 
 
ndards, and samples was measured in duplicate wells, using the Luminex 200 reader 
(Lum blanks was subtracted from all readings. Concentration of each 
cytokine mete istic curve obtained from the known concentration of cytokines. All results were 
normaliz ation asured from each tissue lysate (pg/25 μg of total protein). B.D.L represented a value 
below th ge o h analyte and was regarded as zero for statistical calculation. Statistical significance 
was dete follo by Student-Newman-Keuls test (*: comparison with control mice; #: comparison with 
3 dpi mi mice comparison with 21 dpi mice; ¶: comparison with 60 dpi mice; *, #, †, ¶ and @: p<0.05; 
**, ##, †† mb .). 
Mean fluorescent intensity of blanks, sta
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e detectable concentration ran
rmined by one-way ANOVA 
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e 3.5 Level of Cytokines, Chemokines and Growth Factors
ines Control Dpi 3 Cytok Dpi 10 Dpi 21 Dpi 60 Dpi 90 
14.71 ± 1.12 22.26 ± 4.52 IL-1β 14.18 ± 4.14 11.83 ± 3.62 14.73 ± 2.26 14.82 ± 1.68 
B.D.L 2.28 ± 0.68 ** IL-2 B.D.L # 1.39 ± 0.67 # 0.73 ± 0.06 # 0.88 ± 0.12 # 
12.54 ± 3.97 25.42 ± 5.45 * ## 9.02 ± 2.43 # 1.76 ± 0.81 ## 3.19 ± 0.73 ## IL-9 B.D.L 
B.D.L 0.92 ± 0.33 1.06 ± 0.43 *,† IL-10 B.D.L 0.82 ± 0.72 0.65 ± 0.05 
2.55 ± 0.27 4.46 ± 0.35 Eotaxin 8.76 ± 5.39 1.60 ± 0.54 2.08 ± 0.20 1.71 ± 0.35 
1.11 ± 0.30 19.18 ± 17.64 IP-10 1140.80 ± 1103.95 1.46 ± 0.41 B.D.L B.D.L 
1.95 ± 0.27 2.84 ± 0.70 KC 17.60 ± 15.38 0.98 ± 0.78 0.97 ± 0.23 0.64 ± 0.09 
B.D.L 0.52 ± 0.05 MCP-1 120.64 ± 116.40 B.D.L B.D.L B.D.L 
0.52 ± 0.12 0.73 ± 0.03 M-CSF 3.00 ± 1.88 1.00 ± 0.61 0.49 ± 0.16 0.54 ± 0.18 
2.68 ± 0.17 0.76 ± 0.07 4.02 ± 1.17 #,†,@ 4.21 ± 1.02 #,†,@ VEGF 0.39 ± 0.05 1.51 ± 0.62 
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Mean fluorescent intensity of blanks, standards, and samples was measured in duplicate wells, using the Luminex 200 reader 
( , TX). T ian fluoresce ty of  a gs. Concentr each 
cytokine was calculated from a 5-parameter logistic curve obtained from the known concentration of cytokines. All results were 
n zed w n co easure ssue lysa f total L repre  
below the detectable con tatistical sig
was determ man-Keuls arison ice; #  
ice; † arison with 10 dpi m i arison with 60 dpi m #, †, 
**, ##, ††, ¶¶, and @@: P<0.001; mean number ± s.e.m.). 
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zero for statistical calc
protein). B.D.
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nificance 
ined by one-way ANOVA followed by Student-New
ice; @
test (*: comp
ce; ¶: comp
with control m
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: comparison with
¶ and @: p<0.05; 3 dpi m : comp : comparison with 21 dpi m
Table 3.5 (continued) 
 
 
within the brain. Th mmation is characterized by an increase in the number of both 
resting a ac glia and differential expression of a number of cytokines, 
chemokines and growth factors. 
 
  nervous system has been associated with both the initiation 
and progression of a number of neurological disorders, including Parkinson’s disease 
(301, rdinal pathologies seen in Parkinson’s disease include 
dopa ath in the substantia nigra pars compacta and other regions of 
the brain, aggregation of ubiquitinated proteins including alpha-synuclein (Lewy bodies) 
throughout the brain and generalized increases in cerebral oxidative stress (303). 
Coin esses, there is an activation of the microglia within the brain.  
 
  to be determined is whether the inflammatory reaction seen in 
the C , or initiates these pathologies or both. There is significant 
research to support each of these possibilities. For example, increases in microglial 
numb roduction of cytokines have been shown to occur in response 
to overexpression of alpha-synuclein (304-307), death of neurons (308), and increased 
oxidative stress (309-311). Others have shown that activation of the immune system is 
likely a predisposing factor that contributes to the initiation and progression of these 
patho ple, in rodent PD model, a single systemic injection of 
inflammogen lipopolysaccharide (LPS) produced an elevation of TNF-α expression and a 
progressive cell loss in the SN that were sustained for 10 months after injection (315). In 
addit posed to LPS in prenatal period showed a prolonged 
inflam onse and a progressive DA neuron loss when they exposed 
LPS in adulthood, while the prenatal saline control mice did not (316). 
 
 d that microglia become activated coincident with the 
physical presence of the H5N1 virus and after this microglial induction we observe loss 
of the henotype (atrophy of TH-positive neurons and lack of 
dopa ation of phosphorylated alpha-synuclein (270) and 
induc pid microglial activation following peripheral inoculation 
of the influenza virus raises an important question: Is the initial microglial activation due 
to the direct sensing of the virus within the brain parenchyma or does it result from 
signa on of a “cytokine storm” in 
lung 
 
 fect comes from studies demonstrating that both microglia 
(317) and neurons (318) are capable of directly interacting with the HA protein on the 
surfa  by binding to sialic acid (SA)-alpha 2,3-galactose receptors, 
r matory cytokine production (317, 319). Other studies, 
u ic 1918 H1N1 influenza, lend support for an indirect adaptive 
h lve a humoral microglial interaction (320, 321).  
dings showing the physical presence of influenza virus in 
b tions with circulating T-cells (322, 323), we suggest that a 
b that cytokine expression in the brain, a 
is infla
nd tivated micro
Inflammation in the
 302). Some of the ca
minergic neuronal de
cident with these proc
 
Thus, what remains
NS is the outcome of
er, morphology and p
logies (311-314). For exam
ion, mice had been ex
matory immune resp
In this study, we fin
 dopaminergic cellular p
mine production), aggreg
tion of cell death. The ra
ls initiated outside of the brain, i.e. response to inducti
or gut?  
Support for a direct ef
ce of the influenza virus
e they can induce inflam
ding studies of pandem
anism which would invo
Based on previous fin
rain and probable interac
ination of mechanisms occur. We find 
whe
incl
mec
 
 
the 
com
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measure of immune activation/response, in most cases closely follows a pattern initiated 
in lung including IL-6, IL-12, G-CSF, IFN-γ, KC, MIP-1α, and TNF-α and GM-CSF 
(with a delayed response), and thus are likely to be, at least in part, initiated in from a 
ng-initiated cytokine storm. 
ain 
nigra 
 originally known as an anti-inflammatory cytokine that suppresses TNF-
, IL-1
pro-
 
r, 
creased 
roduction of dopamine in both the substantia nigra and striatum. Previous studies 
xamin wn that 
6). 
 
, their 
later insults or even normal age-induced changes, which could exacerbate a 
sponse that would not normally occur (340, 341). Specifically, one could hypothesize 
r 
” 
lu
 
 However, there are clear examples where we find cytokine expression in the br
that have no apparent relationship to the response in lung. IL-13 in the substantia 
and IL-2 in the striatum were particularly interesting as they showed a rapid induction 
followed by return to baseline levels and then a reinduction long after H5N1 virus is 
absent from the brain.  
 
 IL-13 is
α β, and IL-6 production in activated microglia and inhibits MHC class II and CD4 
receptor expression in macrophage both in vivo and in vitro (324-328). However, the 
inflammatory effects of IL-13 also have been documented. Microglia derived IL-13 
stimulates nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, a major 
source for reactive oxygen species (ROS) in microglia, and contributes to the 
neurodegeneration observed in thrombin-treated hippocampus. Neutralization of IL-13,
mediated by anti-IL-13 antibodies attenuates the production of inducible nitric oxide 
synthase (iNOS) and pro-inflammatory cytokines (329). IL-2 is a potent mediator of 
inflammatory immune response and expressed in response to insults (330, 331) and 
related with a progressive neuronal loss in rodent PD model (329, 332-335).  
 
 In our study, the stimulus for reinduction of this cytokines is unknown. Howeve
we note that the timing of cytokine re-induction is coincident with the in
p
e ing the effects of catecholamine expression on immune activation have sho
dopamine, as an inducer of oxidative stress via quinone formation (310, 336-339), can 
activate microglia, leading to progressive dopaminergic cell dysfunction and loss (33
 
 In conclusion, we have found that influenza infection, although resolved within 3
weeks of infection, can instigate a long-term activation of microglia with cytokine 
production. Since activated microglia function in surveillance and response to insult
continued presence in certain regions of the brain could make these regions particularly 
vulnerable to 
re
that influenza, which does not directly damage the basal ganglia enough to lead to 
induction of a full-blown disease state could make the basal ganglia sensitive to anothe
insult that would in and of itself also be non-pathogenic. In this manner, it can be 
proposed that idiopathic Parkinson’s disease may result from multiple sub-toxic “hits
(including neurotropic influenza) that occur over the course of a lifetime. 
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CHAPTER 4. PRIOR H5N1 INFLUENZA VIRUS INFECTION CONFERS 
PROTECTION FROM PARAQUAT-INDUCED TOXICITY IN MICE 
 
 
4.1 Introduction 
y 
r 
set of symptoms (342). Mice exposed to environmental toxins, 
ch as paraquat (PQ), during the postnatal period have been shown to become more 
voke a 
 
 
Therefore, to determine if prior H5N1 virus infection increased the sensitivity to 
as an 
hen 
f 
 
ch 
Stock viruses were prepared by propagating neurotropic A/VN/1203/04 (H5N1) 
llantoic cavity of 10-days-old embryonated chicken eggs for 40 to 48 hours at 37˚C. 
Virus stock was aliquoted then stored at -70˚C until use. Viral infectious titers were 
determined using the method of Reed and Muench (271) and expressed in log10 of the 
 
 The “multiple hit” hypothesis suggests that Parkinson’s disease may be caused b
the combination and/or accumulation of multiple insults to the brain throughout life 
where the initial event that initiates or contributes to the disease process may occur fa
earlier than the actual on
su
vulnerable to neurotoxins given in adulthood (74). For example, rats exposed to 
lipopolysaccharide (LPS) at prenatal stages become more sensitive to 6-hydroxy- 
dopamine (6-OHDA) as adults (75). These studies support the concept of a “multiple hit” 
hypothesis. 
  
 Previously, we have shown that acute H5N1 influenza infection can pro
long-term activation of microglia with specific patterns of cytokine production (Chapter 
3). This lead us to hypothesize that pre-existing neuroinflammation in certain regions,
including the substantia nigra could make these regions vulnerable to or increasingly 
sensitive to later insults that might not occur without the earlier exposure (313, 341).
  
 
PQ we intranasally infected C57BL/6J mice with H5N1 virus. We included mice in the 
study that showed at least 15% total body weight loss following H5N1 infection (
indication that these animals were infected (343)) and administered paraquat-HCl w
these animal recovered (60 days post infection). We found that early exposure to H5N1 
did not increase the sensitivity of C57BL/6J mice to intraperitoneal (ip) administration o
paraquat.  
 
 
4.2 Materials and Methods 
 
 All experiment using infectious pathogenic H5N1 viruses, including animal 
infection, were conducted in a Biosafety level 3+ laboratory approved for use by the U.S. 
Department of Agriculture and the Center for Disease Control and exclusively utilized by
the Division of Virology and other approved scientists at St Jude Children’s Resear
Hospital for highly pathogenic avian influenza work. 
 
 
4.2.1 Virus stock preparation and inoculation of mice with H5N1 
 
 
a
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50% e 
mice ( d 
fected intranasally with 30 µL of allantoic fluid diluted in PBS to the target virus 
fectious titer (102 EID50). One group of animal received 0.9% saline and was used as an 
tive control. The body weight of infected animals was monitored 
corded daily.  
 
e that 
ed by 
mg/kg of paraquat, every third day for three weeks, starting from 60 days 
he second group was treated with ip saline (0.9%). Two control groups 
l 
 
nd 
 ensure that any virus particles present in the tissue had been killed. Brains 
ere cryoprotected with 30% sucrose in PBS, serially sectioned in the coronal plane at 40 
icro sections and placed in PBS filled-24 well plates. Sections were immunolabeled for 
eeze, Rogers, AK, 1:500) overnight, and the primary 
ntibody was visualized using the ABC method (PK-6102, Vector Laboratories, 
me, 
, 
d 
tor 
Npc 
 egg infectious dose per 1.0 ml of fluid (EID50/mL). 6-8 week old C57BL/6J femal
Jackson Labs, Bar Harbor, ME) were anesthetized by isofluorane inhalation an
in
in
age-matched nega
re
 
 
4.2.2 Paraquat (PQ) administration 
 
 Paraquat HCl was purchased from Sigma (856177, Sigma, St. Louis, MO) and
diluted with sterilized saline (0.9%) to the working concentration of 1mg/ml. Mic
survived acute H5N1 infection with loss of -at least -15% total body weight follow
recovery, were divided into two groups. The first group was administered with ip 
injection of 5
post infection. T
were used for comparison. The first control group was aged matched, non-infected 
C57BL/6J mice administered paraquat using the same injection paradigm as experimenta
animals to ensure that the paraquat caused a lesion. The second control group was aged
matched, non-infected C57BL/6J mice administered ip saline to ensure that handling a
injection were not a variable in paraquat-induced neurological effects. 
 
 
4.2.3 Immunocytochemistry 
 
 One week after the final injection of PQ, mice were deeply anesthetized with 
Avertin and transcardially perfused with 0.9% saline followed by 10% neutral buffered 
formalin. Brains were removed and postfixed for 3 weeks in 10% neutral buffered 
formalin to
w
m
TH (rabbit, P40101-0, PelFr
a
Burlingame, CA) and 3,3-diaminobenzidine (SK-4100 Vector Laboratories, Burlinga
CA) as a chromogen. Sections were mounted on Superfrost-Plus (12-550, Fisher, 
Pittsburgh, PA) slide and counter stained with neutral red to visualize Nissl substance, 
and then dehydrated, cleared and mounted with Permount (SP15-500, Sigma, St. Louis
MO). 
 
 
4.2.4 Stereological cell count using the optical fractionator metho
 
 The total number of TH-positive dopaminergic neurons in both hemispheres of 
SNpc was estimated by the optical fractionator method (279) using the StereoInvestiga
software (version 7.0, MicroBrightField, Colchester, VT). The broad outlines of the S
in both hemispheres were delineated at low power (4× magnification). An unbiased 
78 
counting frame (60 × 60μm) was placed at the intersections of a grid (frame size 200 × 
200μm) randomly superimposed on a video image of the contoured sections. Sections 
were examined under a high power (100× objective lens, numerical aperture (NA)= 
on a BX51 microscope (Olympus, Center Valley, PA) with a MAC5000 motorized XYZ 
axis computer-controlled stage and a CX9000 CCD video camera (MicroBrightField
Colchester, VT).
1.3) 
, 
 TH-positive cells were counted at the depth that their nucleus was 
cused in each counting area. The reliability of the estimates were measured by 
alculation of the coefficient of error (344). Gundersen coefficients of error for m=1 was 
al significance was calculated using a one-way 
NOVA followed by Student-Newman-Keuls post hoc test (280). 
laced 
 
s (Bregma: -1.70 
 -2.70mm) (273). Tissues were homogenized in a chilled 0.3M perchloric acid and 
entrifuged for 15 minutes at 10,000g at 4˚C. The supernatants were saved and stored at -
 monoamine transmitters; dopamine (DA), and its 
etabolites 3,4-dihydroxyphenylacetic acid (DOPAC), and homovanillic acid (HVA); 
C, 
 by 
, IFN-γ, GM-CSF, G-CSF, M-CSF, Eotaxin, IP-10, KC, MCP-1, MIP-1α, MIP-1β 
nd VEGF proteins was simultaneously analyzed from dissected brain regions and lung, 
sing the Luminex 200 system (Luminex Corp., Austin, TX) and the Milliplex mouse 
0 
fo
c
all less than or equal to 0.10. Statistic
A
 
 
4.2.5 Biochemical measurement of monoamine neurotransmitters 
 
 One week after the last injection of PQ or saline, C57BL/6J mice were deeply 
anesthetized with Avertin and transcardially perfused with 0.9% saline to remove the 
majority of the blood from the brain vasculature. Brains were rapidly removed and p
in a brain matrix (BS-AL-5000C, Braintree Scientific, Braintree, MA) and sliced into 1 
mm thick sections and placed on an ice-cooled plate. Tissues were dissected from the SN
(Bregma: -2.70 to -3.70), striatum (Bregma: +0.14 to +1.26mm), brainstem (Bregma: -
5.40 to -6.70mm), cortex (Bregma: -1.70 to -2.70mm), and hippocampu
to
c
70˚C until used. A variety of
m
norepinephrine (NE); 5-hydroxytryptamine (5-HT) and its metabolites 5-
hydroxyindoleacetic acid (5-HIAA) were analyzed using reverse-phase ion pairing HPL
combined with electrochemical detection (EC) detection under isocratic elution 
conditions. The amount of monoamine neurotransmitters in the tissues was determined
injecting known concentration of monoamine neurotransmitters and extrapolating from a 
standard curve. Statistical difference was determined using a one-way ANOVA followed 
by Student-Newman-Keuls post hoc test 
 
 
4.2.6 Quantification of cytokines, chemokines and growth factors 
 
 The concentration of IL-1α, IL-1β, IL-2, IL-6, IL-9, IL-10, IL-12(p70), IL-13, 
TNF- α
a
u
cytokine kit (MPXMCYTO-70K-20, Millipore, Billerica, MA).  
 
 One week after the last injection of PQ or saline, dissected tissues were 
homogenized in a buffer containing 50 mM Tris-HCl (pH 7.4), 2.5mM EDTA, 0.1% 
Triton X-100, 150mM NaCl, protease and phosphatase inhibitor cocktail (Complete mini, 
PhosphoStop, Roche, Indianapolis, IN). The tissues lysates were then incubated for 3
79 
minutes on ice and centrifuged at 12,000g for 15 minutes. Supernatants were aliquoted 
and stored at -70˚C until used. To quantify cytokines, the supernatants were incubated 
with the microspheres coated with capture antibodies for each analyte for 2 hours. After 
rinsing, biotinylated detection antibodies were added into each well and incubated for 1 
hour. Streptavidin-phycoerythrin conjugates were added and fluorescence intensity wa
measured by the Luminex 200 reader (Luminex Corp., Austin, TX). Concentration o
each cytokine was calculated from a 5-parameter logistic curve obtained from the
concentration of cytokines, using MILLIPLEX Analyst software (Millipore, Billerica, 
MA, USA). 
 
s 
f 
 known 
.3 Results 
 
ted 
s 
radigm) into 
quat 
redisposing factor in the reduction of SNpc DA neurons, may in fact be protective. 
.3.2. Does prior infection with H5N1 synergize with PQ to effect changes in dopamine, 
 
rainstem, hippocampus 
nd cortex, and to determine if prior H5N1 exposure modified the levels of these 
s 
 
4
 
 
4.3.1. Does H5N1 infection synergize with PQ to alter dopaminergic neuron number in
the SNpc? 
 
 We assessed, using stereological methods (280), the number of tyrosine 
hydroxylase positive dopaminergic neurons in the SNpc (Fig 4.1A). We found that 
5mg/kg PQ treatment reduced the numbers of TH-positive dopaminergic neurons in 
SNpc in mice by 22%. Examination of the effect of H5N1 on TH-positive dopaminergic 
neuron number revealed no significant reduction compared to non-infected saline trea
control. 
 
 To examine if prior infection with H5N1 sensitized C57BL/6J mice to the effect
of paraquat, we injected 5 mg/kg paraquat (using the 3 weeks injection pa
mice that survived acute H5N1 infection with loss of -at least -15% total body weight 
followed by recovery, at 60 days after inoculation. The animals treated with para
after H5N1 infection showed a non-significant 10% reduction in the number of TH-
positive dopaminergic neurons, compared to non-infected saline treated control animals; 
a number that was approximately the same as the number determined in H5N1 + saline 
treated mice. These findings suggest that H5N1 infection, rather than being a 
p
 
 
4
DOPAC and HVA levels in the CNS? 
 
 Reverse phase HPLC with electrochemical detection was used to determine if 
exposure to H5N1 infection affected the levels of dopamine and its metabolites DOPAC
and HVA in five regions of the CNS: striatum, substantia nigra, b
a
neurochemicals observed following 3 weeks of 5mg/kg paraquat. 
 
 Although 5mg/kg PQ treatment alone significantly decreased the number of TH-
positive dopaminergic neurons in the SNpc (Fig 4.1), we found that these concentration
80 
 
 
Figure 4.1 Change in the Number of TH-Positive Dopaminergic Neurons Following 
H5N1 Infection and PQ Treatment  
 
Prior H5N1 infection did not potentiate PQ-induced neurotoxicity to dopaminergic 
neuron. 5mg/kg PQ treatment alone reduced TH-positive SNpc dopaminergic neurons
C57BL/6J mice by 22% (8768 ± 172, n=5) compared to non-infected saline treated 
control animals (11170 ± 599, n=4). Examination of the effect of H5N1 on TH-positive 
dopaminergic neurons (10090 ± 259, n=4) revealed no significant change compared to 
non-infected saline treated controls. Mice received 5mg/kg PQ treatment after H5N1 
nfection showed no change in TH-positive DA neuron number compared to non-infe
 in 
cted 
line treated control animals (5mg/kg of PQ + H5N1, 10410 ± 481); this number was 
 by one-way ANOVA followed by Student-
ewma ted 
@
i
sa
significantly higher than the number of TH-positive DA neurons in the PQ only treated 
group and was approximately the same as the number seen in H5N1 only-treated mice. 
tatistical significance was determinedS
N n-Keuls test (*: comparison with control mice; #: comparison with H5N1 infec
mice; : comparison with PQ 5mg/kg treated mice; *, # and @: p<0.05; **, ## and @@: 
P<0.001; error bars, s.e.m.).
81 
of PQ did not permanently alter the concentration of DA nor the amount its metabolites 
DOPAC and HVA in the striatum (Fig 4.2). We also detected no change in the rate of 
DA turnover, measured as (DOPAC + HVA)/DA, when comparing any of the 
experimental groups. Similar findings were also seen in substantia nigra (Fig 4.3), 
brainstem (Fig 4.4), hippocampus (Fig 4.5) and cortex (Fig 4.6). All the experiments 
examining the predisposing effects of H5N1 on PQ-mediated changes were only 
performed at 5 mg/kg dose. In this paradigm, H5N1 did not exacerbate the effects of 
paraquat on dopamine release or turnover in the striatum (Fig 4.2). In the other regions of 
the brain examined (and that contain significantly lower levels of dopamine), we 
observed that PQ treatment after H5N1 infection lower total dopamine in the SN 
compared to DA amount of saline treated control mice (Fig 4.3), while only turnover 
changes were noted in brainstem (Fig 4.4) and cortex (Fig 4.6). 
 
 
4.3.3 Does prior infection with H5N1 synergize with PQ to effect changes in NE, 5-HT 
and 5-HIAA levels in the CNS? 
 
 Reverse phase HPLC with electrochemical detection was used to determine if 
prior infection with H5N1 exacerbated paraquat’s effects on the level of NE, 5-HT, and 
5-HIAA in the SN, striatum, brainstem, cortex, and hippocampus. In the striatum, neither 
H5N1 nor PQ induced any long-term changes in NE levels. However, both H5N1 
infection and paraquat individually reduced the level of 5-HT and 5-HIAA by 
pproximately 50% compared to basal level. No synergistic effect between the H5N1 
(Fig 
 
.3-4.6), there appeared to be no synergistic effects of 
 
d
n levels in the lung, since PQ is a well known pneumotoxin 
(345). Previous studies have shown that concentrations of PQ ranging from 30mg/kg to 
120mg/kg could induce a significant increase in the level of serum cytokines, including 
TNF-α, IL-1 β, IL-6, and IL-10 (346). In our studies, much lower concentration of PQ 
was used since our goal was to establish whether there were synergistic effects between 
H5N1 and paraquat rather than to study the systemic effects of PQ alone.
a
infection and paraquat treatment to increase the loss of these monoamines was found 
4.2). Although there were some significant changes to NE, 5-HT and 5HIAA in other
egions of the CNS examined (Fig 4r
H5N1 and paraquat. 
 
 
4.3.4 Effect of PQ and H5N1 on activation of the immune response in brain 
 
 In the previous chapter, we demonstrated that infection with H5N1 led to a long-
term increase in the number of resting and activated microglia that reside in the SNpc. 
We also showed long-term changes in the expression of a number of proinflammatory 
cytokines, chemokines, and growth factors. This activated immune response implied to 
speculation that H5N1 infection could render the substantia nigra (and perhaps other 
brain regions) into a heightened state of readiness that could then potentiate the response
of the brain to PQ-induced neurotoxicity. 
 
 We next examined if the dosage of PQ we used in these studies coul  alter 
peripheral cytokine expressio
82 
 
 
 
Figure 4.2 Percent Change in Monoamine Neurotransmitter Level in the Striatum 
Following H5N1 Infection and PQ Treatment 
 
(A-C), No significant change was detected in the amount of striatal DA and its 
metabolites compared to that of control, regardless of treatments of among H5N1 or PQ 
alone or combined. (D), DA turnover rate, (DOPAC + HVA)/DA, was conserved 
roughout all experimental groups. No significant change in the amount of NE was 
1 
 
th
found in any group of animals. (E-F), The amount of 5-HT and 5-HIAA in the H5N
infected, H5N1+PQ treated, and H5N1+saline treated animals was decreased by 50% 
from that of control, but there was no significant difference among the groups. Statistical
significance was determined by one-way ANOVA followed by Student-Newman-Keuls 
test (*: comparison with control mice; #: comparison with H5N1 infected mice; @: 
comparison with PQ 5mg/kg administered mice; *, # and @: p<0.05; **, ## and @@: 
P<0.001; error bars, s.e.m.).
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igure 4.3 Percent Change in Monoamine Neurotransmitter Level in the SN Following 
5N1 Infection and PQ Treatment 
owed a significant reduction in the level of 
opamine in the SN. (B-C), A similar trend was observed in the amounts of DOPAC and 
as found 
uls 
F
H
 
(A), Mice received PQ after H5N1 infection sh
d
HVA, but failed to reach statistical significance. (D-E), No significant change w
in the amount of NE and 5-HT in any group of animals. (F), 5-HIAA was significantly 
decreased with PQ treatment, compared to basal level in control mice. Statistical 
significance was determined by one-way ANOVA followed by Student-Newman-Ke
test (*: comparison with control mice; #: comparison with H5N1 infected mice; @: 
comparison with PQ 5mg/kg administered mice; *, # and @: p<0.05; **, ## and @@: 
P<0.001; error bars, s.e.m.). 
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Figure 4.4 Percent Change in Monoamine Neurotransmitter Level in the Brainstem 
 
parison 
 mice; *, # and @: p<0.05; **, ## and @@: P<0.001; error 
ars, s.e.m.). 
Following H5N1 Infection and PQ Treatment 
 
(A), No additive or synergistic effect between H5N1 infection and paraquat treatment 
was observed in the level of dopamine in the brain stem. (B-C), DOPAC was 
significantly increased with H5N1+PQ treatment while HVA didn’t changed, compared
to counterparts in the control mice. (D-F), No significant change was found in the amount 
of NE, 5-HT, and 5-HIAA in any group of animals. Statistical significance was 
determined by one-way ANOVA followed by Student-Newman-Keuls test (*: 
comparison with control mice; #: comparison with H5N1 infected mice; @: com
with PQ 5mg/kg administered
b
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Figure 4.5 Percent Change in Monoamine Neurotransmitter Level in the Hippocamp
Following H5N1 Infection and PQ Treatment 
us 
he 
 
trol mice; 
 
(A-D), No additive or synergistic effect between H5N1 infection and paraquat treatment 
was observed in the amount of DA, DOPAC, HVA, and NE in the hippocampus. (E), T
amount of 5-HT was significantly decreased in mice that received PQ alone, compared to
H5N1+saline treated mice. A similar trend was observed in the amounts of 5-HIAA, but 
that failed to reach statistical significance. Statistical significance was determined by one-
way ANOVA followed by Student-Newman-Keuls test (*: comparison with con
#: comparison with H5N1 infected mice; @: comparison with PQ 5mg/kg administered 
mice; *, # and @: p<0.05; **, ## and @@: P<0.001; error bars, s.e.m.). 
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Figure 4.6 Percent Change in Monoamine Neurotransmitter Level in the Cortex 
 
ted group. (E-F), 
No significant change was found in the amount of 5-HT and 5-HIAA in any group of 
animals. Statistical significance was determined by one-way ANOVA followed by 
Student-Newman-Keuls test (*: comparison with control mice; #: comparison with H5N1 
infected mice; @: comparison with PQ 5mg/kg administered mice; *, # and @: p<0.05; **, 
## and @@: P<0.001; error bars, s.e.m.).
Following H5N1 Infection and PQ Treatment 
 
(A), No additive or synergistic effect between H5N1 infection and paraquat treatment 
was observed in the level of DA in the cortex. (B), The level of DOPAC was significantly
increased in the H5N1+PQ treated group, compared to the control, H5N1 infected, and 
PQ alone treated group. (C), A similar trend was observed in the amount of HVA, but 
that failed to reach statistical significance. (D), The level of NE was significantly 
increased in the H5N1+PQ treated mice, compared to the H5N1 infec
87 
 When the lower dose of PQ was administered (5mg/kg), a small number of 
changes in lung cytokine expression were detected, including increases in GM-CSF and 
IFN-γ. The levels of each of the other cytokines, chemokines and growth factors 
examined including IL-1α, IL-1β, IL-2, IL-6, IL-9, IL-10, IL-12(p70), Eotaxin, G-CSF, 
IP-10, KC, M-CSF, MIP-1α, MIP-1β, and VEGF were not changed in response to this 
low level of PQ (Fig 4.7, Table 4.1). To examine if H5N1 infection “primed” the lung to 
respond to a second challenge we administered 5 mg/kg PQ at 60 dpi with H5N1. In no 
cases did we observe synergistic effects of these two agents in any of the cytokines 
examined. On the contrary, we found that H5N1 priming appeared to dampen the 
cytokine-mediated immune response, reducing the level of pro-inflammatory cytokines 
IL-2 and GM-CSF (Fig 4.7, Table 4.1). 
 
 In the brain, we found that PQ could induce a specific pattern of cytokines 
chemokines and growth factors expression dependent on brain region. In the substantia 
nigra, paraquat significantly increased the level of pro-inflammatory cytokines, 
chemokines, and growth factors, including IL-2, IL-12(p70), IL-13, Eotaxin, G-CSF, 
GM-CSF, IFN-γ, KC, MIP-1α and MIP-1β compared to cytokine levels measured from 
the control mice. We found that priming with H5N1 lowered the expression of both pro-, 
anti-inflammatory mediators including IL-1β, IL-2, IL-6, IL-12(p70), IL-13, Eotaxin, G-
CSF, GM-CSF, IFN- γ, KC, MCP-1, M-CSF, MIP-1α and MIP-1β, compared to PQ 
alone treatment without H5N1 priming (Fig 4.8, Table 4.2).  
 
 In the striatum, administration of the 5mg/kg of PQ increased the expression of 
pro-inflammatory cytokines, chemokines, and growth factors including IL-12(p70), IL-13, 
GM-CSF, IFN-γ, KC, MCP-1, MIP-1 α and MIP-1β (Fig 4.9, Table 4.3). As was 
observed in the lung and substantia nigra, prior exposure to H5N1 either lowered (IL-13, 
GM-CSF, KC, MCP-1, MIP-1α and MIP-1β) or did not affect (IL-1β, IL-2, IL-9, IL-10, 
IL-12(p70), Eotaxin, IFN-γ, M-CSF and VEGF) of the inflammatory response to 
paraquat (Fig 4.9, Table 4.3). 
 
A similar pattern of cytokines/chemokines/growth factors expression was noted in 
e brainstem (Fig 4.10, Table 4.4) and cortex (Fig 4.11, Table 4.5), suggesting that in 
 
e 
 
th
the CNS, prior infection with H5N1 either had no effect or reduced PQ-induced immune 
response.  
 
 
4.4 Discussion 
 
 The etiology of the vast majority of Parkinson’s disease is unknown. One 
hypothesis put forward regarding how this disorder is initiated states that there is either
additive or synergistic combinatorial effect of different sub-threshold insults that 
ultimately leads to the development of a parkinsonian pathology. This is the basis for th
“multiple hit” hypothesis (70-73). 
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 PQ Treatment  
P-1α and MIP-1β and anti-inflammatory cytokine IL-10 were not 
e control, suggesting that 5mg PQ treatment 
lone did not provoke an massive innate immune response. No synergistic effect between 
 and PQ treatment to increase the cytokine-mediated immune response 
as observed. On the contrary, we found that priming with H5N1 appeared to dampen 
ined 
ented as mean ± s.e.m (*: comparison with control 
ice; #: comparison with H5N1 infected mice; @: comparison with PQ 5mg/kg treated 
: p<0.05; **, ## and @@: P<0.001; error bars, s.e.m.). 
 
 
Figure 4.7 Expression of Cytokines, Chemokines and Growth Factors in the Lung 
Following H5N1 Infection and
 
Pro-inflammatory cytokine, IFN-γ and growth factors GM-CSF were increased with ip 
administration of 5 mg/kg PQ. The rest of the pro-inflammatory mediators examined, 
including IL-1α, IL-1β, IL-2, IL-6, IL-9, IL-13, Eotaxin, G-CSF, IP-10, KC, M-CSF, 
MCP-1, MI
significantly different from basal levels in th
a
H5N1 infection
w
the cytokine-mediated immune response after PQ exposure. The level of pro-
inflammatory cytokine IL-2 and growth factor GM-CSF was significantly decreased 
compared to levels in the PQ alone treated mice. Statistical significance was determ
by one-way ANOVA followed by Student-Newman-Keuls test and cytokine levels 
(pg/25ug of total protein) were pres
m
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Tabl s in the Lung Following H5N1 Infection and PQ Treatment 
 
e 4.1 Level of Cytokines, Chemokines and Growth Factor
Cytokines Control H5N1 PQ H5N1 + PQ 
1α 14.95 ± 4.47 IL- 11.18 ± 5.63 10.45 ± 3.30 16.69 ± 4.27 
1β 52.92 ± 11.44 IL- 41.26 ± 6.63 41.83 ± 5.99 24.63 ± 3.67 
2 3.73 ± 0.57 1.47 ± 0.25 *,@ IL- 2.41 ± 0.49 3.93 ± 0.83  
9 59.77 ± 16.66 IL- 5.14 ± 2.43 38.61 ± 15.52 25.52 ± 5.15 
IL-6 1.88 ± 0.23 4.14 ± 3.84 1.48 ± 0.27 1.24 ± 0.56 
10 2.74 ± 0.38 IL- 1.52 ± 0.83  4.75 ± 0.99 1.68 ± 0.29 
IL-12(p70) 2.06 ± 0.21 2.19 ± 0.44 # 2.31 ± 0.35 # B.D.L * 
Eotaxin 56.17 ± 7.13 62.56 ± 18.70 63.25 ± 10.32 68.36 ± 6.60 
G-CSF 1.43 ± 0.25 10.51 ± 3.92 1.78 ± 0.42 18.17 ± 8.82 
GM-CSF B.D.L 4.32 ± 1.41 **,## 1.47 ± 0.31 @ B.D.L 
IFN-γ B.D.L 1.16 ± 0.37 **,# 0.89 ± 0.15 **,# B.D.L 
10 7.48 ± 0.94 IP- 9.83 ± 3.31 13.50 ± 5.03 18.22 ± 2.37 
KC 5.46 ± 0.64 17.12 ± 6.75 8.23 ± 3.11 12.93 ± 2.68 
CSF 1.44 ± 0.43 2.82 ± 0.98 # M- 5.90 ± 1.54 * 4.39 ± 0.39 * 
1 6.75 ± 1.11 MCP- 5.99 ± 2.94 8.30 ± 2.08 11.81 ± 1.24 
MIP-1α 7.44 ± 1.85 25.07 ± 1.09 5.36 ± 1.97 15.54 ± 12.80 
MIP-1β B.D.L B.D.L 5.00 ± 1.91 7.50 ± 5.14 
VEGF 56.96 ± 5 2 .7 86.88 ± 9.35 63.83 ± 10.47 73.85 ± 7.68 
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Mean fluorescent intensity of blanks, standards, and samples was measured in duplicate wells, using the Luminex 200 reader 
 all r ach 
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Figure 4.8 E mokines and Growth Factors in the SN 
Following H5N1 Infection and PQ Treatment 
 
Pro-inflammatory cytokines/chemokines/growth factors, including IL-2, IL-12(p70), IL-
13, Eotaxin, G-CSF, GM γ, KC, MIP-1α and MIP-1β were increased in 
response to 5m ent, compared to basal levels measured in the control animals. 
Prim ensitization and in no cases was there any increases 
in the inflamm  and anti-inflammatory mediators including 
IL-1β -13, Eotaxin, G-CSF, GM-CSF, IFN-γ, KC, 
MCP-1, M-CSF, MIP-1 β were decreased in H5N1+PQ groups, compared to 
ficance was determined by one-way ANOVA 
an-Keuls test and cytokine levels (pg/25ug of total protein) 
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T Factors in the SN Following H5N1 Infection and PQ Treatment  
 
able 4.2 Level of Cytokines, Chemokines and Growth 
Cytokines Control H5N1 PQ H5N1 + PQ 
 36.77 ± 10.73IL-1α  30.99 ± 9.27 35.81 ± 6.74 1.87 ± 1.30 
IL-1β 18.54 ± 3.67 13.12 ± 2.86 @ 17.27 ± 0.78 30.73 ± 3.69 
8.50 ± 1.28 *,# 2.44 ± 0.73 @ IL-2 5.56 ± 1.27 1.28 ± 0.29 
4.30 ± 0.61 ## B.D.L **,@@ IL-6 3.31 ± 0.49 B.D.L ** 
IL-9 27.48 ± 4.81 16.79 ± 3.71 37.74 ± 3.46  29.58 ± 18.49  
IL-10 22.50 ± 4.00 26.59 ± 2.12 ## 4.40 ± 1.43 **,@@ 1.66 ± 0.06 ** 
IL-12(p70) B.D.L 4.81 ± 0.62 **,## 2.70 ± 0.61 **,#,@ B.D.L 
IL-13 B.D.L 3.17 ± 0.40 **,## 1.98 ± 0.53 *,#,@ B.D.L 
10.40 ± 1.56 *,# 3.57 ± 0.69 @ Eotaxin 4.95 ± 1.02 3.86 ± 0.34 
1.59 ± 0.42 **,## 0.71 ± 0.11 *,#,@ G-CSF B.D.L B.D.L 
F 7.81 ± 1.25 10.73 ± 1.30 *,## 2.00 ± 0.43 @ GM-CS B.D.L 
13.20 ± 1.89 **,## 2.27 ± 0.55 @@ IFN-γ 6.48 ± 2.55 B.D.L 
IP-10 4.24 ± 1.02 B.D.L 43.97 ± 26.75 B.D.L 
6.20 ± 1.06 *,## 2.16 ± 0.29 @@ KC 3.16 ± 0.54 1.27 ± 0.05 
10.91 ± 1.62 # 3.61 ± 1.11 @ MCP-1 7.68 ± 1.59 B.D.L * 
6.94 ± 0.70 # 3.72 ± 0.31 @ M-CSF 4.99 ± 1.02 2.75 ± 0.23 
9.57 ± 2.28 **,## 2.82 ± 0.81 @@ MIP-1α B.D.L B.D.L 
 4.79 ± 0.61 9.10 ± 1.97 *,## 3.09 ± 0.79 @ MIP-1β B.D.L 
VEGF 3.75 ± 0.65 4.33 ± 0.78 2.39 ± 0.30 2.28 ± 0.50 
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Figure 4.9 E mokines and Growth Factors in the Striatum 
Following H5N1 Infection and PQ Treatment  
 
Pro-inflammatory cytokines/chemokines/growth factors including IL-12(p70), IL-13, 
GM-CSF, IFN- α and MIP-1β were increased responds to ip 
admi l levels measured in the control animals. 
As was observed in the lung and substantia nigra, prior exposure to H5N1 either lowered 
(IL-13, GM-CSF, KC, MCP-1, MIP-1α, and MIP-1β) or did not affect (IL-1β, IL-2, IL-9, 
IL-12(p70), Eotaxin, IF , IP-10, M-CSF and VEGF) the inflammatory response to 
paraqua  determined by one-way ANOVA followed by 
Student-Newm cytokine levels (pg/25ug of total protein) were presented 
as mean ± s.e.m  control mice; #: comparison with H5N1 infected 
mice; g/kg treated mice; *, # and @: p<0.05; **, ## and @@: 
P<0.001; error bars, s.e.m.). 
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Table 4.3 Level triatum Following H5N1 Infection and PQ Treatment  
 
 of Cytokines, Chemokines and Growth Factors in the S
Control H5Cytokines N1 PQ H5N1 + PQ 
5.54 ± 0.91 7.6 3.60 ± 0.81 # IL-1β 1 ± 0.97 6.06 ± 0.62 
1.88 ± 0.12 0.8IL-2 4 *  ± 0.26 1.44 ± 0.22 0.80 ± 0.22 * 
19.10 ± 5.67 16.IL-9 5 1 8 ± 5.5 6.68 ± 1.07 9.05 ± 0.78 
3.81 ± 0.94 0.5IL-10 8 ± 0.11 3.80 ± 1.10 0.60 ± 0.10 
B.D.L B. 0.66 ± 0.18 *,# 0.57 ± 0.16 *,# IL-12(p70) D.L 
B.D.L B. 0.47 ± 0.01 **,## B.D.L @@ IL-13 D.L 
2.25 ± 0.39 2.6Eotaxin 9 ± 0.52 2.96 ± 0.46 1.69 ± 0.21 
B.D.L B. 1.84 ± 0.47 **,## 0.62 ± 0.11 @ GM-CSF D.L 
B.D.L B. 0.74 ± 0.35 *,# IFN-γ D.L 0.54 ± 0.15 
11.42 ± 4.73 12.IP-10 48 ± 3  6.2 11.89 ± 5.03 B.D.L 
1.73 ± 0.26 0.9 2.70 ± 0.51 *,# 1.21 ± 0.14 @ KC 5 ± 0.07 
1.24 ± 0.28 1.1M-CSF 8 ± 0.27 1.57 ± 0.25 1.45 ± 0.13 
B.D.L B. 3.65 ± 0.72 **,## 1.37 ± 0.22 *,#,@@ MCP-1 D.L 
B.D.L B. 2.82 ± 0.54 **,## 0.80 ± 0.22 @@ MIP-1α D.L 
B.D.L B. 2.55 ± 0.58 **,## 1.05 ± 0.25 *,#,@ MIP-1β D.L 
3.02 ± 0.44 4.2 1.32 ± 0.17 *,# 1.00 ± 0.15 *,# VEGF 9 ± 1.29 
96 
97 
Mean fluorescent intensity of blanks, standards, and samples was measured in duplicate wells, using the Luminex 200 reader 
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Figure 4.10 Expression of Cytokines, Chemokines and Growth Factors in the Brainstem 
Following H5N1 Infection and PQ Treatment  
 
Pro-inflammatory cytokines/chemokines/growth factors including IL-12(p70), GM-CSF, 
IFN- α, MIP-1β and VEGF were increased responds to 5mg PQ 
treatm easured in the control animals. Prior exposure to 
H5N1 lowered (IL-2 and IP-10) or raised (IL-12(p70), IFN-γ, and, M-CSF) or did not 
affect (IL-1 α, MIP-1β and VEGF) 
the inflammatory response to paraquat. Statistical significance was determined by one-
way ANOVA followed by Student-Newman-Keuls test and cytokine levels (pg/25ug of 
total protein) were presented as mean ± s.e.m (*: comparison with control mice; #: 
comp ice; @: comparison with PQ 5mg/kg treated mice; *, # 
and @ : P<0.001; error bars, s.e.m.). 
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Table 4.4 Level of Cy Brainstem Following H5N1 Infection and PQ Treatment  
 
tokines, Chemokines and Growth Factors in the 
Control H5Cytokines N1 PQ H5N1 + PQ 
9.27 ± 1.05 11 5.33 ± 0.98 *,# 3.80 ± 0.66 *,## IL-1β .6 5 2 ± 1.3
1.23 ± 0.13 0.2 0.62 ± 0.14 **,# 0.24 ± 0.05 **,@ IL-2 2  **  ± 0.06
7.23 ± 3.32 5.8IL-9 2   ± 1.64 1.97 ± 0.59 3.08 ± 0.58 
5.11 ± 1.19 1.4IL-10 9   ± 0.11 5.04 ± 0.71 1.65 ± 0.21 
B.D.L B. 0.36 ± 0.05 **,## 0.60 ± 0.10 **,##,@ IL-12(p70) D.L 
5.73 ± 0.57 6.6 4.33 ± 0.40 # 3.17 ± 0.22 *,## Eotaxin 7   ± 0.67
B.D.L B. 1.28 ± 0.48 **,# 0.92 ± 0.10 *,# GM-CSF D.L 
B.D.L B. 0.35 ± 0.06 **,## 0.61 ± 0.11 **,##,@ IFN-γ D.L 
B.D.L B. 6.32 ± 2.74 *,# 1.34 ± 0.49 @ IP-10 D.L 
2.86 ± 0.30 2.7KC 3 ±  0.30 2.74 ± 0.29 2.05 ± 0.24 
MCP-1 B.D.L B. 1.82 ± 0.73 *,# 2.09 ± 0.50 *,# D.L 
M-CSF 4.81 ± 0.51 4.4 2.54 ± 0.33 *,# 4.27 ± 0.30 @ 2 ±  0.38
MIP-1α B.D.L B. 1.06 ± 0.38 **,# 0.92 ± 0.09 *,# D.L 
B.D.L B. 1.15 ± 0.37 **,# 1.49 ± 0.33 **,## MIP-1β D.L 
VEGF 1.  070 ± .36 3.0 0.66 ± 0.07 # 0.70 ± 0.07 # 0 ±  * 0.71
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Figure 4.11 Expression of Cytokines, Chemokines and Growth Factors in the Cortex 
Following H5N1 Infection and PQ Treatment  
 
Pro-inflammatory cytokines including IL-12 (p70), GM-CSF, IFN- γ, MIP-1α, MIP-1β 
and VEGF were increased responds to 5mg PQ treatment, compared to basal levels 
measured in the control animals. Prior exposure to H5N1 either lowered (IL-1β, IFN-γ, 
IP-10, KC, MIP-1 , IL-10, Eotaxin, GM-CSF, MCP-1, M-
CSF, MIP-1 atory response to paraquat. Statistical significance 
was determ wed by Student-Newman-Keuls test and 
cytokine levels (pg/25ug of total protein) were presented as mean ± s.e.m (*: comparison 
with control m  H5N1 infected mice; @: comparison with PQ 
5mg/kg treated m @: p<0.05; **, ## and @@: P<0.001; error bars, s.e.m.). 
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Table 4.5 ortex Following H5N1 Infection and PQ Treatment 
 
Level of Cytokines, Chemokines and Growth Factors in the C
Cytokines Control H5N1 PQ H5N1 + PQ 
IL-1β 16.71 ± 1.30 14 9.66 ± 0.81 *,#,@ .8 8 2 ± 1.6 16.12 ± 1.71 
IL-2 1.44 ± 0.36 0.88   ± 0.12 1.54 ± 0.29 0.88 ± 0.10 
IL-9 12.11 ± 2.84 2.39  *  ± 0.95 2.03 ± 0.47 * 4.72 ± 0.95 * 
IL-10 1.98 ± 0.86 0.65   ± 0.05 1.48 ± 0.28 0.53 ± 0.13 
IL-12(p70) B.D.L B. 0.40 ± 0.03 **,## 0.51 ± 0.02 **,##,@@ D.L 
Eotaxin 2.41 ± 0.23 1.71   ± 0.35 2.20 ± 0.30 1.76 ± 0.23 
GM-CSF B.D.L B. 0.89 ± 0.13 **,# 1.09 ± 0.36 **,# D.L 
IFN-γ B.D.L B. 0.39 ± 0.04 **,## 0.32 ± 0.04 **,##,@ D.L 
IP-10 3.13 ± 2.03 B. 4.86 ± 1.80 # B.D.L @ D.L 
KC 2.16 ± 0.28 0.6 2.27 ± 0.29 # 1.24 ± 0.12 *,@ 4 ±  * 0.09
M-CSF 0.75 ± 0.13 0.54 ±  0.18 0.75 ± 0.12 0.73 ± 0.09 
MCP-1 2.33 ± 0.91 B.D.L * 1.67 ± 0.34 1.26 ± 0.40 
MIP-1α B.D.L B. 0.99 ± 0.37 *,# 0.86 ± 0.27 *,# D.L 
MIP-1β B.D.L B. 0.91 ± 0.05 **,## 0.73 ± 0.10 **,##,@ D.L 
VEGF 2.49 ± 0.16 4.2 1.13 ± 0.06 *,## 0.79 ± 0.12 *,## 1 ±  * 1.02
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 In this set of eriments we examined one combination of insults, that of a 
neurotropic virus, H5N1 (A/VN/1203/1204) and paraquat, an agent that generates 
oxidative stress by a direct redox mechanism. The highly pathogenic H5N1 
(A/VN/1203/04) strain is neurotropic and induces both short-term and long-term effects 
in the central nervous system, including a transient reduction of the dopamine (270) and a 
long-lasting increase in inflammation in the brain, characterized by an increase in the 
numb  activated microglia and differential expression of a number of 
cytok  growth factors (Chapter 3). 
 
 idely used throughout the world as an herbicide; compounds 
that have shown to have an etiological link with Parkinson’s disease (74, 170). Paraquat 
is actively transported into the brain through neutral amino acid transporters (347). Once 
in the  evidence has shown that paraquat acts as a direct redox cycling 
agent, where it first undergoes a one-step reduction catalyzed by NADPH oxidase, NOS 
and c icroglial cells (307, 348). The paraquat cation radical then 
transfers its electrons to molecular oxygen that results in the formation of superoxides. 
Additionally, by virtue of the SNpc having significant dopamine metabolism and a 
signif roglial density compared to other brain regions (12), there is a 
prope n peroxide and superoxides that react with nitrated proteins to 
for pe ructure, eventually initiating apoptosis through a Bcl-2 
homo ler (BAK) dependent mechanism (349).  
 
 othesis, the results of this study suggest that H5N1 (as a first 
insul effect or may even protect the dopaminergic neurons in the 
substantia nigra pars compacta from paraquat-induced neurotoxicity. This conclusion is 
based on the findings that H5N1+PQ mice show no loss of TH-positive SNpc 
dopa  this same combination appears to suppress most of the long-
term cytokine responses seen following intranasal H5N1 inoculation. 
 
 is raised regarding how H5N1 priming may protect the CNS 
(and in particular the basal ganglia) from paraquat-induced neurotoxicity and 
neuro ossibility (and an area that was not examined in this thesis) is 
that in addition to induction of proinflammatory cytokines, H5N1 may also induce, either 
directly or indirectly, neurotrophic factor expression. Neurotrophins are small molecules 
that g ve survival influence on neurons, allowing these cells to 
survive after a variety of insults that would normally injure or kill them (350). In the 
CNS, neurotrophins are expressed by both neurons and glia (astrocytes and microglia) 
(351) and several studies have shown that inflammation in the CNS and the subsequent 
relea induce production of these proteins (351-353) 
) g a “Yin and Yang” function to microglial activation and 
am 4-357), where in the case of these two agents, there is a 
i s the neurotrophins 
text of the individual insults may also affect the combined 
tp nts. For example, Mangano et al. reported that pre-LPS 
s iated paraquat-induced neurotoxic effect on dopaminergic 
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neuron, when PQ was delivered 2 days after the endotoxin in C57 BL/6J mice. This 
combination of toxins showed opposite results when paraquat was administered 7 d
after LPS infusion (358). In our experiment, the timing of the two insults cou
factor, if the 60 day interval between insults either does not allow for the reinitiation of 
an inflammatory response or if the initial insult is self-limiting. Examination of the 
cytokine profiles in the basal ganglia suggests that these possibilities exist, as there is n
example of higher levels of cytokine induction in the H5N1+paraquat condition 
compared to paraquat or H5N1 alone. This precondition
same 
ays 
ld be a 
o 
ed repression has been described 
fter exposure to ionizing radiation (359), ischemia (360), or LPS (358). Although the 
echan
sm is 
 the 
ufficient oxidative 
ress on dopaminergic neurons to generate a cytokine response (that would overcome 
 paraquat’s 
roduce a massive cell loss of the dopaminergic neurons nor effect release of dopamine 
 the s
son’s 
n to 
 
hat 
ence 
pothesis.  
a
m ism for this inflammatory repression is not fully elucidated, it has been shown 
that elevation of heat shock protein 70 (HSP70) (361), which ultimately inhibits 
expression of the nuclear factor-κB (NF-κB) pathway, can modulate the inflammatory 
response. NF-κB is an essential transcription factor that regulates transcription of genes 
shown to be involved in immune function, inflammation, and apoptosis (362-364). One 
mechanism for the protective effects of HSP70 appears to be its ability to inhibit 
reinduction of cytokines by blocking NF-κB p65 nuclear translocation and IκBα 
degradation (361, 365, 366). Further studies are needed to determine if this mechani
involved in the influenza induced cytokine repression.  
 
 It is also possible that the dosage of paraquat used in this study (5mg/kg) as
second stressor may not have been at a high enough level to induce s
st
any inhibition, see above). This hypothesis could be tested by examining cytokine 
reinduction after administration of higher levels of paraquat (such as 10 mg/kg). 
However, Klinworth et al. (367) reported that paraquat was unable to induce midbrain 
microglia to produce any proinflammatory cytokines and suggested that any of
inflammatory effects are not a direct response from microglia but are a direct result of 
dopaminergic neuron damage. As the dose of paraquat we used (5 mg/kg) does not 
p
in triatum, this second insult (paraquat) may either not be a sufficient stressor at 
these low levels or may not be a factor in any “multiple hit” cascade for Parkin
disease. A literature search looking for direct cases of proven paraquat-induced 
parkinsonism in humans shows no case reports (368) and it is possible other agents that 
induce oxidative stress in the brain, such as MPTP or rotenone, that work via direct 
inhibition of Complex I in the electron transport chain (12, 369) and have been show
induce human parkinsonism, will provide evidence for this “multiple hit” hypothesis.  
 
 In conclusion, we found that acute H5N1 influenza infection, although producing
a long-term activation of microglia with proinflammatory cytokine production, appears to 
protect the dopaminergic neurons from paraquat-induced neurotoxicity. We suggest t
the timing and the context of each insult may be critical for determining the consequ
of combinatorial effects in the “multiple hit” hy
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CHAPTER 5. IMPLICATIONS, LIMITATIONS AND FUTURE STUDIES 
 
 Since James Parkinson first described Parkinson’s disease in 1817 (1), more t
50,000 research papers have been published on the topic of Parkinson’s disease (370). 
Despite the knowledge accumulated and progress made in understanding PD, thus fa
mechanisms underlying the development of Parkinson’s disease have not been fully 
elucidated. 
 
 During the last two decades, studies in Parkinson’s disease-related genetics hav
shed light on some of the pathogenesis of Parkinson’s disease, as genetic mutations 
linked to the early onset and familial forms of PD were identified. However, the P
related to individual genetic mutations account for at most 10% of the total PD cases (7
 
 Other factors from the environment, such as infectious agents have also been 
suggested as a risk factor in the development of Parkinson’s disease. Reports of 
influenza-associated neurological symptoms are found as far back as 1385 and ha
continued through more recent influenza outbreaks (5). Among the influenza pandemics 
in the twentieth century, the 1918 Spanish flu (H1N1) pa
han 
r, the 
e 
D cases 
). 
ve 
ndemic was the most severe, 
sulting in 20-100 million casualties, with an unusually high rate of mortality in the 
 
 
 and 
ality 
 
ic 
in their 
N1 
euroinflammation, B) to determine if the H5N1 influenza virus infection in the CNS 
echanism where the original 
sult is no longer present but the secondary sequelae persists (5). If it is recognized that 
fluenza activates the innate CNS immune system (225, 374) , identification of potential 
cond hits that may lead to development of parkinsonian symptoms is useful. 
re
young (371). A significant number of patients exhibited unusual neurological symptoms
known as Encephalitis lethargica (EL) (24). Approximately 50% of patients surviving EL
later developed post-encephalitic Parkinsonism (PEP), providing epidemiological links 
between EL and PEP (5, 42, 372), although direct evidence linking H1N1 infection
the subsequent development of EL or PEP has not been published.  
 
 The recently publicized highly pathogenic avian influenza (HPAI/H5N1) virus is, 
and continues to be, a severe threat to public health. Until May 2010, the H5N1 global 
outbreak has caused 498 human cases of flu and 294 deaths, resulting in a 60% mort
rate (255). Like the 1918 H1N1 influenza virus, H5N1 virus originated in avian species, 
and demonstrates its highest mortality rate in young adults (371). In at least two of the
reported human cases of H5N1, patients died with acute encephalitis without the class
respiratory symptoms, and in these patients, H5N1 influenza virus was detected 
cerebrospinal fluid (207). This suggests that H5N1 virus can infect the CNS, and even 
survivors may have some degree of encephalitis at some point in the course of the H5
infection (269, 373). Therefore, the primary objectives of this dissertation are A) to 
determine if intranasally delivered H5N1 virus can infect the CNS and induce 
n
results in parkinsonian pathology. 
 
 In many cases of encephalitis or toxin-induced parkinsonism the offending agent 
may cause a long lasting immune response in the brain, persisting many years after the 
initial insult has been resolved, leading to a “hit and run” m
in
in
se
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 One class of agents that could act as a “second hit” includes agricultural products, 
ch as paraquat. Each of these chemicals induce oxidative stress and the generation of 
 
 this 
is to determine if H5N1 priming of the immune system potentiates paraquat-
duced neurotoxicity and neurodegeneration. 
In Chapter 2, I demonstrated that the highly infectious, neurotropic 
, 
the 
raxis, 
tor 
 
to 
an be transported 
traneuronally. Using microfluidic chambers, I confirmed that H5N1 is transported 
in 
ts 
 
rity to 
a virus (202). The distribution of the receptors in 
rret resembles that seen in humans and initially mediates lower respiratory tract 
su
free radicals, either through blockade of complex I (rotenone) (375, 376) or direct free 
radical formation, independent of complex I inhibition (paraquat) (347, 377). Whatever
the cause of increased oxidative stress, it is clear that prior activation of microglia 
increases sensitivity to these agents (378, 379). Therefore, the secondary objective of
dissertation 
in
 
 
5.1 Chapter 2 
 
 
A/VN/1203/04 (H5N1) virus travels from the peripheral nervous system into the CNS
first appearing in the Solitary nucleus and adjacent dorsal motor nucleus of X in 
brainstem. This pattern of viral spread, from the periphery to higher levels of the neu
mimics the progression of Parkinson’s disease described by Braak (121) . Braak 
postulated that some viruses might infect the mesenteric and myenteric (Auerbach’s) 
plexi of the enteric nervous system and be retrogradely transported into the dorsal mo
nucleus (DMN) of the vagus nerve, since a synuclein pathology characterized by swollen
neurites and inclusions were commonly found in the fibers that project to this region from 
the vagus nerve (enteric origin) as well as the neurons of this nucleus (380). In addition 
considering the physiological relevance of Braak’s hypothesis to Parkinson’s disease 
pathology, his insight leads me to examine whether the H5N1 virus c
in
retrogradely. I also observed the activation of microglia as well as the phosphorylation 
and aggregation of alpha-synuclein that persists long after the presence of viral protein, 
regions infected by H5N1 virus.  
 
 
5.1.1 Implications and limitations 
 
 In general, when performing influenza research using mammalian models, ferre
are thought to be the ideal animal model as they are susceptible to the human influenza 
viruses and develop upper respiratory tract infection and clinical signs such as fever,
rhinitis, and sneezing, similar to humans (381). The likely reason for this simila
humans is the presence of α2,3 sialic acid oligosaccharide linkages, which bind 
preferentially to the H5N1 influenz
fe
infection in ferret (382). The drawbacks of the ferret model are the high cost for housing 
and the difficulty in obtaining influenza seronegative animals (382). For our purposes, 
there is little known about the ferret as a Parkinson’s disease model, and mice provide a 
useful genetic as well as environmental model to study the etiology of PD.  
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 In this study, we choose not to use ferrets, but instead used C57BL/6J mice since 
these animals are the preferred species and strain for experimental Parkinson’s disease 
research (12). However, what is advantageous for ferrets may be a limiting factor in mice 
since human influenza virus generally doesn’t easily infect mice unless the virus has bee
“adapted” by serial passage into the lung of mice. Adaptation may arise due to mutations 
that may occur during this process, and as this virus mutates the original pathogenesis of 
the influenza virus may change (382). However, the strain of highly pathogenic H5N1 
influenza virus used in this study (A/VN/1203/
n 
04), collected from a human victim, 
fects mice without adaptation (263) and thus any experimental results obtained are 
kely direct and correlatable effects to humans and will not reflect alterations due to 
induced mutations.  
trains of mice 
fluenza 
 
 and 
rveillance in the periphery. We showed, empirically, 
e in vitro intraneuronal transport of H5N1 virus using adult DRG cells grown in 
icrofluidic chambers. We also showed using transmission electron microscopy the 
have all the morphological characteristics of viral 
articles in myelinated nerves in the brainstem; and what would have to be influenza 
ve 
s is 
iod 
he 
 
 
 It will also be critical to determine what are the genetic signatures that mark a 
particular influenza strain as neurotropic? This can be examined through two approaches. 
in
li
serial passage-
 
 Although we were able to infect mice without adaptation, different s
have been shown to have differential susceptibility to influenza virus depending on 
polymorphisms of the interferon-regulated Mx gene in each strain (382). Mx protein 
encoded by the Mx gene inhibits influenza virus replication. Thus, mice carrying Mx+ 
alleles such as T9 are resistant and mice carrying Mx- alleles are susceptible to in
virus infection (259). C57BL/6J, a standard inbred laboratory strain, possess defective
alleles of the Mx1 gene, so they don’t have a complete antiviral defense system (259). 
 
 
5.1.2 Future studies  
 
 One of the keys to understanding pathogenesis of any viral-induced infection of 
the CNS is to determine how the virus enters the CNS. We suggested that the sensory
autonomic nervous system, particularly the vagus nerve which innervates the lung and 
the peritoneal cavity, may provide “a back door” for the H5N1 virus to reach the CNS, 
while evading the host immune su
th
m
presence of cellular inclusions that 
p
virus as the animals used are certified pathogen free and were raised in a pathogen free 
environment with the additional finding that control non-inoculated animals never 
contained these structures. However, this does not provide evidence that the vagus ner
is the single route of CNS infection of H5N1 in vivo. This could be directly tested by 
performing unilateral vagotomy followed by H5N1 administration. If H5N1 viru
detected only in the side with an intact vagus route  at day 2-3 post-operation, the per
when the H5N1 virus begins to appear in the solitary nucleus, it would prove that t
vagus nerve is one route for the H5N1 virus to infect the CNS. Further studies could them
be performed to examine: 1) the mechanisms in which virus enters the nerve (clathrin 
coated pits? (383)) and 2) how the virus is transported to the cell body (microtubule 
dependent transport? (384)). 
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First, we can randomly generate a recombinant strain between neurovirulent 
A/VN/1203/04 (H5N1) and non-neurovirulent strain, such as A/Jap/305/57 (H2N2) (38
Second, we can also mutate specific gene sequences in the H5N1 genome to identify the 
genes related to neurotropism. These studies could be performed using the microfluidic 
chambers we used to test the intraneuronal transport of H5N1 virus in chapter 2 (270). 
We could also use a direct in vivo test where we inoculate the chimeric viruses into mice 
and ask if the brains get infected. This information would be beneficial for informing 
clinicians and other public health officials in the case of pandemic flu. 
 
 
5.2 Chapter 3 
5). 
 the 
he 
e 
opaminergic neurons. One possible explanation for these observations in that active 
5N1 infection causes SNpc dopamine neurons to transiently reduce their metabolic 
g both TH activity and reducing cell size.  
 
 
e 
o 
, a 
 
t viral-neuronal interactions and/or viral-microglia 
teractions; or if the damage is secondary to humoral-nervous system immune 
terac
 
 In Chapter 3, I demonstrated that H5N1 infection can produce a pathology that 
has similarities with those seen in Parkinson’s disease. I found a transient decrease in
number of TH-positive neurons in the SNpc as well as a similar transient decrease in t
amount of striatal dopamine content. These transient decreases were seen at days post 
infection (dpi) 10, 21 and 60, but recovered by 90 dpi. The dopaminergic neurons of the 
SNpc appeared shrunken and atrophic at 10-60 dpi, but recovered by 90 dpi. Although w
saw an increase in TH-positive neuron number, we saw no evidence of neurogenesis in 
d
H
capacity compromisin
Unlike the transient changes in the dopaminergic system, the effects of H5N1 
infection on the serotonergic system in the brain were more persistent, displaying a 
significant decrease of serotonin in the striatum, cortex and brainstem through 90 dpi. 
Due to limitations in animal protocols, these studies could not be expanded beyond 90 
days, so if a later recovery of this neurotransmitter would occur, we would not have 
detected it. 
 
 I also found a long-term activation of microglia with cytokine production. Sinc
activated microglia function in surveillance and response to insult, their continued 
presence in certain regions of the brain may make these regions particularly vulnerable t
later insults or even normal age-induced changes, which could exacerbate, or cause
degenerative response that would not normally occur. 
 
 
5.2.1 Implications and limitations 
 
 An important question to ask is whether the effects of the H5N1 strain of 
influenza virus on the basal ganglia and the brain in general, are direct or indirect. We see 
the presence of H5N1 in the brain, however we do not know if the progression of this
infection is mediated by direc
in
in tions. 
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 The cytokine profiles we observed support both types of effects. In su
indirect action, there is a slight delay of most of the cytokine induction in the brain 
compared to the point of cytokine induction in the lungs, which is the primary target of 
H5N1 infection. A similar pattern of delayed cytokine expression in the brain was also 
reported by another group, where they showed that mice had a massive and sustained 
infiltration of macrophages and neutrophils with a strong induction of IL-1β, TNF-α, 
IFN-γ, IL-6, MIP-1α, MIP-2, and RANTES in the lung at 3-5 day. Delayed induction o
IL-1β, TNF-α, IFN-γ, IL-6, MIP-2, and MIP-1α in the brain were obser
pport of 
f 
ved at day 6 post-
fection (371).  
ort of viral-neuronal interactions and/or viral-microglia interactions, we 
w a reinduction of cytokine expression after H5N1 virus was no longer present in the 
m 
 is a secondary bacterial 
fection that occurs due to decreased resistance generated by the initial viral infection. 
 
 
ents 
 cleared by the primary immune response that seems to end by day 21, and 
ay trigger the secondary immune response at 60 and 90 dpi. A latent H5N1 infection or 
 its 
nd 
 stress through quinone formation 
nd activate microglia (310, 336-339). That dopamine itself can generate a redox signal 
as been shown both in vitro (389) and in vivo (390-392). 
 
 
CNS 
ncept may be questioned, since the immune response in the CNS is 
vealed to be tightly regulated by the cross communication of neuron and glial cells with 
in
 
 In supp
sa
brain (21 days post infection) and no other insult was provided. Some cytokines were 
reinduced both in the SN and the lung. In particular, IL-13 and IL-2, that are known to be 
derived from microglia and lymphocytes and influence an inflammation response and 
neuronal survival (386), were only observed in a second response in the SN and striatu
respectively. Taken together, this evidence suggests that both a direct viral-neuronal and 
viral-microglia interaction, and a humoral-nervous system immune interaction may occur 
during the course of H5N1 virus infection. 
 
 It is also important to determine what might be the stimulus that generates the 
reinduction of cytokines in the brain. One possibility is that there
in
However, the secondary bacterial infection is less likely to occur in the BSL3+ 
environment, which provides an isolated and secured environment for these animals
(387). Our group, as well as other independent groups, report that H5N1 virus is not 
detectable beyond 15 days after infection in mice, by immunohistochemical methods or
PCR (270, 343, 388). However, while not easily detectable, some of the viral compon
might not be
m
secondary infection from dormant H5N1 influenza virus has not yet been described. 
Another possible cause for the reinduction of cytokine expression is found based on
temporal correlation of reinduction with that of dopamine. We detected increased levels 
of DA in both the substantia nigra (by expression of tyrosine hydroxylase and HPLC) a
striatum (HPLC) at 60 dpi, which may cause oxidative
a
h
 
 
5.2.2 Future studies 
 
 The CNS has been viewed as immune privileged site due to the presence of the
blood brain barrier, the reduced major histocompatibility complex (MHC) class II
expression on cells in the brain and the low T-cell and B-cell number within the 
(393). This co
re
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immune cells (394). In line with this view, it is not surprising that peripheral leukocyte
including CD8+ and CD4+ T cells and granulocytes infiltrate the CNS and modulate
immune response, controlling disease progression in many chronic neurodegenerative 
disorders, including multiple sclerosis (MS) and PD (301, 394).  
  
 Although subsequent induction of cytokine expression and increased numbers 
activated microglia appeared 60 days post-infection, activated microglia may not be the 
only initiator of latent cytokine induction. We have hypothesized that T-cells may also 
play an important
s, 
 the 
of 
 role in both the acute and chronic immune responses in our model. We 
re interested in knowing if the interaction between lymphocytes and microglia is 
 CNS.  
 
 
 
in 
 
.3.1 Implications and limitations 
es, including IL-1α, IL-1β, IL-6, IL-10, IL-13, and TNF-α have 
leomorphic functions and regulate the activation, proliferation and suppression of cells 
lexity 
a
essential for microglia activation and the induction of proinflammatory cytokines. One 
way to test this hypothesis is through the use of transgenic mice, such as the RAG-1 
(recombination activating gene-1) deficient mice that lack T-cells (395), LAG-3 null 
mice that lack natural killer cells (396) and MT mice (B6-Igh6-6tm1Cgn) that lack B-
cells (397). One caveat in these experiments is that since these mice don’t have a 
complete immune system; they may show different susceptibility and pathophysiology in 
response to acute H5N1 viral infection. However, testing these models with the proper 
controls may suggest which population of peripheral immune cells is critical for the 
communication with neurons and glia in the
5.3 Chapter 4 
 
 In Chapter 4, we tested if acute H5N1 priming affects paraquat-induced 
neurotoxicity. We detected a transient reduction of the dopamine output in striatum, a
long-lasting increase in proinflammatory cytokines and chemokines, and an increase 
the number of both resting and activated microglia in the SN at day 60 post infection. 
These observations lead us to hypothesize that the change in the microenvironment of the 
CNS produced by H5N1 infection could make the basal ganglia sensitive to PQ-induced
oxidative stress. 
 
 In contrast to our expectations, the results suggest that H5N1 priming might 
protect the dopaminergic neurons from PQ-induced neurotoxicity and desensitize the 
immune response produced by PQ in the lung, SN, and striatum. The desensitization 
effect of H5N1 priming was the most obvious in the SN. 
 
 
5
 
 Many cytokin
p
with different time course and ability (398). Each cell is also a part of a huge cellular 
network which is composed of thousands of communicating cells. Therefore, comp
in the net effect from the milieu of cytokines is inevitable. 
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 One cell type we did not examine in context of influenza (and paraquat) effects 
was astrocytes; and any pathology seen (or not seen) needs to take the biology of these 
cells into the calculation of net effects. Several studies showed that astrocytes produce 
neurotropic factors, including nerve growth factor (NGF) and glial cell line-derived 
tor (GDNF) that respond to inflammatory stimulation including 
 
 
 
ent 
 to 
H5N1 priming was protective for paraquat-induced neurotoxicity in our 
rotocol. However, we do not know at this time if the H5N1 priming is 
nsitizing or desensitizing mice to secondary insults, including aging, genetic mutations, 
ered by 
cal and physiological relevance for testing the “multiple hit” hypothesis 
r PD. Rotenone, a mitochondrial complex 1 inhibitor and insecticide, was isolated from 
 or 
ide 
 
rbicide since 1954, but it had 
een synthesized by the reaction of 4,4’-bypyridium with methyl iodide and used as an 
xidation reduction indicator prior to used as an herbicide (400). Therefore, it is possible 
 to paraquat or rotenone in advance of the 1918 flu 
andemic.  
ost 
deposition of α-synuclein and 
e selective loss of dopaminergic neurons and activation of microglia in C57BL/6J mice 
(378). In this injection paradigm, the first paraquat administration did not cause 
neurotrophic fac
lipopolysaccharide and pro-inflammatory cytokines such as TNF-α, interleukin-1β (IL-
1β) and interferon-γ (IFN-γ), (351-353) (350) (351).  
 
 The immune response is a very dynamic process. Different cells may be involved 
in the immune response at different times during the course of infection. For example, 
after exposure to MPTP, microglia in the SN are quickly activated and proliferate in 1-2
days, T-cells then begin to infiltrate at day 2-7, and later, astrocytes become activated
(301). Therefore, the timing and the context of the insults could significantly affect the
final pathology. To further elucidate the course of events during infection and subsequ
cellular effects, a non-invasive and continuous observation method would be ideal
study the effect of multiple insults as a PD model.  
 
 
5.3.2 Future studies 
 
 
experimental p
se
other types of neurotoxin such as rotenone, and/or infectious pathogens, encount
the subject at various time points. 
 
 Another experimental design would be to switch the sequence of insults, for 
example, paraquat administration followed by H5N1 infection, to determine how neurons 
damaged by oxidative stress respond to H5N1-induced neuroinflammation. This study 
has epidemiologi
fo
the roots and stems of several plants (399). This chemical has been used in one form
another as a crop insecticide since 1848 and has been recognized as a registered pestic
in the United States under the Federal Insecticide Fungicide Rodenticide Act (FIFRA)
since 1947 (5). Paraquat has also been recognized as an he
b
o
that people may have been exposed
p
 
 A 5mg/kg dose of paraquat is approximately 40 times lower than the 50% lethal 
dose (196mg/kg) (401) and does not cause systemic toxicity in peripheral organs in m
experimental cases in mice (402). Multiple low doses of PQ (10mg/kg, one injection per 
week for 3 weeks, ip), however, produce the intraneuronal 
th
112 
d inergic neuron loss, however it produced a substantial activation of microglia by 
days post administration. The second paraquat injection, which was delivered a week 
after the first injection caused a significant loss of dopaminergic neurons. When the ant
inflammatory drug, minocycline, was delivered to block microglia response after the
paraquat injection, no dopaminergic cell loss was observed (378). This observatio
suggests that the first PQ injection may prime the microglia and cause reversible injury 
dopaminergic neurons, while the second PQ injection 
opam 7 
i-
 first 
n 
to 
would trigger events causing 
reversible damage to dopaminergic neurons (368). 
 
d by H5N1 infection would represent 
 reverse scenario. 
.4 Conclusions 
. 
, A) a temporal reduction of the dopamine in striatum, 
) increased phosphorylation and aggregation of alpha synuclein, C) a long-lasting, 
creas  of 
o 
y vary depending on the timing and the context of a subsequent insult.  
ir
 
 In previous experiments, the primary insult was an acute H5N1 infection that 
produced a massive proinflammatory cytokine induction in both the periphery and the 
CNS, that may lead to reversible damage to dopaminergic neurons and the persistent 
activation of microglia. The secondary insult was PQ, which may influence cells in the 
SN and the CNS specifically. In view of a multiple hit hypothesis, this experimental 
regime can be considered as the combination of a broad systemic insult, followed by a
CNS specific insult. Therefore, PQ priming followe
a
 
 
5
 
 Chapter 2 and 3 provide evidence that H5N1 induced a parkinsonian pathology
Chapter 2 and 3 demonstrated that the highly infectious neurotropic A/VN/1203/04 
(H5N1) virus progresses from the peripheral nervous system into the CNS and induces 
three cardinal PD related pathology
B
in e in inflammation within the brain, characterized by an increase in the number
both resting and activated microglia and differential expression of a number of cytokines 
and chemokines.  
 
 Chapter 4 demonstrates that acute H5N1 influenza infection, although it produced 
a long-term activation of microglia with proinflammatory cytokine production, appears t
protect the dopaminergic neurons from paraquat-induced neurotoxicity.  
 
 Thus, we suggest that H5N1 virus or any pandemic influenza that activates the 
immune system in brain may be an important etiological agent in itself to initiate the 
sequelae of neurodegenerative diseases including Parkinson’s disease. We also suggest 
that the consequence of pre-existing inflammatory response produced by H5N1 virus, 
however, ma
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